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Cannabis has always been used to treat gastrointestinal (GI) symptoms and pain. By considering the 
beneficial effects obtained in human medicine, the research in veterinary medicine has focused on 
the endocannabinoid system (ECS), developing products to treat inflammatory conditions and 
nociception. The target of these products are cannabinoid receptors (CBRs), with the two canonical 
cannabinoid receptor 1 (CB1R) and 2 (CB2R), and different putative cannabinoid receptors, such as 
G protein coupled receptor 3 (GPR3) and 55 (GPR55), peroxisome proliferator-activated receptors α 
(PPARα) and γ (PPARγ), transient receptor potential vanniloid (TRPV1) and ankirin (TRPA1), or 
serotonin receptor (5-HT1a, 5-HT2a or 5-HT3a).  
The principal aim of this research was to evaluate the role of CBRs in the GI tract and in the 
dorsal root ganglia (DRGs) of different species. The first chapter focuses on the ECS and its 
components. The second chapter focuses on the GI tract, describing its structure, the interaction with 
the ECS and the principal pathologies affecting the species of interest, in which the ECS could be 
involved. The third chapter focuses on DRGs, describing the structure, the role in neuroinflammation 
and the interaction with the ECS. 
The experimental studies are divided in: 
 experimental studies about the GI tract; 
 experimental studies about the DRGs; 
 other experimental studies (focus: endoscopy). 
The localization of CBRs has been investigated in the GI tract of dog, cat and horse and in canine and 
equine DRGs. The receptors showed similarities and differences in their distribution, underlining how 
the ECS modulates its expression adapting to physiological (and pathological) conditions between 
the different species. 
This research could provide an anatomical substrate upon which it would be possible to develop 
preclinical and clinical studies aimed to investigate and possibly support the therapeutic use of non-
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The endocannabinoid system 
The endocannabinoid system (ECS) is composed of cannabinoid receptors, their endogenous ligands, 
and the enzymes involved in endocannabinoids turnover (Stella, 2004; Ligresti et al., 2016; Lu and 
Anderson, 2017). The term “endocannabinoid system” was first coined by Di Marzo and Fontana in 
1995. The etymology of this term derived from cannabis, because this phytocompound, as the 
endocannabinoids, can act on cannabinoid receptors. The medical use of cannabis has a long history: 
thousands of years ago the Chinese and Indian society used it for the control of anxiety and visceral 
pain (Figure 1). The ECS has great importance for the physiological functions of the organism. It is 
widely expressed in the central nervous system (CNS), cardiovascular, gastrointestinal, immune and 
reproductive system and, moreover, it is similar among different species (Maccarrone et al., 2015; 
Cabral et al., 2015). The ECS is present in mammals, birds, fish, echinoderms and mussels (Salzet et 
al., 2000). A growing body of evidences indicates that activation of cannabinoid receptors by 
endogenous, plant-derived, or synthetic cannabinoids may exert beneficial effects on inflammation 
and visceral pain.  
 
Figure 1: Illustration of Cannabis sativa. Scientific drawing (1887). In Franz Eugen Köhler's Medizinal-Pflantzen. 
Published and copyrighted by Gera-Untermhaus, FE Köhler. Drawing by W. Müller. 
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Cannabinoids receptors  
G protein-coupled receptors 
The G protein-coupled receptors (GPCRs) are the largest family of receptors and the principal target 
of current therapeutic drugs (Lefkowitz, 2004). In the human genome, about 1000 genes encode such 
receptors (Fredriksson et al., 2003). GPCRs are involved in all known physiological processes in 
mammals (Lefkowitz, 2004). A GPCR system is composed of a ligand, a receptor, and a transducer. 
Stimulated by hormones, neurotransmitters, and lipids, GPCRs change in an “active” conformation 
that leads to a wide range of intracellular responses (Figure 2) (Hodavance et al., 2016). The most 
important cannabinoid receptors are part of this family (Maccarrone, 2015). After the discovery of 
CB1R and CB2R receptors in the Eighties, other G protein-coupled receptors were identified, 
considered “putative cannabinoid receptor”, such as GPR55, GPR3, GPR6, GPR12, GPR18 and 
GPR119 (Gribble and Reimann, 2016, Ryberg et al., 2007, Morales et al., 2018). 
 
Figure 2: G protein coupled receptor system. Modified from Manglik and Kruse, 2017. 
CB1R 
The cannabinoid receptor 1 (CB1R) is a G protein-coupled receptor expressed mostly in the CNS and 
peripheral nervous system (PNS). It is primarly involved in cognition and short-term memory 
(cerebral cortex and hippocampus) and in motor function and movement (basal ganglia and 
cerebellum), so the receptor is more concentrated in these areas (Pertwee, 1997; Hu and Mackie, 
2015; Freundt-Revilla et al., 2017). CB1 receptor is also present, with a lower concentration, in a 
variety of peripheral tissues and cells (Pacher et al., 2006). CB1R is involved in feeding behavior: its 
activation can increase appetite, whereas the inhibition of CB1R suppresses hunger and induces 
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hypophagia (Terragon and Moreno, 2019). The wide distribution of the CB1R in the CNS limits its 
properties, due to the psychoactive side effects linked to its activation (Moreira et al., 2009). For 
example, the CB1R antagonist rimonabant was used for several years for the treatment of obesity, 
reducing food intake as well as abdominal adiposity and cardiometabolic risk factors (Bermudez-
Silva et al., 2010). In 2009, it was banned due to psychiatric side effects, including depression, anxiety 
and suicidal thoughts (Simon and Cota, 2017).  
CB2R 
CB2 receptor, another G protein-coupled receptor, is mainly expressed by cells of the hematopoietic 
and immune systems, such as monocytes, macrophages, and lymphocytes B and T, hihglighting its 
immunomodulatory properties (Staiano et al., 2005; Pacher et al., 2006; Matias and Di Marzo, 2007). 
In human medicine, CB2R has a potential as target in the treatment of chronic inflammatory diseases, 
such as rheumatoid arthritis, atherosclerosis, and Inflammatory Bowel Disease (IBD) (Turcotte et al., 
2016). CB2R seems to be involved also in the pathogenesis of IBD: in humans, the CB2-Q63R 
genetic variant increases the risk of pediatric IBD. This variant is linked to the balance between Th1 
and Th2 cells. Children affected by pediatric IBD with the CB2- Q63R variant develop a more severe 
phenotype of IBD (Strisciuglio et al., 2018). CB2R has recently been identified in neurons and 
microglia (Malfitano et al., 2014). This receptor seems to be upregulated in different CNS diseases 
involving microglia and/or astroglia activation, suggesting a possible role of CB2 receptor as 
pharmacological target in neuroinflammatory diseases (Skaper et al., 2013; Navarro et al., 2016; 
Cassano et al., 2017; Chen et al., 2017; Freundt-Revilla et al., 2018). The absence of CB2R in the 
brain result in no psychotropic effects linked to its activation (Dhopeshwarkar and Mackie, 2014). 
Moreover, recent evidences demonstrate the role of ECS in modulating cell-signaling targets in 
diabetes mellitus (DM) (Kumawat and Kaur, 2019). The activation of CB2R inhibits the expression 
of inflammatory cytochines, as tumor necrosis factor alpha (TNF-α), Interleukin 6 (IL-6), Nuclear 
factor kappa beta (NF-κβ) (Horváth et al., 2012). Moreover, CB2R is present in pancreatic β-cells in 
human and rat, and can stimulate the secretion of insulin through Ca2+ signal regulation (Juan-Picó et 
al., 2006). In human and rat kidney, CB2 receptor has been localized in glomeruli and tubules (Cakir 
et al., 2019). Several studies demonstrate that CB2R activation can reduce kidney damage, while 
CB2R inhibition increase renal damage (Mukhopadhyay et al., 2010; Zoja et al., 2016). Activation of 
CB2 receptor with CB2R-agonists reduce apoptosis, inflammation, and oxidative stress in the kidney 






The G protein-coupled receptor 55 (GPR55) was first described in 1999 (Sawzdargo et al., 1999). 
GPR55 shares 10–14% homology with CB1 and CB2 receptors (Lauckner et al., 2008). It is widely 
distributed in the enteric nervous system (ENS) of humans and rodents, especially in the myenteric 
and submucosal plexus (Lin et al., et al., 2011; Ross et al., 2012; Li et al., 2013; Goyal et al., 2017). 
GPR55 has been identified in a large number of cell types, as macrophages, plasma cells, neutrophils, 
natural killer, monocytes, or lymphatic cells (T-cells) (Balenga et al., 2011; Stancic et al., 2015; 
Chiurchiù et al., 2015; Taylor et al., 2015; Lanuti et al., 2015; Grill et al., 2019). It is also expressed 
by microglia, the principal cells in the CNS involved in the innate immune response, playing essential 
roles in the homeostasis and responses to inflammatory stimuli (Ransohoff and Pery, 2009). An 
overexpression of microglia is associated with neurodegenerative diseases, as Alzheimer’s disease 
(AD) or Parkinson disease (PD) (Streit et al., 2005). GPR55 antagonists, blocking microglia 
activation, can potentially provide anti-inflammatory effects (Saliba et al., 2018). As other 
cannabinoid receptors, GPR55 seems to be involved in human IBD. In inflammed colonic samples 
of patients affected by Crohn’s disease, GPR55 mRNA expression is significantly higher than in 
patients with Ulcerative Colitis or non-inflammed patients. GPR55 shows strong affinity with 
palmitoylethanolammide (PEA), a lipid mediator structurally related to the endocannabinoids 
(Petrosino and Di Marzo, 2016). Otherwise cannabidiol (CBD), another therapeutic 
phytocannabinoid, acts as an antagonist of the GPR55 (Ligresti et al., 2016), so the function of this 
receptor is still questioned.  
Peroxisome proliferator-activated receptors 
Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors 
belonging to the family of nuclear hormone receptors (NRs), part of the steroid receptor superfamily 
(Figure 3) (Berger and Moller, 2002). After interacting with specific ligands, NRs move to the 
nucleus, modify their structure and regulate gene trascription (Grygiel-Gòrniak, 2014). They act as 
transcription factors, modulating various metabolic processes, principally lipid and glucose 




Figure 3: Superfamily of nuclear hormone receptors. Modified from Berger and Moller, 2002. 
The structure of PPARs is a three-dimensional structure, composed by a DNA binding domain (N-
terminus) and a ligand binding domain (C-terminus) (Grygiel-Gòrniak, 2014). There are different co-
activators and co-repressors of PPAR, which can activate or inhibit receptors function (Viswakarma 
et al., 2010). The family of PPAR comprises PPARα, PPARβ/δ and PPARγ (Berger and Moller, 
2002). Natural ligands of PPARs are essential fatty acids (EFA) or eicosanoids, involved in glucose 
and lipid homeostasis (Krey et al., 1997). Synthetic ligands are, for example, fibrates, involved in the 
treatment of hypertriglyceridemia, and thiazolidinediones, used in the treatment of DM (Taniguchi et 
al., 2001).  
PPARα 
 The PPARα receptor is a ligand-activated transcription factor. PPARα can modulate gene expression, 
playing a key role in glucose and lipid homeostasis and inhibiting inflammation (Naidenow et al., 
2016). This receptor is highly expressed in metabolic active tissue like heart, liver, mucosal intestine, 
skeletal muscle, and brown adipose tissue. In the liver, increased fatty acid concentrations activate 
PPARα, which uptakes oxidized forms of fatty acids. Oxidation prevents steatosis of the liver, in case 
of starvation/fasting (Sethi et al., 2001). Administration of PPARα agonists prevents hepatic fibrosis 
in animal models (Ip et al., 2003). The antinflammatory action of palmitoylethanolamide, a natural 
fatty acid ethanolamide, is also mediated by the interaction with PPARα. Indeed, PPARα-/- mice 
display longer inflammatory responses than wild type mice (Lo Verme et al., 2005). 
PPARγ 
PPARγ is another ligand-activated transcription factor. It is widely expressed in white and brown 
adipose tissue, spleen and intestine. PPARγ plays a key role in adipogenesis and lipid metabolism, 
and it is essential for the control of insulin sensitivity (Grygiel-Gòrniak, 2014). The activation of 
PPARγ balances the secretion of adipocytokines, mediators of insulin action in peripheral tissues 
(Kintscher and Law, 2005). PPARγ is also present in endothelial and vascular smooth muscle cells, 
and it is involved in regulation of vascular inflammation and atherosclerosis (Marx et al., 1999). This 
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receptor seems to have neuroprotective potential in CNS diseases (Hung et al., 2019). The natural 
agonists of PPARγ are polyunsatured fatty acid (PUFA), but they not always determine an activation 
of the receptor and consequently a gene transcription (Grygiel-Gòrniak, 2014). This interaction 
between PUFA and PPARγ seems to regulate cancer development. Indeed, the activation of PPARγ 
has an apoptotic action on cancer cells, while in vitro activation of PPARα or PPARβ/δ in human cell 
lines of breast cancer stimulates cell proliferation (Suchanek et al., 2002). PPARγ is a target of CBD, 
which reduce intestinal inflammation mainly through a modulation of the neuro-immune axis (De 
Filippis et al., 2011; Couch et al., 2017). 
Transient receptors potential channel  
The transient receptors potential channel (TRP) are integral membrane proteins that modulate the 
entrance of ions Ca++ in the cells (Morales et al., 2017). Hormones, growth factors and 
neurotransmitters allow Ca++ entry through receptor-activated cation channels. All channels have six 
transmembrane segments (from S1 to S6), with a pore region (P) between S5 and S6 (Figure 4) (Nilius 
and Owsianik, 2011). These proteins are conserved in invertebrates and vertebrates. TRP are widely 
expressed, both in excitable and non-excitable tissues; they are localized mostly in all cellular 
membranes. The superfamily of TRP contains seven subfamilies: TRPC (canonical), TRPV 
(vanilloid), TRPM (melastatin), TRPP (polycystin), TRPML (mucolipin), TRPA (ankyrin), and 
TRPN (NOMPC-like, only in invertebrates and fish) (Nilius et al., 2007). Cannabinoids can interact 
with three subfamilies of TRP: TRPV, TRPA and TRPM. In particular TRPV1, TRPV2, TRPV3, 
TRPV4, TRPM8 e TRPA1 interact with cannabinoids (De Petrocellis et al., 2008; De Petrocellis et 
al., 2011; De Petrocellis et al., 2012). 
 
Figure 4: Predicted structural topology of TRP channels. Modified from Nilius and Owsianik, 2011.  
TRPV1 
The TRPV family contains six members, from TRPV1 to TRPV6. These receptors are tetrameric 
complexes, and every subunit contains six N-terminal ankyrin repeats (Du et al., 2019). The TRPV1 
is located in DRG and trigeminal ganglia, spinal and peripheral nerve terminals, brain, skin, pancreas, 
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gastrointestinal tract and bladder (Nilius and Owsianik, 2011). In the brain, TRPV1 has been found 
in dopaminergic neurons of the substantia nigra, hippocampal pyramidal neurons, hypothalamic 
neurons, locus coeruleus in the brainstem, and in various layers of the cortex (Mezey et al., 2000). 
TRPV1 is activated by heat (>43°C), low pH and capsaicin (Caterina et al., 1997). It usually 
undergoes desensitization by endocannabinoids (Ambrosino et al., 2013; Zygmunt et al., 2013). 
TRPV1 is involved in different functions, such as thermo-regulation, nociception, pain management 
or food intake regulation (Nilius and Owsianik, 2011). The stimulation of TRPV1 by caspaicin seems 
to prevent adipogenesis and obesity in wild type mice (Zhang et al., 2007). In primary sensory 
neurons, TRPV1 is essential for the development of inflammatory hyperalgesia (Davis et al., 2000). 
In the gastrointestinal tract, TRPV1 is mainly expressed by the submucosal plexus (SMP), myenteric 
plexus (MP), muscolaris mucosae, gastric mucosal and parietal cells, and gastric antral G cells (Akbar 
et al., 2010). On gastric functions, TRPV1 acts reducing gastric acid secretion (Hirokuni et al., 2012), 
accelerating gastric emptying process (Debreceni et al., 1999), increasing mucosal blood flow 
(Satyanarayana, 2006) and protecting gastric mucosa through the secretion of prostaglandins (PGE2) 
and epidermal growth factor (EGF). TRPV1 is involved also in Irritable Bowel Syndrome (IBS), a 
human functional bowel disorder that causes abdominal pain, abdominal distention, and changes in 
stool characteristics (Du et al., 2019). Shi et al. (2013) demostrated that TRPV1 expression on nerve 
fibers was significantly upregulated in colonic samples with IBS, and this upregulation was positively 
correlated with the severity of abdominal pain. 
TRPA1 
The TRPA family contains one mammalian receptor, TRPA1 (Nilius et al., 2007). TRPA1 is an ion 
channel that reacts to mechanical, thermal (cold) and chemical stimulation. It can be activated by 
different chemical substances present in herbs and spices, like allicin (obtained from garlic), 
cinnamaldehyde (from cinnamon) or wasabi. It is expressed by nociceptive/thermo-receptive 
neurons, which detect temperature below -17°. This receptor is also expressed by non-neuronal cells, 
such as, in human and mice, T cells. Sahoo et al. (2019) found that TRPA1 is expressed at the surface 
of these immune cells, rather than intracellularly, and it is overexpressed in activated T cells, where 
it mediates Ca++ influx and determines the release of certain citokines (Figure 5). TRPA1 seems to 
act as a proinflammatory regulators, involved in neurogenic inflammation (Bautista et al., 2013), 
dermatitis (Liu et al., 2013) and colitis in mice-models (Utsumi et al., 2018). So, TRPA1 inhibition 
should reduce T cells activation. Otherwise, other studies suggest an anti-inflammatory role of 
TRPA1, via CD4+ T cells involvement (Bertin et al., 2016). TRPA1, cold-sensitive channel and 
TRPV1, a heat-sensitive channel, are often co-expressed (Story et al., 2003). The anti-inflammatory, 
anti-nociceptive and analgesic properties of CBD might be due, in part, to the capability to activate 
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and/or desensitize both the TRPA1 (De Petrocellis et al., 2008) and the TRPV1 (Bisogno et al., 2001; 
Ligresti et al., 2016). TRPA1 is involved in the etiology of FEPS (Familial Episodic Pain Sydrome), 
an autosomal dominant disease that gives upper body pain, provoked by physical stress or fasting 
(Kremeyer et al., 2010). 
 
Figure 5: Expression and involvement of TRPA1 in Tcells. Modified from Sahoo et al., 2019.  
Serotonin receptors 
Serotonin (5-HT) was first discovered by Vittorio Espramer in 1938, isolated from the gastrointestinal 
tract, and named “enteramine” (Espramer and Boretti, 1950). The name serotonin derives from its 
vasoconstriction properties (“sero” serum and “tonin”, to constrict). Now, it is one of the most studied 
chemical messengers for its wide distribution and functions. Serotonin receptors (5-HTR) family 
comprises seven subtypes, six G protein-coupled receptor and one (5-HT3) ligand-gated cation 
channel receptor, and 13 receptors (Mc Corvy and Roth, 2015). In the human CNS, almost all the 5-
HTRs are expressed (except 5-HT5b), and they are involved in different functions, such as sleep-
wake cycle, appetite, emesis, mood, memory or breathing (Ray et al., 2011). Surprisingly, the major 
quantity of 5-HT in the body is found in the gastrointestinal tract, playing an important role in 
motility, secretion and gastrointestinal syntoms (Gershon et al., 1990). Cannabinoids can interact with 
different serotonin receptors, such as 5-HT1a, 5-HT2a and 5-HT3a, as both agonist and antagonist 
(Russo et al., 2005; Cascio et al., 2010; Cascio et al., 2015 Viñals et al., 2015). 
5-HT1aR 
5-HT1aR is the most widely distributed of all 5-HT receptors (Pytliak et al., 2011). In the CNS, the 
highest density of 5-HT1aR was found in areas important for learning and memory, such as the frontal 
cortex, hippocampus and septum (King et al., 2008). It is expressed as pre-synaptic receptor in the 
raphe nuclei, where inhibits the release of serotonin at CNS level, and as post-synaptic receptor in 
different cortical areas, where it modulates the release of dopamine (Altieri et al., 2013). 5-HT1aR is 
involved in anxiety, and its agonists are getting interest as anti-depressant and anti-psychotic drugs 
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(Celada et al., 2013). CBD acts as an agonist of 5-HT1aR, with ansiolitic properties (Campos and 
Guimarães, 2008). Other phytocannabinoids, as cannabigerol (CBG), act as antagonist (Cascio et al., 
2010). In an animal model of Alzheimer’s disease (AD), 5-HT1aR antagonist (NAD-299) helps to 
attenuate the neuronal apoptosis, as reported in AD (Shahidi et al., 2019). 5-HT1aR can be found in 
the gastrointestinal (GI) tract, comprising the myenteric plexus (Pytliak et al., 2011). 5-HT1aR is 
involved in numerous GI functions, such as secretion and motility. On the stomach, 5-HT1aR agonists 
act as mucosal protectants, reducing acid and pepsin secretion and increasing adherent mucus 
production (Farré et al., 1995). These agonists are also involved in inhibition of the gastric motility 
(Tack et al., 1992), and modulation of colonic motility (Dickson et al., 2010).  
Glycine receptors 
Glycine receptors are ionotropic receptors that belong to the cys-loop superfamily. These receptors 
are composed by α (α1 to α4) and β subunits, with a α1 and α3 subunit mainly expressed in the spinal 
cord, and α2 in the brain (Hejazi et al., 2006). Glycine receptors are involved in pain trasmission and 
dopamine release, so they play a key role in analgesia and drug addition. They are an important target 
for nociception at the spinal level (Xiong et al., 2012). Tetrahydrocannabinol (THC) and anandamide 
(AEA) directly interact with glycine receptors; this interaction contributes to the antinflammatory and 
analgesic effects of phytocannabinoids in neuropathic diseaes (Morales et al., 2017). 
Endocannabinoids  
The endocannabinoids are the endogenous ligands of cannabinoid receptors, first isolated in the 
Nineties (Devane et al., 1995). These molecules are eicosanoids, capable of binding to and activating 
cannabinoid (Malfitano et al., 2014). Endocannabinoids derived from long chain polyinsatured fatty 
acids, especially arachidonic acid. Circulating endocannabinoids come from different organs, such as 
brain, muscle, adipose tissue and circulating cells (Hillard, 2018). Various stimuli can enhance the 
production of endocannabinoids, and these molecules can have effects on different organs or tissue, 




Figure 6: Stimuli and effects of circulating endocannabinoids. Modified from Hillard, 2018.  
The principal endocannabinoids are anandamide (N-arachidonylethanolamine or AEA) and 2-AG (2 
arachydonyl-glicerol). Other endocannabinoids are 2-arachidonyl-glycerylether (or noladin), O-
arachidonoyl-ethanolamine (or virodhamine, or O-AEA), N-arachidonoyl dopamine or (NADA) and 
other compounds (Pertwee, 2015). Palmitoylethanolamide (PEA) or oleoylethanolamide (OEA) are 
considered endocannabinoid-like and can directly or indirectly act on cannabinoid receptors 
(Bradshaw and Walker, 2005). 
AEA 
Anandamide was the first endocannabinoid to be discovered in porcine brain and belongs to the N-
acylethanolamine family (Devane et al., 1992). Anandamide is synthesized on demand from the 
hydrolysis of a phospholipid precursor, N-arachidonoyl-phosphatidylethanolamine, by a 
phospolipase D enzyme, in a calcium ion-dependent manner (Di Marzo et al., 1994). The release of 
AEA is not by vescicles, but via facilitated diffusion through the cell membrane (Mechoulam et al., 
1998). AEA is a partial agonist of CB1R and CB2R, with greater affinity for CB1R (De Petrocellis 
and Di Marzo, 2010). Moreover, it can bind to PPARα (O’Sullivan, 2007), GPR55 (Ryberg et al., 
2007) and TRPV1, supposing a possible role of anandamide as “endovanilloid” (Di Marzo et al., 




The 2-AG is a monoacylglicerol, first isolated from rat brain and canine gut (Mechoulam et al., 1995; 
Sugiura et al., 1995). The production of 2-AG is mediated by diacylglycerol lipase, which converts 
the phospholipase C (PLC) product diacylglycerol to 2-acylglycerols, including 2-AG and 2-
oleoylglycerol (2-OG) (Hillard, 2018). 2AG is a pure agonist of CB1R and CB2R, with greater 
affinity for CB2R than AEA (Pertwee et al., 2010). As AEA, it can interact with PPARα and GPR55. 
2AG is also a metabolic intermediate in lipid synthesis, being the principal source of arachidonic acid 
in the synthesis of prostaglandin (Nomura et al., 2011).  
Palmitoylethanolamide 
Palmitoylethanolamide (PEA) is a lipid mediator structurally related to AEA. It was first isolated 
from egg yolk, soybeans, and peanut meal (Coburn et al., 1954) and then from a variety of food 
sources (Petrosino et al., 2016). PEA can also be synthesized in the organism, through the hydrolysis 
of N-palmitoyl-phosphatidyl-ethanolamine by the enzyme N-acyl-phosphatidyl-ethanolamine-
selective phospholipase D (NAPE-PLD) (Okamoto et al., 2004). The degradation is mediated by 
FAAH and NAAA (N-acylethanolamine-hydrolyzing acid amidase) (Ueda et al., 2001). The 
mechanisms of action of PEA are different. The first method was identified by Rita Levi-Montalcini 
laboratory, and was named “ALIA” (Autocaoid Local Injury Antagonism) (Aloe et al., 1993). They 
showed how lipid amides, when administered systematically, could reduce mast cell degranulation, 
suggesting a strong local anti-inflammatory effect of PEA. PEA can also act directly on different 
receptors, as PPARα (Lo Verme et al., 2005; Gabrielsson, et al., 2016), GPR55 (Ryberg et al., 2007) 
and weakly on CB2R. The action on CB2R is principally mediated by an entourage effect, reducing 
the metabolism/ stimulating the synthesis of endocannabinoids AEA and 2-AG (Di Marzo et al., 
2001). Finally, PEA acts directly and indirectly on TRPV1 (De Petrocellis and Di Marzo, 2010), 
increasing the activation of TRPV1 by AEA and 2AG, or activating it through PPARα receptors 
(Ambrosino et al., 2013). PEA is used both in human and veterinary medicine for its anti-
neuroinflammatory, neuroprotective, analgesic, and anti-pruritic properties, and for the action against 
visceral pain (Re et al., 2007; Gabrielsson et al., 2016; Petrosino and Di Marzo, 2016). The benefits 
of PEA have been evidenced in several neurodegenerative diseases, such as Alzheimer’s disease 
(AD), Parkinson’s disease (PD), or Multiple Sclerosis (MS). PEA seems to act on neurodegenerative 
disease modulating the altered expression of proteins in AD or PD and inhibiting pro-apoptotic 
markers or pro-inflammatory factors (Petrosino and Di Marzo., 2017). The anti-inflammatory 
properties, as the antipuritic, are principally linked to the ALIA mechanism, with the down regulation 
of mast cells. The analgesic properties seem to derive from the direct action on PPARα and the 
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indirect modulation of CB2R (Petrosino and Di Marzo., 2017). A recent study demonstrated that the 
analgesic effects of PEA are progressive, not linked to age and gender, and not related to the 
aetiopathogenesis of chronic pain (Paladini et al., 2016).  
Phytocannabinoids 
Phytocannabinoids are cannabis meroterpenoids and their analogues of plant origin (Hanuš et al., 
2016). To date, about 104 phytocannabinoids have been isolated, divided in 11 types: (-) -delta-9-
trans-tetrahydrocannabinol (Δ9-THC), (-) -delta-8-trans-tetrahydrocannabinol (Δ8-THC), 
cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabidiol (CBD), 
cannabinodiol (CBDN), cannabielsoin (CBE), cannabicyclol (CBL), cannabitriol (CBT), and 
myscellaneous-type cannabinoids (Elsohly and Gul, 2014). They have different affinity and function 
on cannabinoid receptors (Figure 7).  
 
Figure 7: Molecular structure and mechanism of action of phytocannabinoids. Modified from Pisanti et al., 2017. 
Δ9-THC is the main compound of Cannabis sativa, isolated for the first time in 1964, and well known 
for its psychoactive side effects (Gaoni and Mechoulam, 1964). Many of the other compounds are 
non-psychotropic, so they are of extreme interest for their therapeutic properties (Figure 8). The 




Cannabidiol is the second major component of cannabis, after THC, and it is not associated with 
psychoactivity, alteration of motor function, memory or thermoregulation (Bisogno et al., 2001). For 
this reason, CBD has been investigated in several models of pathologies, like inflammatory and 
neurodegenerative diseases, epilepsy, or autoimmune disorders like multiple sclerosis, arthritis, 
schizophrenia and in neoplastic diseases (Izzo et al., 2009; Pisanti et al., 2017). CBD plays an 
important role in IBD treatment, through modulation of inflammatory cytokines (Sacerdote et al., 
2005), inhibition of mast cells and macrophages recruitment (De Filippis et al., 2011), and reduction 
of intestinal permeability (Couch et al., 2019). Cannabidiol can act directly on cannabinoid receptors, 
with low affinity with CB1R and CB2R, or as an entourage molecule, both reducing side effects of 
Δ9-THC (Pisanti et al., 2017). It is also an agonist of TRPV1 (Bisogno et al., 2001), PPARγ and 5-
HT1aR (Russo et al., 2005). Moreover, CBD acts on AEA, by inhibiting its uptake and preventing its 
hydrolisis (Bisogno et al., 2001). CBD can reduce intoxication, sedation and tachycardia induced by 
THC; on the other hand, it can enhance its analgesic, anti-emetic or anti-carcinogenic properties 
(Russo and Guy, 2006). So combined preparations with THC and CBD can allow to use higher doses 
of THC, mantaing the safety for patients. CBD is getting more interest in recent years, as treatment 
for people unsatisfied by conventional therapies or absence of therapies. CBD is not considered an 
abuse drug, but the regulation for its sale is not clear. Several products as CBD oil, tinctures and vapor 
are in commerce, but the absence of regulation exposes to the risk of a poor-quality product, with 
lower concentration than the effective one, or with biological contamination of the compounds 
(Pisanti et al., 2017).  
 
Figure 8: Pharmacological actions of non-psychotropic cannabinoids. Modified from Izzo et al., 2009.  
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Enzymes for synthesis and degradation 
Synthesis 
AEA and 2-AG both contain arachidonic acid, but synthesis and degradation are mediated by different 
enzymes (Pacher et al., 2006). They are synthesized and released on demand, in a Ca+- dependent 
way, following physiological or pathological stimuli (Di Marz  o and Deutsch, 1998).  
AEA belongs to the family of N-acyl-ethanolamines and is produced from the hydrolysis of the 
corresponding NAPEs (N-acyl-phosfatidylethanolamines), in a phospholipid-dipendent pathway. 
The enzyme responsible for this hidrolysis is NAPE-PLD, a phospholipase D selective for NAPE 
(Schmid and Berdyshev, 2002).  
2-AG is principally produced from diacylglycerols (DAGs) hydrolysis by a DAG lipase (DAGL) 
(Bisogno et al., 2005). There are two isoforms of DAGL: DAGLα and DAGLβ: the first one is 
predominant in adult CNS; the second plays an important role in 2AG synthesis during immune 
responses (Hsu et al., 2012).  
Degradation 
FAAH (fatty acid amide hydrolase) is the principal enzyme involved in anandamide turnover and, in 
some cases, 2-AG hydrolisis (Cravatt et al., 1996; Cravatt and Lichtman, 2002). FAAH is responsible 
for the degradation of multiple fatty acide amides, including PEA. It is a membran protein and it has 
a high degree of conservation between mouse and human (Bisogno et al., 2005). In addition to FAAH, 
AEA can be degradated via oxidation by COX-2 (cyclooxygenase-2), to create prostamides 
(Woodward et al., 2008). The third route of degradation is via N-acylethanolamine-hydrolizing acid 
amidase (Tsuboi et al., 2005). 2-AG can be degradated by FAAH hydrolysis or COX-2 oxidation, but 
there are other enzymes primarly involved in its degradation, as MAGL (monoacyl-glycerol lipase), 




The gastrointestinal tract 
The digestive system (systema digestorium) includes all the organs involved in the digestive 
processes. In addition to digestion and absorption, due to its continuous contact with the external 
environment, the digestive system is the largest immunological organ in the body (Denbow, 2015). 
The gastrointestinal tract is a long tube starting with the oral cavity (cavum oris) and terminating with 
the anal canal (canalis analis), and, with the teeth (dentes) and the annexed glands, composes the 
digestive system (Figure 9) (Barone, 2006). All the anatomical references are based on the Nomina 
Anatomica Veterinaria (Constantinesco et al., 2017).  
 
 





From the esophagus (esophagus) to the colon (colon), the gastrointestinal wall is composed of four 
layers (from the inner to the outer layer): mucosa (tunica mucosa), submucosa (tela submucosa), main 
muscular coat (tunica muscularis) and serosa (tunica serosa) (Figure 10). 
The tunica mucosa is composed by the epithelium (epithelium), lamina propria (LP, lamina propria 
mucosae) and muscularis mucosae (mm, lamina muscularis mucosae). The epithelium, in close 
contact with the ingested food, is responsible for the absorption of nutrient, water and electrolytes. 
The lamina propria is the home of intestinal immunitary cells, i.e. B and T lymphocytes, 
macrophages, mast cells and dendritic cells. The mm is composed of two layers: the inner circular 
layer and the outer longitudinal layer (Frappier, 2000).  
The tela submucosa is composed by connective tissue, rich in lymphatic and blood vessels, nerves, 
immune cells and, in some tracts (esophagus, duodenum), submucosal glands (Gelberg, 2014). Where 
there is no mm, the submucosa, in contact with the lamina propria, becomes a propria-submucosa. In 
the submucosa, there is the Meissner plexus, or submucosal plexus (SMP) (plexus submucosus), part 
of the ENS.  
The tunica muscularis is made of two parts: the circular muscle layer (CML, stratum circulare) and 
the longitudinal muscle layer (LML, stratum longitudinale). The CML is the inner part, and it is 
responsible for the mixing movements of the intestinal contents, while the external portion (i.e. LML) 
helps in the progression of the digested food. Between the two muscular layers resides the Auerbach 
plexus, or myenteric plexus (MP) (plexus myentericus), responsible for the contractile actions of the 
tunica muscularis (Collins and Badireddy, 2019). 
The tunica serosa is the external layer of the gastrointestinal wall, in the portion included in serosal 
cavities (mediastinum, abdomen and pelvic cavity). It is composed by connective tissue covered by 
mesothelium, a simple squamous epithelium. In the portions of the gastrointestinal tract outside from 
serosal cavity (cervical esophagus, retroperitoneal rectum), the external portion is called tunica 




Figure 10: Schematic diagram of the anatomic and histologic organization of the digestive tube. Modified from 
Kierzenbaum, 2002. 
Esophagus 
The esophagus is a muscular-membranous tube that connects the pharynx (pharynx) with the stomach 
(ventriculus). It starts with a proximal esophageal sphincter and ends with the cardias (ostium 
cardiacum), the sphincter that controls the passage in the stomach (Barone, 2006). The esophagus, 
through the course in the neck, is dorsal to the trachea except for the distal part, where it moves to the 
left (in Carnivores it remains quite dorsal). In the mediastinum, it moves again to a dorsal position 
and passes to the right of the aorta. Through the esophageal hiatus, the esophagus crosses the 
diaphragm, and after a small abdominal portion, it becomes stomach (Barone, 2006).  
The mucosa is composed of three layers: the stratified epithelium, keratinized in swines, equids, 
ruminants, rats, and mice and non-keratinized in carnivores and humans; the LP, composed by 
collagens and elastic fibers; and the mm, which is incomplete in the dog and the pig (just in the distal 
part) (Barone, 2006; Gelberg, 2014). The submucosa is made of connective tissue, rich in elastic 
fibers and really loose, to allow wide movements of the mucosa (Barone, 2006). Submucosal mucus 
glands (i.e. Brunner’s glands) are present at the pharyngeal junction in equids, ruminants, rabbits and 
rodents; in the first half of the esophagus and just some sporadic glands in the rest of the esophagus 
in the pig; throughout the esophagus in dogs and humans (Gelberg, 2014). In the horse, these glands 
are also present in the third caudal of the esophagus (Chiocchetti et al., 2015). The tunica muscularis 
is composed by the LML and the CML; it includes striated muscle cells partially mixed with smooth 
cells. Smooth muscle cells replace entirely the striated cells at the cardias in ruminants and dogs and 
in the last 4-5 cm in the pig. In humans, cats and equids, the change is gradual and it becomes complete 
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when the esophagus crosses the aorta (Chiocchetti et al., 2015). The tunica adventitia wraps the 
esophagus in the cervical portion, becoming thicker in the thorax; a full serosa is present in the small 
abdominal portion of the esophagus (Gelberg, 2014). 
Stomach 
The stomach is the first essential organ for the digestion, where the enzymatic and hydrolytic 
processes start (Frappier, 2000). It is connected to the esophagus with the cardias, and to the 
duodenum (duodenum) with the pylorus (pylorus); it is divided in fundus (fundus ventriculi), corpus 
(corpus ventriculi) and antrum (antrum pyloricum). It is more developed and dilatable in carnivores 
than omnivores or herbivores (Barone, 2006). The mucosa is completely glandular in carnivores, 
humans and rabbits. In equids, pigs ans rodents, the mucosa is just partially grandular; the aglandular 
portion is covered with stratified epithelium, and is linked to the glandular portion with an irregular 
linear area called margo plicatus. The mucosa has big gastric folds that disappear with the distension 
of the organ. The surface of the mucosa has diffuse gastric pits (foveolae gastricae), which denote 
entrances to tubular shaped gastric glands, located in the LP. The mucous secrete of the glands 
protects the mucosa from autolytic processes. The mucosa is divided, based on the kind of glands, in 
cardial region (pars cardiac), fundic region (fundus ventriculi) and pyloric region (antrum pyloricum) 
(Frappier, 2000). The cardial region is widely extended in the pig but limited to the margo plicatus 
in other species. These glands have a mucous secrete. In the fundic region, glands are composed by 
a bottom, a body, a collar, and an isthmus that comes out at the level of the gastric pits. These glands 
contain mucous cells of the collar (mucocytes), principal cells, and parietal cells in the body and 
endocrine cells in the bottom. Mucocytes are cuboid cells secreting mucus that covers the collar of 
the glands. Principal cells are the most numerous in the gastric region, and are responsible of the 
production of pepsinogen, transformed in pepsin by cloridric acid (HCl) (Frappier, 2000). The latter 
(HCl) is the product of parietal cells. Endocrine cells provide gastrointestinal hormones, such as 
gastrin, cholecystokinin or PYY (Fothergill et al., 2019). The pyloric region occupies half of the 
stomach in carnivores, and the pyloric glands contain typical mucus secreting cells. The submucosa 
is closely linked to the mucosa, following the gastric folds (Barone, 2006). The tunica muscularis, as 
the other intestinal tracts, includes a LML and CML; the serosa is made up by the visceral peritoneum 
(Barone, 2006).  
Small intestine 
The small intestine (intestinum tenue) is a fundamental component of the digestive system, which 
allows the absorption of important nutrients. The small intestine includes duodenum, jejunum 
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(jejunum) and ileum (ileum). The duodenum is the first section, connected to the antrum of the 
stomach by the pylorus. The duodenum surrounds the right lobe of the pancreas (in Carnivores), in 
the shape of a "C." The duodenum is a “mixing pot”, where the intestinal digestion starts. It receives 
the chyme from the stomach, pancreatic enzymes to break down the products from the stomach, and 
bile from the liver for the digestion and absorption of fat from food products. The jejunum is the 
longest (and the most mobile) portion of the small intestine, and with the ileum is principally involved 
in absorption. The ileum is the last part of the small intestine; its major absorptive products are vitamin 
B12 and bile acids (Collins and Badireddy, 2018). The histological structure of the wall is almost 
similar in all the small intestine, showing just little differences. The serosa consists of loose 
connective tissue covered by mesothelium (Frappier 2000). The tunica muscularis consists of the thin 
LML (thicker in the horse), and the CML. In the connective tissue between the two layers there is the 
MP (Frappier, 2000; Collins and Badireddy, 2018). The submucosa is made of connective tissue that 
contains blood and lymphatics vessels, and the SMP. Brunner’s glands are submucosal mucous glands 
in dogs and ruminants, serosal glands in equids and sero-mucosal in the cat (Frappier, 2000). All 
along the small intestine, but especially in the ileum, the submucosa includes the Peyer’s patches, 
which are aggregated lymphatic nodes. The mucosa is composed by epithelium, LP and mm. The 
mucosa is designed for the maximal absorption, so it is covered by intestinal villi (villi intestinales), 
protrusion of the mucosa that increases the surface area (Collins and Badireddy, 2018). The intestinal 
glands, also called crypt of Lieberkühn or intestinal crypt, are located between the villi. Villous height 
and crypt depth decrease aborally. There is a variety of epithelial cell types in the intestine, produced 
by progenitor cells in the crypts: enterocytes, mucous goblet cells, enteroendocrine cells (EECs), 
Paneth cells, and M cells (Figure 11) (Leibich, 2012).  
 
Figure 11: Schematic illustration of the epithelial cell types of the small intestine. Modified from Gelberg, 2014. 
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Enterocytes are the principal cells of the intestinal mucosa. Microvilli, on the apical surface of 
enterocytes, increase their surface area, creating the brush border. Mucous goblet cells decrease going 
from the botton to the apex of the villi, and increase going aborally towards the large intestine 
(Gelberg, 2014). These cells produce mucus, fundamental to help the progression of the intestinal 
content, protect the mucosa from bacterial invasion or to avoid autolytic processes (Liebich, 2012). 
Enteroendocrine cells (EECs) are the source of gastrointestinal hormones, like gastrin, secretin, 
cholecystokinin, PYY, 5HT or others (Fothergrill and Furness, 2018). Historically, they were named 
with a letter code, considering the hormone produced or ultrastructural features identified by electron 
microscopy (Table 1). In the last decades, different studies highlight the fact that EECs usually 
contain more than one hormone, usually concentrated in separated vescicles (Helander and Fändriks, 
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GIP, ghrelin, secretin, 
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ECL (EC-like) Similarity to EC cells histamine pancreastatin 
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A for similarity to 
















N Neurotensin content Neurotensin GLP-1, PYY 




M Motilin content Motilin 5HT, ghrelin 
Table 1: The historical naming of enteroendocrine cells. Modified from Fothergrill and Furness, 2018.  
Paneth cells are interspersed between the intestinal stem cells in the intestinal glands. Their cytoplasm 
contains large acidophil granules, rich in lysozyme (Frappier, 2000). M cells are considered as 
phagocytary cells, able to tie to alimentary, bacterial or viral antigens and to bring them to the closest 
lymphocytes, causing an immunitary response (Samuelson, 2007). The lamina propria of the mucosa 
creates the axis of the villi and surrounds the intestinal glands. Inside this layer, there are blood and 
lymphatic vessels, smooth muscle cells, fibrocytes, lymphocytes, plasmacells, and mast cells 
(Frappier, 2000). In the central portion of the lamina propria of the villus, there is the central lacteal, 
a lymphatic capillary that absorbs dietary fats. Two layers of smooth muscular cells, longitudinal and 
circular, as usually compose the muscular layer (mm) of the mucosa. 
Large intestine 
The large intestine (intestinum crassum) begins at the terminal ileum with the cecum (cecum), 
continues with the colon, rectum (rectum), and terminates with the anal canal (Kahai et al., 2018). In 
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the large intestine there is the absorption of water and electrolyte and the secretion of mucus, to help 
washing the intestinal contents and extracting the last nutrients (Frappier, 2000; Barone, 2006). The 
large intestine is more developed in herbivores (especially non-ruminants) than carnivores, to help 
the demolition of great amount of aliments containing cellulose. The characteristic of the large 
intestine, preserved in all the tracts, are absence of villi and development of intestinal glands, increase 
number of goblet cells, and increasing number of lymphatic nodules (noduli lymphatici) (Frappier, 
2000). The cecum is a fermentation chamber, important in equids and not developed in carnivores. 
In all its extension, the cecum shows a great number of lymphatic nodules. The colon, as the cecum, 
is developed in equids and in the pig. The mucosa of the colon is thicker than in the small intestine 
because of the longer intestinal glands. The rectum is the terminal part of the large intestine. The 
mucosa is similar to the cecum and colon, with an increased number of goblet cells. The serosa 
surrounds the rectum in the cranial portion, while the retroperitoneal tract is covered by an adventitia. 
The anal canal is the termination of the digestive tube that connect the rectum with the outside 
(Barone, 2006). As highlighted before, the structure of the large intestinal wall is quite similar along 
its course.The serosa surrounds the large intestine until the cranial portion of the rectum. The inner 
circular and outer longitudinal muscle layers compose the tunica muscularis. The submucosa is 
similar to the small intestine, except for the cecum and rectum, where it is thicker for the presence of 
numerous lymphatic nodules. The mucosa shows thick mm, a lamina propria rich in lymphocytes, 
and an epithelium with numerous intestinal glands, longer than in the small intestine and richer in 
goblet cells that deepen until the mm. At the bottom of the glands, numerous stem cells are responsible 
for the epithelial renewal (Barone, 2006). The anal mucosal drastically changes, showing a stratified 
squamous epithelium.  
The Enteric Nervous System  
The enteric nervous system (ENS) is a complex network of neurons and glial cells in the gut wall that 
controls many functions of the intestinal tract, such as motility, absorption, secretion, and it is 
involved in pathological processes of the digestive system (Lake and Heuckeroth, 2013). The ENS 
interacts with the CNS, but in the same way, it can control the digestive functions without relying on 
commands from the CNS. The enteric nervous system interacts also with the endocrine and immune 
systems, and has roles in modifying nutrient absorption and maintaining the mucosal barrier (Furness, 
2012). In humans, the ENS is composed of 400-600 millions of neurons and even more supporting 
cells. Nerve cells and glial cells are grouped in small clusters that compose the enteric ganglia, which 
are connected to each other by nerve fiber bundles (Furness, 2006). There are two major plexuses, 




Figure 12: Organization of the ENS in human and medium/large mammals. Modified from Furness, 2012. 
The MP is located between the longitudinal and circular layers of the tunica muscularis, while the 
SMP is located in the submucosa, between the muscularis mucosae and the CML. MP and SMP are 
connected between each other by vertical fibers, perpendicular to the CML (Furness, 2006). The MP 
is continuous around the wall and along the entire gastrointestinal tract, from the upper esophagus to 
the internal anal sphincter (Figure 13). MP ganglia are larger and more numerous than those within 
the SMP, and are connected with primary strands, with longitudinal course, which constitute, together 
with the ganglia, the MP primary plexus. The secondary plexus is composed by nerve fibers parallel 
to the CML. The tertiary plexus includes the smallest interconnecting strands, which supply the LML. 
The SMP can be identified in the intestine; sporadic ganglia can be found also in esophageal and 
gastric submucosa, but they do not constitute a real plexus (Schemann et al., 2001). In the esophagus 
of the horse, the SMP is well developed and organized in two layers (Chiocchetti et al., 2015). As the 
MP, the SMP is continuous around the circumference and for all the length of the small and large 
intestine (Furness, 2006). In the SMP of large mammals, ganglia form different plexuses that lie on 
distinct layers, constituting an inner and an outer plexus. Briefly, neurons of the MP mainly regulate 
muscle functions, while SMP neurons should control epithelial functions. However, it is known how 
some neurons of the outer SMP participate, in large mammals, in the innervation of the CML and 
LML, while the inner SMP supplies principally the mucosa (Porter et al., 1999). Both plexuses control 




Figure 13: Distribution of enteric ganglia in the tubular digestive tract. Modified from Furness, 2006. 
Neurons 
Enteric neurons are classified considering their shape, neurochemical code, projections, 
electrophysiological properties, and function. In 1989, using a methylene blue staining, Dogiel 
identified three type of neurons, named Dogiel types I, II and III. In the following years, several 
authors proposed new classifications, arriving at a new classification including type I, II, III, IV, V, 
VI and VII and “mini-neurons” (Brehmer, 2006). The neurochemical code is the combination of 
messengers that a neuron contains (Costa et al., 1996). Primary neurotransmitters include 
Acetylcholine (Ach) and tachykinins (as substance P, SP) in excitatory motor neurons, vasoactive 
intestinal polypeptide (VIP) and nitric oxide (NO) in inhibitory motor neurons. While primary 
neurotransmitters are conserved across species and along the gastrointestinal tract, secondary 
neurotransmitters are different considering the various tract and the different species (Furness, 2006). 


















Enteric inhibitory muscle motor neuron NO 
VIP; ATP carbon 
monoxide 
PACAP, opioids 
Ascending interneuron Ach Tachikinin, ATP Calretinin, enkephalin 
ChAT, NOS descending interneuron ATP, Ach ND NO, VIP 
ChAT, 5-HT descending interneuron Ach 5HT, ATP ND 
ChAT, somatostatin descending interneuron Ach ND Somatostatin 






Interneurons supplying secretomotor 
neurons 
Ach ATP, 5HT ND 
Non cholinergic secretomotor neuron VIP PACAP NPY (in most species) 
Cholinegic secretomotor neuron Ach ND Calretinin 
Motor neuron to gastric cells GRP, Ach ND NPY 
Motor neurons to parietal cells Ach Potentially VIP ND 
Sympathetic neurons, motility inhibiting Noradrenaline ND NPY in some species 




Sympathetic neurons, vasoconstrictor Noradrenaline, ATP Potentially NPY NPY 
Intestinofugal neurons to sympathetic 
ganglia 
Ach VIP 
Opioid peptides, CCK, 
GRP 
Table 2: Neurotransmitters in the digestive tract. Modified from Furness, 2012.  
Abbreviations: 5-HT, 5-hydroxytryptamine; ACh, acetylcholine; CCK, cholecystokinin; ChAT, choline acetyltransferase; 
CGRP, calcitonin gene-related peptide; GRP, gastrin releasing peptide; ND, not determined; NPY, neuropeptide Y; NOS, 




Considering their function, enteric neurons can be classified in motor neurons, interneurons, intrinsic 
primary afferent neurons (IPANs), and intestinofugal primary afferent neurons (IFANs) (Furness, 
2003). Motor neurons can be excitatory and inhibitory, and are responsible to innervate gut 
musculature (LML, CML and mm); they are located principally in the MP and, to a lesser extent, in 
outer and inner SMP (outer> inner) in humans and large mammals (Hens et al., 2001). Enteric 
interneurons are present in all the gut, but differ among the different tracts (Furness, 2006); these 
neurons are mainly localized in the MP, but have long projections that extend orally and anally 
(Bornstein et al., 2004). IPANS are intrinsic primary afferent neurons that respond to different stimuli, 
such as luminal chemicals, distortion and mechanical stimulation of the mucosa (Furness, 2006). 
IFANS are intestinofugal primary afferent neurons that have the cell bodies in the gut wall, with their 
processes going to prevertebral ganglia, where they interact with post-ganglionic sympathetic neurons 
(Szurszewski et al., 2002). The sympathetic neurons innervated by IFANs are inhibitor neurons for 
motility and secretion (Furness, 2006). 
Enteric glial cells  
Enteric glial cells (EGCs) were first observed in 1899 by Dogiel. The word glia derived from the 
Greek “γλοια”, that means “glue” of the enteric nervous system (ENS). EGCs are satellite cells, which 
represent the largest cell population of the ENS, outnumbering from three to five times enteric 
neurons (Gabella, 1981; Jessen, 2004; Furness, 2006). EGCs are small cells with a star-like shape, 
comparable to astrocytes in the CNS. They envelop enteric neuronal cell bodies and axon bundles, 
and their processes reach the intestinal mucosa (Ruhl, 2005). Differently from neurons, they are not 
excitable cells, but they communicate through Ca++ signalling, and integrate their informations with 
neurons, immune cells, and other cells of the gastrointestinal tract (Ochoa-Cortes et al., 2016). EGCs 
can be found in MP and SMP, but also in smooth muscle layers and gut mucosa (Hoff et al., 2008). 
Considering their localization, EGCs are divided into four types: type I, with a star-shaped 
morphology within ganglia; type II, more elongated, for interganglionic EGCs; type III for mucosal; 
and type IV for intramuscular EGCs (Boesmans et al., 2015). Until recently, structural support was 
considered their main function, but recently it was highlighted their vital role in gut homeostasis 
(Ochoa-Cortes et al., 2016). In physiological conditions, EGCs are principally involved in neuronal 
functions (neuroprotection, neuromediator expression, or neuronal renewal) and regulation of 
intestinal epithelial barrier (IEB) homeostasis. Under pathological conditions, such as inflammation 
or bacterial stimulation, reactive enteric gliosis can develop. Altered enteric gliosis can both 
exacerbates intestinal inflammation and protect IEB and neurons from inflammatory processes 
(Neunlist et al., 2014).  
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Intertitial cells of Cajal  
Interstitial Cajal cells (ICC) were first described by Santiago Ramòn y Cajal in 1889, and he defined 
them “interstitial neurons” because they were labeled through staining techniques specifically for 
neurons (as methylene blue or silver impregnation), and were found in the interstitium between nerve 
endings and smooth muscle cells (Cajal, 1911). ICC are fusiform cells with few processes, with a 
large oval nucleus containing one or more nucleoli (Faussone-Pellegrini and Thuneberg, 1999). 
According to Cajal, these cells modulate the contraction of smooth muscle cells of the GI tract. After 
him, several groups studied these cells, understanding they were not neuronal cells, and defined them 
as Interstitial Cajal cells. ICC are considered as pace-maker cells of the alimentary tract. Cajal cells 
are characterised by ability to spontaneously depolarise and create slow waves, generating the basic 
electrical rhythm of smooth muscle cells. Slow waves migrating from ICC toward myocytes of the 
longitudinal layer, induce electrotonic energy within internal circular layer. Removal of ICC causes 
a lack of slow waves in the remaining part of smooth muscle cells (Pasternak et al., 2016). Pacemaker 
ICC activity starts with periodic release of Ca++ from endoplasmatic reticulum, which activates 
mitochondria to intake ions, generating the potential energy (Ward et al., 2000).  
The endocannabinoid system and the GUT  
The endocannabinoid system (ECS) participates in many physiological functions of the gut (Taschler 
et al., 2017). Its role has been demonstrated in regulation of the appetite, intestinal motility, secretion, 
nausea and emesis, visceral nociception and inflammation (Izzo and Sharkey 2010). The CB1R is 
involved in the regulation of appetite: CB1 agonists, such as THC, stimulate appetite and promote 
weight gain (Matias and Di Marzo, 2007). Otherwise, CB1 antagonists, as rimonabant, were used in 
the treatment of obesity, reducing the ingestion of food and the body weight (Riedel et al., 2009). The 
PPARα stimulation evokes satiety as an answer to the ingestion of food (Lo Verme et al. 2005). The 
principal problem with CB1R drugs is the distribution in the CNS, with psychoactive effects. 
Therefore, in these last years researchers focus on developing new drugs to act selectively in the 
periphery, avoiding the action on the CNS (Izzo and Sharkey, 2010).  
Different cannabinoid receptors, e.g. CB1R, GPR55 and TRPV1, reduce intestinal motility both in 
physiological and pathological conditions. Their action is principally linked to the presence of CBRs 
in the muscular layers and in the myenteric and submucosal plexuses, highlighting the importance of 
the interaction between the ECS and ENS (Pertwee, 2001). The CB1R has also an inhibitory effect 
on gastrointestinal secretion and on visceral hyperalgesia, as CB2 receptor; this effect is enhanced in 
inflammatory conditions (Mahmud et al., 2009). Moreover, CBR agonists are used to reduce nausea 
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and emesis associated with chemotherapy. In animal models, the phytocannabinoid cannabidiol 
(CBD) has been demonstrated to significantly reduce nausea and vomit (Izzo and Sharkey, 2010).  
Increasing evidences show that CBR expression and/or the level of endocannabinoids are altered in 
patients with intestinal diseases, suggesting a possible role of the ECS in intestinal pathophysiology 
(Izzo and Camilleri, 2009; Alhouayek and Muccioli, 2012). Studies on animal models reinforce the 
hypothesis that drugs acting on ECS, such as CBR agonists or inhibitors of degradating enzyme 
FAAH and MAGL (resulting in increased endocannabinoids), can have protective properties from 
intestinal inflammation (Kimball et al., 2006; Alhouayek et al., 2011). For example, CBD, with low 
affinity for CB1 and CB2, exerts its protective role in colitis acting both directly on other cannabinoid 
receptors and inhibiting FAAH (Bisogno et al., 2001). PEA reduces intestinal inflammation and 
permeability in murine colitis acting via CB2R, GPR55, PPARα and TRPV1 (Esposito et al., 2013; 
Borrelli et al., 2015). 
Chronic enteropathies  
Chronic gastrointestinal inflammatory pathologies can affect humans and animals, with deep 
consequences in the quality of life and, considering productive livestock, in the production. These 
enteropathies show some common elements in the pathogenesis, clinical presentation or therapies 
between different species. Therefore, studying chronic enteropathies in animals can be useful both 
for veterinary and human medicine.  
Humans 
Inflammatory bowel disease (IBD) is a global healthcare problem, with an increasing incidence in 
the last years (Xavier and Podolsky, 2007). IBD is a chronic, uncontrolled inflammation of the 
gastrointestinal tract; although the etiology remains uncertain, the environment, genetic alterations, 
the intestinal microbiota and the immune system are involved in the pathogenesis (Figure 14) (Zhang 
and Li, 2014). The two most common subtypes are Crohn’s disease (CD) and ulcerative colitis (UC), 
which present some differences (Hanauer, 2006). CD can affect every part of the GI tract (principally 
ileum and perianal region), while UC is usually limited to the colon. Moreover, CD inflammatory 
process is transmural, UC tendentially mucosal. Finally, CD is associated with complications such as 




Figure 14: Factors implicated in the pathophysiology of inflammatory bowel disease (IBD). Modified from Karantos 
and Gazouli, 2011. 
Laboratory animals as rats, mice or guinea pigs are often used as model for human pathologies, 
inducing iatrogenic mucosal inflammation with chemicals. Dextran sulfate sodium (DSS)-induced 
colitis is a model of Th2 mediated immune response; trinitrobenzene sulfonic acid (TNBS)-induced 
colitis is more dominated by a Th1 response (Wirtz et al., 2007; Alex et al., 2009). In these 
experimental models of IBD, the ECS is overexpressed compared to healthy animals (Kimball et al., 
2006). Indeed, the tissue levels of CBR are also altered in these experimental models: CB1R is 
increased in MP neurons of colon of inflamed mice, and blocking CB1 with antagonists increases the 
severity of DNBS (2,4-dinitrobenzene sulfonic acid) and DSS colitis (Massa et al., 2004). In another 
study in models of induced-colitis in mice, CB1R and CB2R agonists both reduced inflammation 
improving disease symptoms and decreasing histological inflammatory scores (Kimball et al., 2006). 
Analysis of the ECS in biopsies from IBD patients evidences increased AEA levels in mucosal 
biopsies of UC colons vs control biopsies (D’Argenio et al., 2006). However, another study shows 
that AEA levels were lower in inflamed mucosa than in controls, with a reduced level of NAPE-PLD 
(AEA- synthesizing enzyme) and increased FAAH (AEA-degrading enzyme) (Di Sabatino et al., 
2011). In the same study CB1R but not CB2R was over-expressed in CD and UC patients; otherwise 
other studies evidenced an increased CB2R in inflamed tissues (Wright et al., 2005; Mahmud et al., 
2009). Although results from literature are often in contrast, different prospective studies found a 
benefit in the use of cannabinoids for IBD. A prospective placebo-controlled study in 21 patients with 
CD, consisting in 8 weeks-protocol with cannabis, shows beneficial effects as improved appetite and 
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sleep in 90% of patients (Naftali et al., 2013). Another study on 100 patients with UC and 191 with 
CD reveals that 33% of UC subjects and 50% of CD were cannabis-lifetime users, to reduce IBD-
related symptoms such as diarrhea and abdominal pain (Longstreth et al., 2006). 
In addition to CD and UC, the role of the ECS has been evidenced in different intestinal diseases in 
humans, as Irritable Bowel Syndrome (IBS), diverticulitis, celiac disease and colon cancer (Table 3) 
(Lee et al., 2016). 
 
Table 3: Expression levels of the endocannabinoid system in intestinal diseases. Modified from Lee et al., 2016. 
A great body of evidences demonstrated a bidirectional pathway between the gastrointestinal tract 
and the central nervous system (CNS), both in healthy conditions and neurodegenerative diseases, 
such as Alzheimer's and Parkinson's disease. Patients affected by AD or PD often show 
gastrointestinal symptoms. Therefore, investigating the ECS in the GI tract can give benefits to the 
research in different fields. 
Although there are different prospective studies and reviews about the use of cannabinoids for 
gastrointestinal diseases, the evidences are not enough to suggest these molecules as approved 
therapies. Their use is nowadays regarded as individual therapeutical trial, based on the effects on 
nociception and symptoms in every different patient (Häuser et al., 2017).  
We performed one study about the ileum of the rat:  





Canine chronic enteropathies (CE) were described as IBD until some years ago. The multifactorial 
etiology (environment, genetic, microbiota and immunity) corresponds to human IBD, but the clinical 
presentation, with a major involvement of the small intestine (duodenum and ileum), and the 
treatment (Figure 15) are quiet different (Jergens and Simpson, 2012; Dandrieux, 2016).  
 
Figure 15: Stepwise medical treatment approach of IBD in humans and CE in dogs. Modified from Dandrieux, 2016. 
5-ASA: 5-aminosalicylyc acids compounds; biologic therapy: TNF antagonists, anti-adhesion molecule. 
The clinical signs are quiet aspecific: vomit and diarrhea, decreased or increased food intake, weight 
loss and other gastrointestinal signs that persist for more than 3 weeks defined a chronic pathology. 
Signalment and medical history can help in evaluating any predisposition, such as breed (Boxer or 
German Shepherd dogs are exemples of predisposed breeds), age (usually allergies are more frequent 
in young patients, while “IBD” phenotype is more typical of middle age dogs) or previous 
gastrointestinal pathologies (e.g. parvovirus, giardiasis) (Cave, 2013). The initial diagnostic protocol 
(Table 4) must exclude other pathologies, because these symptoms can be referred to gastroenteric, 
extragastroenteric or metabolic syndrome (Simpson and Jergens, 2011). After the exclusion of other 
diseases and the identification of a chronic enteropathy, the diagnosis of the phenotype depends on 




Table 4: Initial diagnostic approach to chronic diarrhea. Modified from Simpson and Jergens, 2011. 
The first step is to introduce, for a period of at least two weeks, an exclusive diet, with a novel protein 
or a hydrolyzed diet (Verlinden et al., 2006; Mandingers et al., 2010). It is known that many dogs 
respond to diet alone, so it is important to consider it the first-line treatment with mild to moderate 
symptoms (Dandrieux, 2016). If there is not a complete remission of the symptoms, the second step 
is usually the association of an antibiotic, to act on the dysbiosis to restore a correct gut microbiota. 
The first line-antibiotics in CE are tylosine or metronidazole (Westermark et al., 2005). However, the 
increasing problem of the antibiotic resistance and the uncomplete response of dogs with CE to 
antibiotics is limiting their use. If these therapies are not sufficient to treat the patients, it is 
fundamental to pick up gastrointestinal biopsies during a gastro-duodenum-ileal-colonscopy, for 
histopathological examination. The chronic intestinal inflammation is usually characterized by 
different degrees (from mild to severe) of lymphoplasmacytic enteritis or eosinophilic enteritis, but it 
is fundamental to exclude intestinal lymphoma. Typically dogs that do not respond to the change of 
diet and the antibiotic therapy, need the introduction of an immunosuppressant therapy (Allenspach 
et al., 2007). 
In 2016 Dandrieux proposed a new classification for canine chronic enteropathies, based on the 
answer to the terapeuthical trial (Allenspach et al., 2007). Canine CE were finally classified in food 
responsive enteropathy (FRE), antibiotic responsive enteropathy (ARE), immunosoppressant 




Figure 16: Classification of canine chronic enteropathies based on the response to treatment. Modified from 
Dandrieux, 2016. 
This classification (Figure 16) highlights how a little group of dogs (the top of the pyramid) does not 
respond to any treatment (NRE), so researchers are continuosly studying for new therapeutic 
approach, following findings in human medicine. Probiotics, fecal microbiota transplantation or 
intestinal stem cells (ISCs) are considered a new therapeutical approach during canine CE (Makielski 
et al., 2019). Probiotics have different action on the GI, including the support of the epithelial barrier, 
the regulation of the mucosal immune system and the modulation of the microbiota (Jergens, 2010).  
Between all the new therapeutical possibilities, cannabinoids are gaining more and more interest, due 
to their antinflammatory, analgesic and other beneficial properties. Literature about cannabinoids and 
the dog is still in its infancy. Excluding the CNS distribution, CB1R has been immunohistochemically 
identified in canine salivary gland cells (Dall’Aglio et al., 2010), hair follicles (Mercati et al., 2012) 
and skin, in both healthy subjects and dogs with atopic dermatitis (Campora et al., 2012). As CB1R, 
CB2R were present in hair follicles and skin of healthy and AD dogs; the level of the two receptors 
in atopic dogs were higher than in healthy subjects. The expression of these receptors on cutaneous 
mast cells, notoriously enrolled in allergic disease, suggests potential benefits of cannabimimetic 
compounds, as PEA, in canine allergic cutaneous disease (Campora et al., 2012). A recent 
randomized, vehicle controlled, double blinded study in atopic Beagles using a topical 
endocannabinoid membrane transporter inhibitor (WOL067-531) showed a reduction in allergic 
flares and pruritus without adverse effects (Marsella et al., 2019).  
Despite the multiple evidences in human gastrointestinal diseases, there are no studies about the 
treatment of canine chronic enteropathies with cannabinoids or related compound. For this reason, 




In dogs, we performed one study related to the endocannabinoid system: 
 Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine 
gastrointestinal tract. 
We performed other studies, focusing on chronic enteropathies:  
 The relationship between duodenal enterochromaffin cell distribution and degree of 
inflammatory bowel disease (IBD) in dogs. 
 Effect of an extruded animal protein-free diet on fecal microbiota of dogs with food-
responsive enteropathy. 
 Effects of Chronic Enteropathies on VIPergic and Nitrergic Immunoreactive Neurons in 





Chronic enteropathies in cats include food responsive enteropathy, IBD and intestinal lymphoma 
(Bottero et al., 2019). Risk factors such as genetic and molecular alterations, diet, and chronic 
inflammation have been connected to the development of these disorders (Garraway et al., 2018). 
Chronic intestinal inflammation in cats seems to be linked to an aberrant T cell response to enteric 
bacteria in predispose subjects. As seen in dogs and humans, environmental factors can stimulate an 
inflammatory onset or modulate genetic susceptibility to disease (Jergens, 2012). Affected cats are 
usually middle age, and some breeds as Siamese or other Asian breeds seem to be over-represented 
(Jergens et al., 1992). Gastrointestinal signs in cats with CE include chronic weight loss, vomiting, 
disorexia and diarrhea (Garraway et al., 2018). The clinical presentation is often cyclical, with period 
of remissions and other of exacerbations (Jergens et al., 2012). Trigger factors include dietary 
indiscretions, exposure to intestinal pathogens or drugs (Jergens, 1999). After the exclusion of 
infectious, extra GI or metabolic diseases, anatomical abnormalities, the differential diagnosis are 
FRE, feline IBD and intestinal lymphoma, with some differences in predisposition and clinical 
presentation (Table 5).  
 
Table 5: Comparative features of feline IBD, FRE and lymphoma. Modified from Jergens, 2012.  
Therefore, the first step, as seen in dogs, is a dietary trial with antigen-restricted or hydrolyzed 
petfood. In a study including 55 cats with CE, 49% of the patients responded to dietary modifications 
as primary treatment (Guildford et al., 2001). Differentiating IBD from alimentary lymphoma is more 
challenging, and requires the acquisition of endoscopic - or better laparotomic - biopsies for 
histological, immunohistochemical examination or clonality (Evans et al., 2006). The use of 
antibiotics in feline CE is not well demonstrated as in dogs. The principal antibiotics are, as for canine 
CE, tylosine or metronidazole. Treatment for feline IBD includes corticosteroids and various 
immunosuppressive agents, as chlorambucil or ciclosporin (Jergens et al., 2010).  
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In cats, we performed one study related to the endocannabinoid system: 
 Localization of cannabinoid receptors in the cat gastrointestinal tract. 
We performed a comparison between the dog and the cat: 





Colic is a frequent digestive disorder of equines and includes different form of abdominal pain 
(Pilliner and Davies, 2004). It is an important cause of death for horses and a primary health concern 
of owners (Worku et al., 2017). There could be a breed predisposition: thoroughbreds and Arabs are 
overrepresented (Traub-Dargatz et al., 2001). Horses suffering for chronic gastrointestinal 
inflammation usually present recurrent colic, weight loss, poor performances and lethargy (Kalck, 
2009). Malabsorption syndrome in horses are classified as IBD. Equine IBD can affect both the small 
and/or the large intestine, and it is classified considering the mucosal or submucosal infiltration, 
including granulomatous enteritis (GE), lymphocytic-plasmacytic enterocolitis (LPE), multisystemic 
eosinophilic epitheliotropic disease (MEED), diffuse eosinophilic enterocolitis (DEE) and 
proliferative enteritis (PE) (Boshuizen et al., 2018). Colic can be either medical or surgical; it usually 
involves large colon, followed by small intestine, caecum and small colon (Worku et al., 2017). 
Usually medical treatment includes fluid therapy, analgesics and antimicrobials (Fielding, 2018). 
Colic is one of the most dangerous emergency problem for horses and one of the principal cause of 
death (Curtis et al., 2019). For this reason, also in equine medicine, the research is focusing on novel 
therapies for management of pain and gastrointestinal diseases, but studies on the evaluation of the 
ECS in horses are still lacking.  
Therefore, in horses, we performed a preliminary study about the endocannabinoid system in the 
equine gastrointestinal tract: 





Gut health in pigs is fundamental in all the stage of growth and development, and have consequences 
in swine production (Pluske et al., 2018). Infective pathogens are often involved in diarrhea and 
gastroenteritis in pigs (Burrough, 2017; Rhouma et al., 2017). Stressors associated with breedings 
and critic period as weaning and post-weaning can affect the structure and the function of the GI tract 
(Celi et al., 2017). Therefore, management of an adeguate diet, a functional gut barrier, an appropriate 
microbiota and an effective gut immune system are fundamental to guarantee the gut health. Studies 
about the porcine gastrointestinal tract have consequences both on veterinary and human medicine. 
Pigs are omnivorous animals, whose digestive tract is functionally similar to humans. The interaction 
between the ECS and the gastrointestinal tract in pigs has been poorly investigated. A study in 2000 
analyzed the distribution of CB1R in porcine enteric nervous system (Kulkarni-Narla and Brown, 
2000). In the porcine ileum and colon, CB1R immunoreactivity was found in neurons and fibers in 
MP and SMP, often colocalized with ChAT. The inhibitory effect of CB1R on cholinergic 
neurotransmission in the MP can induce a reduction in peristaltic contractions. The presence of CB1R 
in SMP neurons and nerve fibers explains the effect of this receptor in mucosal secretory and immune 
function. Acetylcoline stimulates also chloride secretion in the mucosa of the colon, therefore 
colocalization between CB1R and ChAT may regulate ion transport across the porcine colonic 
epithelium. Another study found that the vanilloid receptor TRPV1 was also expressed by myenteric 
and submucosal neurons and fibers in the porcine ileum (Poonyachoti et al., 2002). Enteric neurons 
expressing vanilloid receptors, as cannabinoids, may constitute a target for the development of drugs 
alleviating painful intestinal inflammatory or dysmotility diseases.  
In pigs, we performed one study about the gastrointestinal tract: 
 Distribution and co-expression patterns of specific cell markers of enteroendocrine cells in 
pig gastric epithelium. 
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Dorsal root ganglia 
Dorsal root ganglion (DRG) looks like the enlargement of a nerve, made by a group of cell bodies 
(Fletcher, 2009). The DRG contains the cell bodies of primary sensory neurons, responsible for the 
transduction and modulation of sensory information and the trasmission to the spinal cord (Krames 
et al., 2015). Different studies in the last years highlighted the important role of DRGs in managing 
neuropathic pain (Deer et al., 2013; Pope et al., 2013). Therefore, DRGs could be an interesting 
therapeutical target in neuropathic pain-conditions. 
Anatomy 
Spinal nerves, composed by afferent sensory dorsal axons (the dorsal root) and motor ventral efferent 
axons (the ventral root) carry autonomic, motor, and sensory informations between the spinal cord 
and the periphery (Sheng et al., 2010). When the dorsal sensory root exits the intervertebral neural 
foramina between two vertebral segments, it forms the dorsal root ganglion (Krames, 2014). The 
DRG is a collection of cell bodies of neurons surrounded by glial cells; the axons of the DRG sensory 
cells form the primary afferent sensory nerve. DRG neurons are defined pseudounipolar neurons, 
because the axon is divided in two branches, one branch extending from the T-junction to the 
periphery and one branch to the spinal cord. Otherwise, in bipolar cells, the body lies within the path 
of the axon (Figure 17). Primary afferent neurons could be classified according to various 
morphological, physiological and biochemical characteristics. An old morphological classification 
divided neurons into two main groups: ʺlightʺ (L) cells, rich in neurofilament, and the neurofilament-
poor ʺdarkʺ (D) cells, according to the appearance at light and electron microscopy. These cells have 
been further subdivided considering other characteristics, but the most adopted is the subdivision by 
size (Willis and Coggeshall, 1992). The classification in small and large size neurons has been done 
in different species, such as mouse, rat, cat and horse (Lawson et al., 1979; Lawson et al., 1984; Lee 
et al., 1986; Russo et al., 2011). Moreover, DRG neurons can be classified by the characterization of 
their neurochemical code. The neuronal content is a great marker of the functional activity of primary 





Figure 17: A pseuodunipolar sensory neuron (1) and a bipolar cell (2). In a pseuodunipolar sensory neuron one axon is 
divided into two separate branches, one from the periphery to the body and one from the body to the spinal cord. In 
bipolar cells, the body lies within the path of the axon. Modified from Krames, 2014. 
Except of neurons, each DRG contains fibrous tissue, macrophages, nerve fibers, and supporting 
cells, which are glial cells (Kolesár et al., 2017). The glial cells of the PNS primarily include Schwann 
cells and satellite glial cells (SGCs). 
Schwann cells are the most abundant glial cells in the PNS. They include two major phenotypes, 
myelinating and non-myelinating Schwann cells (Wey et al., 2019). 
Schwann cells, as SGCs, originate from migrating cells of the neural crest, which can convert to 
different large polarized cell types, such as peripheral neurons, melanocytes or endocrine cells (i.e 
thyroid C cells or adrenal medulla) (Lobsiger et al., 2002; Mirsky et al., 2008).  
Initially, Schwann cells surround the external margins of the axon bundles (Kidd et al., 2013). During 
maturation, myelinating Schwann cells incorporate larger axons to produce a myelin sheath, 
otherwise non myelinating Schwann cells embed smaller axons (Pereira et al., 2012; Kidd et al., 
2013). Schwann cells support axonal outgrowth by producing a variety of growth factors, such as 
brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and glial cell line-derived 
neurotrophic factor (GDNF) (Kidd et al., 2013). 
SGCs surround the cell bodies of DRG neurons (Ballabh et al., 2004). In general, each sensory neuron 
has its own “envelope”, which consists of several SGCs; the neuron and its surrounding SGCs create 
a morphological and functional unit (Hanani, 2005). Neurons, sending fine processes into 
invaginations of SGCs, create an extension to their surface area (by 30-40%) and may allow an 
interaction between the two cell types (Pannese, 2002).  
DRG and neuroinflammation 
A growing body of literature indicates that DRGs are involved in developing and maintaining 
neuropathic pain (Figure 18) (Vancamp et al., 2017). In response to tissue inflammation, DRG 
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produces changes in glial cells, nerve growth factors, chemokines; and produces genetic change and 
change in ion channels, as an answer to an inflammatory stimulus (Krames, 2014).  
 
Figure 18: DRG response to tissue inflammation. In response to tissue inflammation or injury of a peripheral afferent 
fiber, the dorsal root ganglion (DRG) produces changes in glial cells, chemokines, nerve growth factors, gene expression, 
and ion channels including Na+ channels, K+ channels, and Ca++ channels. Modified from Krames 2014. 
Schwann cells play a key role in the study of neuropathic pain. These cells are involved in the 
development of allodynia through a MHC class II-mediated mechanism. Schwann cells act as 
conditional APCs (antigen presenting cells) under inflammatory conditions: MHC class II activation 
stimulate CD4+ T cells, promoting neuropathic pain (Hartlehnert et al., 2017). TRPA1 expression on 
Schwann cells seems to be involved in the pathogenesis of neuropathic pain. In mice, TRPA1 
silencing in Schwann cells decreased mechanical allodynia and neuroinflammation (De Logu et al., 
2017). By the other hand, Schwann cells are also involved in mechanisms of regeneration after injury. 
These cells both give physical support to the axon and release growth factors for nutriment and 
myelination of associated axons (Kidd et al., 2013). In pathological conditions, such as sciatic nerve 
injury, Schwann cells activation stimulates phenotype modulation, proliferation, migration and 
release of numerous factors, which may promote nerve regeneration (Scheib and Höke, 2013).  
SGCs play a pivotal role in pathophysiological processes involving pain and inflammation (Watkins 
and Mayer 2002). As spinal glial cells (microglia and astrocytes) undergo activation in pain models 
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(gliosis), SGCs are stimulated after painful injuries, and play a key role in the development of chronic 
pain (Hanani et al., 2002; Dublin and Hanani, 2007; Chen et al., 2008). In particular, SGCs are 
involved in the induction and early maintenance of neuropathic pain: their reaction after injuries is 
estabilished within 4 hours, peaks at one week, and decreased in the first three weeks (Zhang et al., 
2009; Liu et al., 2012). Sensory neurons have different receptors for neurotransmitters and hormones 
(i.e. ATP, glutamate, substance P), which allow them to comunicate each other or with other cell 
types, especially glial cells (Amir and Devor, 1996). By the other hand, SGCs have receptors for 
different molecules and can influence neighboring cells, including DRG neurons (Hanani 2005). For 
example, ATP release from neuronal cell bodies activates P2X7 (ion channel) in SGCs, which release 
tumor necrosis factor α (TNFα), which acts on surrounding neurons increasing their excitability 
(Sorkin et al., 1997). In addition, the ATP released by SGCs activates P2X3 receptor in neurons, to 
trigger peripheral sensitization. Persistent nociceptive activity, or opioid receptors-activation by 
morphine, results in release of matrix metalloproteinase-9 (MMP-9) from primary sensory neurons, 
causing the interleukin-1β (IL-1β)-release in SGCs, which elicit neuronal hyperexcitability (Figure 
19) (Ji et al., 2013). Therefore, there is a bidirectional communication between neurons and glial 
cells, which is mediated by gap junctions, and the interaction between these cells (SGC-SGC or SGC-
neuron) is enhanced during chronic pain conditions (Dublin and Hanani 2007; Hanani 2012). Neurons 
in DRGs are completely surrounded by SGCs, forming a tight envelope which functions as a partial 
barrier between the circulation and the neurons (Hanani, 2015). However, DRGs are devoid of a 
blood-brain barrier, therefore molecules released from neurons or SGCs can, from the bloodstream, 
reach and stimulate other DRGs. The role of SGCs seems to be central in neuronal communication: 





Figure 19: Schematic representation of neuronal-glial interactions in dorsal root and trigeminal ganglia. After painful 
injury, neurons release adenosine triphosphate (ATP) in neuronal somata, leading to the activation of P2X7 and 
subsequent release of tumor necrosis factor-α (TNF-α) in satellite glial cells (SGCs). Persistent nociceptive activity 
results in matrix metalloproteinase-9 (MMP-9) release from neurons, causing the cleavage and release of interleukin-1β 
(IL-1β) in SGCs. TNF-α and IL-1β bind respective TNFR and IL-1R on sensory neurons to elicit hyperexcitability. 
Modified from Ji et al., 2013. 
Summarizing, neuropathic pain developes from an interaction between peripheral immune system, 
different cell types (DRG cell bodies and glial cells) and neuronal pathways, so investigating these 
elements can lead to new prospectives to treat neuropathic pain (Watkins et al., 2001). 
DRG and the Endocannabinoid system  
Chronic pain (inflammatory or neuropathic) represents a complicated condition that influences the 
quality of life in both animals and humans. It derives from an injury to the CNS or PNS, resulting in 
an enhancement of the transmission of pain stimuli. Consequently, painful stimuli are amplified 
(hyperalgesia) and normal stimuli are perceived as painful (allodynia) (Luongo et al., 2014). In the 
last years, the DRGs have been identified as a possible target in managing neuropathic pain (Deer et 
al., 2013; Pope et al., 2013). Among the different therapeutical strategies, the activation of 
cannabinoid receptors has been supported by various studies in animal models (Goya et al., 2003; 
Cravatt and Lichtman, 2004; Maione et al., 2006). The distribution of canonical and putative 
cannabinoid receptors in dorsal root ganglia have been partially investigated.  
CB1R has been identified in DRG neurons and SGCs in laboratory rodents, dogs and humans 
(Sanudo-Pena et al., 1999; Anand et al., 2008; Freundt-Revilla et al., 2018). A recent study observed 




CB2 receptor was observed in neurons and glial cells in rodents, dogs and humans (Anand et al., 
2008; Stella 2009; Freundt-Revilla et al., 2018; Sánchez-Zavaleta et al., 2018). In a neuropathic pain-
model in rats, with unilateral sciatic nerve injury, CB2R protein and mRNA were increased bilaterally 
in DRG neurons and glial cells when compared with naive animals (Svíženská et al., 2013). The 
bilateral change can be explain with the propagation of inflammation along the neuraxis, and with the 
neuroprotective effects of CB2R. Being upregulated during PNS diseases, CB2R may be an 
interesting target for managing neuropathic pain and neuroinflammation (Navarro et al., 2016).  
GPR55-immunoreactivity has been detected only in mice DRG neurons (Lauckner et al., 2008). The 
authors observed that GPR55 was abundantly expressed in large-diameter DRG neurons – which can 
be involved in nociception (Neumann et al. 1996; Ruscheweyh et al. 2007) - otherwise small-diameter 
DRG neurons expressed it at low levels. GPR55 acts on ion channels inhibiting potassium current 
and increasing intracellular calcium, thus enhancing neuronal excitability. Contrary, CB1R activates 
some potassium channels, suppressing neuronal excitability (Mackie et al., 1995; Kreitzer et al., 
2002). The stimulation of neuronal excitability together with the expression in large-diameter neurons 
suggest a possible role of GPR55 in the etiopathogenesis of neuropathic and inflammatory pain states.  
The role of Peroxisome proliferator-activated receptors (PPARs) in alleviating peripheral neuropathic 
pain has been confirmed in the last decades. This could be mediated by their anti-inflammatory effects 
(Morgenweek et al., 2010). PPARα and PPARγ are both expressed in DRG neurons (Dunn et al., 
2015; Wu et al., 2017). Aldossary et al. (2019) showed that the analgesic properties of 
palmitoylethanolamide are - at least partially - mediated by PPARα. 
TRPV1-immunoreactivity has been observed in DRG neurons of rodents, pigs and humans (Helliwell 
et al., 1998; Anand et al., 2008; Obreja et al., 2008; Russo et al., 2013). In rats and pigs, the percentage 
of positive neurons was higher than in mice (Zwick et al. 2002; Russo et al. 2013). TRPV1 is a cation 
channel that plays a key role in the transduction of noxious stimuli to the spinal cord (Caterina and 
Julius, 2001). During chronic inflammatory nociception, TRPV1 expression increases in DRG 
neurons in rats. This receptor is involved in the pathogenesis of thermal hyperalgesia and mechanical 
allodynia (Yu et al., 2008).  
5-HT1aR has been observed in rat type 1 DRG cells, which resemble nociceptors (Cardenas et al., 
1997), in contrast with the results obtained by Pierce et al. (1996). In a study on human DRG, 5-
HT1aR mRNA has been detected by PCR in one to four subjects (Pierce et al., 1997). Peripheral 5-
HT2aR is involved in the development of inflammatory and neuropathic pain. 5-HT2aR have been 
identified as a potential therapeutic target for treatment of sciatica in lumbar disc herniation (LDH) 
in an animal model (Kato et al., 2008). 5-HT2aR antagonists attenuate pain and suppress the 
expression of 5-HT2aR in the rat DRG (Kato et al., 2015). In the rat, about 40% of lumbar DRG cells 
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were immunoreactive for 5-HT2aR, principally small to medium-sized cell bodies (Van Steenwinckel 
et al., 2009). 5-HT3 receptor was expressed by rat DRG cells in culture preparations (Robertson and 
Bevan, 1991; Smith et al., 1997). Nicholson et al. (2003) used in situ hybridization to detect serotonin 
receptor mRNA expression in rat dorsal root ganglion neurons. In this study, mRNAs for 5-HT1b, 5-
HT1d, 5-HT2a, 5-HT2b, 5-HT3b and 5-HT4 receptors were detected in small, medium and large 
diameter neurons. Contrary, mRNAs for 5-HT1a, 5-HT1e, 5-HT2c, 5-HT5a, 5-HT5b, 5-HT6 and 5-
HT7 receptors were undetectable in these neurons (Nicholson et al., 2003). Serotonin (5-HT) interacts 
with different 5-HT receptors in pain modulation. Phytocannabinoid, as cannabidiol (CBD), interacts 
with 5-HT1a, 5-HT2a, and 5-HT3a receptors (Pertwee 2015). CBD seems to act on neuropathic pain 
conditions through TRPV1 and 5-HT1aR activation (De Gregorio et al., 2019). 
Given that the ECS system influences neuronal and immune cell function, both involved in the 
etiopathogenesis of pain, targeting this system may hold promise as novel analgesic therapy.  
For this reason, we developed two anatomical studies to identify the distribution of cannabinoid 
receptors in dorsal root ganglia: 
• Cellular distribution of canonical and putative cannabinoid receptors in canine cervical 
dorsal root ganglia. 
• Localisation of cannabinoid receptors in the equine dorsal root ganglia. 
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Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα 
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Monica Forni, Marco Pietra, Roberto Chiocchetti 
Department of Veterinary Medical Sciences – University of Bologna, Italy 
Abstract 
Introduction - The endocannabinoid system (ECS) is composed of cannabinoid receptors, their 
endogenous ligands, and the enzymes involved in endocannabinoid turnover. Modulating the activity 
of the ECS may influence a variety of physiological and pathophysiological processes. A growing 
body of evidence indicates that activation of cannabinoid receptors by endogenous, plant-derived, or 
synthetic cannabinoids may exert beneficial effects on gastrointestinal inflammation and visceral 
pain.  
Objectives - The present ex vivo study aimed to investigate immunohistochemically the distribution 
of cannabinoid receptors CB1, CB2, G protein-coupled receptor 55 (GPR55), and peroxisome 
proliferation activation receptor alpha (PPARα) in the canine gastrointestinal tract.  
Results - CB1 receptor immunoreactivity was observed in the lamina propria and epithelial cells. CB2 
receptor immunoreactivity was expressed by lamina propria mast cells and immunocytes, blood 
vessels, and smooth muscle cells. Faint CB2 receptor immunoreactivity was also observed in neurons 
and glial cells of the submucosal plexus. GPR55 receptor immunoreactivity was expressed by lamina 
propria macrophages and smooth muscle cells. PPARα receptor immunoreactivity was expressed by 
blood vessels, smooth muscle cells, and glial cells of the myenteric plexus.  
Conclusions and relevance - Cannabinoid receptors showed a wide distribution in the gastrointestinal 
tract of the dog. Since cannabinoid receptors have a protective role in inflammatory bowel disease, 
the present research provides an anatomical basis supporting the therapeutic use of cannabinoid 
receptor agonists in relieving motility disorders and visceral hypersensitivity in canine acute or 
chronic enteropathies. 
Introduction 
The endocannabinoid system (ECS) is composed of cannabinoid receptors, endocannabinoids, and 
the enzymes for their production and degradation (Stella, 2004; Ligresti et al., 2016; Lu and 
Anderson, 2017). It classically comprises the cannabinoid receptors types 1 and 2 (CB1R and CB2R), 
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the endocannabinoids N-arachidonylethanolamine (anandamide; AEA) and 2-arachidonylglycerol 
(2-AG), and the enzymes responsible for endocannabinoid biosynthesis and degradation (Iannotti et 
al., 2016). Currently, the definition of the ECS is expanding to include, besides the classical 
cannabinoid receptors and endocannabinoids, several fatty acid derivatives—the so-called 
endocannabinoid -like mediators, such as palmitoylethanolamide (PEA)—as well as other non-CB 
receptors (Kreitzer and Stella, 2009; Iannotti et al., 2016). This is the case, for example, for the G 
protein-coupled receptor 55 (GPR55), nuclear peroxisome proliferator-activated receptor alpha 
(PPARα), and transient receptor potential vanilloid type 1 (TRPV1), all of which are currently 
considered as possible cannabinoid receptors (Brown et al., 2005; Di Marzo et al., 2002; Izzo and 
Sharkey, 2010; Lauchner et al., 2008; Lin et al., 2011; Petrosino and Di Marzo, 2017; Tuduri et al., 
2017). Notably, the ligands of this manifold receptor system often activate more than one target site 
in conjunction to exert their effect (O’Sullivan, 2016). Thus, the evolving idea of the 
“endocannabinoidome”—a more complex system including endocannabinoids and endocannabinoid-
like mediators, their redundant metabolic enzymes and ‘‘promiscuous’’ molecular targets (i.e., 
receptors)—is increasingly gaining ground (Maione et al., 2013). The ECS is widely expressed in the 
central nervous system (CNS), cardiovascular, gastrointestinal, immune, and reproductive system 
(Maccarrone et al., 2015; Cabral et al., 2015). The CB1 receptor is expressed mostly in the CNS and 
peripheral nerves (Hu and Mackie, 2015; Freundt-Revilla et al., 2017), and the CB2 receptor is mainly 
expressed in immune cells (Di Marzo and Izzo, 2006). Many neuronal cell types, distributed in several 
CNS areas, express the CB1 receptor; however, the wide distribution of the CB1 receptor limits its 
potential as a pharmacological target for CNS diseases, due to the psychoactive side effects associated 
with CB1 receptor agonists and antagonists (Moreira et al., 2009). A recent study highlighted the 
expression of the CB2 receptor in neurons and inflammatory non-neuronal cells of the CNS, e.g., 
microglia (Malfitano et al., 2014). The evidence that the CB2 receptor is upregulated in a variety of 
CNS diseases characterized by microglia and/or astroglia activation suggests that the CB2 receptor 
might represent a promising pharmacological target to be considered in diseases characterized by 
neuroinflammation (Skaper et al., 2013 ; Navarro et al., 2016; Cassano et al., 2017; Chen et al., 2017; 
Freundt-Revilla et al., 2018). In the gastrointestinal tract (GIT), cannabinoid receptors regulate 
motility, secretion, sensation, emesis, satiety, and inflammation (Izzo, 2004; Duncan et al., 2005a, 
Duncan et al., 2005b, Duncan et al., 2008; Storr and Sharkey, 2007; Wright et al., 2008; Sharkey and 
Wiley, 2016; Lee et al., 2016; Di Patrizio, 2016). The CB1 receptor is expressed by neurons of the 
enteric nervous system (ENS) of rodents (Duncan et al., 2005a; Duncan et al., 2005b), guinea -pig 
(Coutts et al., 2002), pig (Kulkarni -Narla et al., 2000), and ferret (Van Sickle et al., 2001). The CB2 
receptor may be expressed by macrophages, plasma cells, mast cells, dendritic cells, lymphocytes, 
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smooth muscle cells, epithelial cells, and enteric neurons (Facci et al., 1995; Duncan et al., 2005b; 
Wright et al., 2008; Duncan et al.,, 2008; Svensson et al., 2010; Ke et al., 2016). Several investigations 
suggest that CB1 or CB2 receptors might have a protective role in inflammatory bowel disease (IBD) 
in humans, and support the potential therapeutic effects of targeting these pathways using 
pharmacological agents (Izzo, 2004 ; Di Marzo and Izzo, 2006; Duncan et al., 2008; Di Marzo and 
Piscitelli, 2011; Di Patrizio, 2016; Gyires and Zádori, 2016; Fabisiak and Fichna, 2017). The 
activation of CB1 receptor reduces emesis, intestinal motility and secretion, and inhibits gastric acid 
secretion and relaxation of the lower esophageal sphincter (Izzo and Coutts, 2005). Activation of the 
CB2 receptor in pathological conditions such as inflammatory bowel disease (IBD) or endotoxic 
inflammation reduces intestinal motility (Izzo, 2004); thus, activation of CB2 receptor seems to 
represent a novel mechanism for the re-establishment of normal gastrointestinal transit after an 
inflammatory stimulus. Palmitoylethanolamide (PEA), a lipid mediator structurally related to AEA, 
is used in human and veterinary medicine for its neuroprotective, anti-neuroinflammatory, analgesic, 
and antipruritic properties (Re et al., 2007; Gabrielsson et al., 2016; Petrosino and Di Marzo, 2017; 
Cremon et al., 2017). It was isolated for the first time from lipid fractions of soybeans, egg yolk, and 
peanut meal and was then found in a wide variety of food sources (data reviewed in Petrosino and Di 
Marzo, 2017). Several investigators have identified different mode of action of PEA (Iannotti et al., 
2016; Petrosino and Di Marzo, 2017), which seems to have a direct effect upon PPARα (Lo Verme 
et al., 2005a; Lo Verme et al., 2005b; Gabrielsson et al., 2016), GPR55 (Ryberg et al., 2007; 
Cantarella et al., 2011), and CB2R (Facci et al., 1995). The latter receptor may also be activated 
through an indirect mechanism (De Petrocellis et al., 2001; Guida et al., 2017). Finally, PEA directly 
and indirectly acts on TRPV1 (Ho et al., 2008; De Petrocellis and Di Marzo, 2010), a receptor usually 
expressed by nociceptive dorsal root ganglia sensory neurons (Caterina et al., 1997) that undergoes 
desensitization by endocannabinoids (Zygmunt et al., 1999; Ambrosino et al., 2013). PEA, which 
also seems to act favourably on visceral pain (Jaggar et al., 1998; Farquhar- Smith et al., 2002; 
Gabriels-son et al., 2016), represents a promising natural approach for hypersensitivity management 
in dogs with intestinal inflammation. A prerequisite for the therapeutic potential of PEA in 
pathological GIT conditions, such as acute or chronic enteropathies, is the cellular distribution of the 
receptors. PEA is known to act upon, i.e., the cannabinoid receptors, in different tracts of the canine 
digestive system. Therefore, the present study aimed to immunohistochemically characterize the 
cellular expression of CB1, CB2, GPR55, and PPARα receptors in ex-vivo GIT tissues of dogs. 
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Materials and methods 
Animals 
Gastrointestinal tissues were collected from three dogs (#1 female, 8-month-old Chihuahua; #2 
spayed female, 11-year-old Labrador Retriever, and #3 male, 17-year-old West High-land White 
Terrier), that did not have a history of gastrointestinal disorders and did not show gross alteration of 
the gastrointestinal wall. Animals died spontaneously or were euthanized for human reasons due to 
different diseases and tissues were collected following consent from the owners. According to the 
Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the 
protection of animals used for scientific purposes, the Italian legislation (D. Lgs. n. 26/2014) did not 
require any approval by competent authorities or ethics committees, because this research did not 
influence any therapeutic decisions. 
Tissue collection 
GIT samples (pylorus, descending duodenum, ileum, and distal colon) were collected within 1 h of 
death and were longitudinally opened along the pyloric small curvature and intestinal mesenteric 
border. Tissues were then washed in phosphate-buffered saline (PBS), fixed, and processed to obtain 
cryosections (2.0 cm × 0.5 cm), which were later processed for immunohistochemistry, as previously 
described (Chiocchetti et al., 2015; Giancola et al., 2016, Giancola et al., 2017). 
Immunofluorescence 
Cryosections were hydrated in phosphate-buffered saline (PBS), and processed for immunostaining. 
To block non-specific binding, the sections were incubated in a solution containing 20% normal goat 
or donkey serum (Colorado Serum Co. Denver, CO, USA), 0.5% Triton X-100 (Sigma-Aldrich, 
Milan, Italy, Europe), and bovine serum albumin (1%) in PBS for 1 h at room temperature (RT). The 
cryosections were incubated overnight in a humid chamber at RT with a cocktail of primary 
antibodies (Table 1) diluted in 1.8% NaCl in 0.01M PBS containing 0.1% sodium azide. After 
washing in PBS (3 × 10 min), the sections were incubated for 1 h at RT in a humid chamber with the 
secondary antibodies (Table 2) diluted in PBS. Cryosections were then washed in PBS (3 × 10 min) 
and mounted in buffered glycerol at pH 8.6 with 4′,6-diamidino-2-phenylindole—DAPI (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). Since classic (CB1R and CB2R) and “new” cannabinoid 
receptors (GPR55 and PPAR-α) might be located on different cellular types, we employed a panel of 
specific antibodies with the aim of colocalizing the cannabinoid receptors’ immunoreactivity on 
enteric neurons, enteric glial cells (EGCs), mast cells (MCs), macrophages, and plasma cells. In 
particular, to identify enteric neurons and glial cells, anti-human neuronal protein (HuC/HuD) and 
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anti-GFAP antibodies were used, respectively. To identify MCs, different antibodies against MC 
tryptase were used. To identify macrophages, we utilized the anti-ionized calcium binding adapter 
molecule 1 antibody (IBA1). Plasma cells were identified using the anti-IgA antibodies. Endothelial 
cells were identified using two different endothelial markers, i.e., the mouse anti-CD31 antibody, and 
the rabbit anti-Factor VIII-related antigen/von Willebrand factor. To identify enterochromaffin cells, 
we utilized the anti-serotonin antibody. 
Specificity of the primary antibodies 
The specificity of the mouse anti-HuC/HuD antibody was recently demonstrated in dog tissues by 
Western blot analysis (Giancola et al., 2016). The supplier of the anti-CB1 receptor antibody, raised 
in rabbit against the human CB1 receptor, predicts cross-reactivity with the dog, mouse, and rat 
antigen. The sequence of canine CB1 protein is homologous (98.3%) to the sequence of human CB1 
protein (https:// www.uniprot.org/) (Anday and Mercier 2005). The anti-CB2 receptor antibody was 
raised in rabbit and directed against residues 200–300 of the rat CB2 receptor. The sequence of the 
canine CB2 protein is homologous (98.3%) to the sequence of the rat CB2 protein 
(https://www.uniprot.org/). The anti-CB2 receptor antibody utilized in the present study has already 
been tested on dog tissues (Campora et al., 2012). Based on the sequence identities, the antibodies 
against CB1 and CB2 receptors should cross-react with the same antigens in the dog. The antibody 
anti-GPR55 receptor was raised against a17 amino acid synthetic peptide of human GPR55 receptor. 
The sequence of canine GPR55 protein is homologous (83.5%) to the sequence of human GPR55 
protein (https:// www.uniprot.org/); furthermore, the antibody supplier indicated greater (94%) cross-
reactivity of the antibody with the canine GPR55 protein. Taken together, this suggests that this 
antibody should cross-react with the same antigen in the dog. The anti -PPARα receptor antibody was 
raised in rabbit against the synthetic peptide of mouse PPAR-α. The sequence of canine PPARα 
protein is homologous (90%) to the sequence of mouse PPARα protein (https://www.unipr ot.org/). 
Furthermore, the supplier of the anti-PPARα recep-tor antibody predicted cross-reactivity with the 
same antigen in the dog. 
Despite the presumed or already demonstrated specificity of the anti-cannabinoid receptor (CB1, 
CB2, GPR55, PPARα) antibodies utilized in the present research on canine tissues, we tested their 
specificity by Western blot (WB) analysis (Fig. 1). In addition, to confirm that CB1 antibody staining 
was specific for CB1 protein, the rabbit anti-CB1 antibody was tested on brain cryosections obtained 
from wild-type mice and mice with congenital deficiency of CB1 (Marsicano et al., 2002). In the 
cryosections of CB1 null mice, the specific CB1 staining of axons was absent (Supplementary Fig. 
1a–f). Furthermore, the rabbit anti-CB1 antibody was tested on wholemount preparations of rat MP 
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and SMP, in which neurons of both the plexuses showed CB1 receptor immunolabelling 
(Supplementary Fig. 1g–l). To identify MCs, we utilized the only commercially available anti-dog 
tryptase antibody (Cloude-Clone, PA B070Ca01, Huston, TX, USA). Since this antibody was raised 
in rabbit, as were all the anti -cannabinoid receptor antibodies utilized in this study, we colocalized 
the dog-specific anti-tryptase antibody with two commercially available anti-human tryptase 
antibodies raised in mouse: Dako,M 7052 (Clone AA1) and Novus Biol (NBP1-40202). The first 
antibody (clone AA1) has already been used in canine intestinal tissues (Kleinschmidt et al., 2007). 
The supplier of the second antibody (NBP1-40202) indicated cross-reactivity with canine tryptase 
(canine tryptase shows 76% homology with human tryptase; http://www.uniprot.org/). The dog-
specific rabbit anti-tryptase antibody labelled a greater number of MCs in all GIT layers (data not 
shown) than those labelled by the human-specific anti-tryptase antibodies, which were not 
immunolabelled with the other two antibodies (data not shown). Nevertheless, since both the mouse 
anti-tryptase antibodies labelled a large number of lamina propria MCs (Novus Biol. > Dako), which 
were also immunolabelled by the dog-specific anti-tryptase antibody, we utilized these two mouse 
anti-human tryptase antibodies in colocalization studies to identify lamina propria MCs bearing 
cannabinoid receptors. The goat anti-IgA antibody (Novus Biol., NB100-1028) is directed against 
porcine IgA; although the specificity of this antibody has not been tested on dog tissues, in the present 
research we colocalized the goat anti-IgA antibody with the rabbit anti-IgA antibody (Bethyl Lab., 
A80-103A). The two antibodies co-localized perfectly in the same immunocytes/ plasma cells (data 
not shown). Thus, in the present study, the goat anti-IgA antibody was utilized to identify 
immunocytes bearing cannabinoid receptors. The anti-IBA1 antibody should recognize CNS 
microglia (Pierezan et al., 2014) and macrophages; in the present study the antibody recognized 
canine gut macrophages (and canine CNS microglia; data not shown). The anti-IBA1 antibody used 
(Novus Biol. NB100-1028) was raised in goat and is directed against porcine IBA1. Since the dog 
IBA1 molecule shows 91.2% identity with the porcine one (https:// www.uniprot.org/), it is plausible 
that this antibody may also recognize canine IBA1. Nevertheless, the specificity of this antibody has 
not been tested on dog tissues. The antibody anti-CD31, that has been already used in dog tissues 
(Kader et al., 2001), unequivocally identified the endothelial cells of blood vessels. The specificity 
of this antibody was tested in a colocalization study with the other endothelial marker, i.e., the anti-
Factor VIII-related antigen/ von Willebrand factor antibody (Preziosi et al., 2004). The two antibodies 
co-localized in the same endothelial cells (data not shown). 
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Specificity of the secondary antibodies 
The specificity of the secondary antibodies was tested by applying them after omission of the primary 
antibodies. Neither stained cells could be detected after omitting the primary antibodies. In double-
immunostaining protocols, control experiments were also carried out to check for non-specific 
binding of secondary antibodies to the inappropriate primary antibodies by omission of one or other 
of the first stage reagents. Furthermore, incubation with two primary antibodies followed by only one 
secondary antibody was carried out to check for the existence of any cross-reactivity between primary 
and secondary antibodies. Finally, incubation with any single primary antibody followed by the 
appropriate secondary antibody was also performed to ensure that the labeling pattern for each marker 
in the double- stained sections was in agreement with that observed in the single-labeled sections. No 
evidence of nonspecific binding was found. 
Fluorescence microscopy 
Preparations were examined on a Nikon Eclipse Ni microscope equipped with the appropriate filter 
cubes to distinguish the fluorochromes employed. The images were recorded with a Nikon DS-Qi1Nc 
digital camera and NIS Elements software BR 4.20.01 (Nikon Instruments Europe BV, Amsterdam, 
Netherlands). Slight adjustments to contrast and brightness were made using Corel Photo Paint, 
whereas the figure panels were prepared using Corel Draw (Corel Photo Paint and Corel Draw, 
Ottawa, ON, Canada). 
Western blot: specificity of the primary antibodies 
Tissue samples (canine small intestine) were collected, frozen in liquid nitrogen, and stored at − 80°C 
until sample processing. In addition, the mouse small intestine was utilized as positive control. 50 mg 
of tissue was homogenized in 500 µl of SDS buffer (Tris–HCl, 62.5 mM; pH 6.8; SDS, 2%; and 
glycerol, 20%) supplemented with a protease inhibitor cocktail (Sigma-Aldrich, Co, St. Louis, MO, 
USA). Total protein content was determined by Peterson’s Modification of Lowry Method using a 
Protein Assay Kit. Aliquots containing 20 µg of total proteins were separated on Bolt 4–12% bis-Tris 
Plus (Life Technologies Ltd, Paisley, UK) for 45 min at 165 V. The proteins were then 
electrophoretically transferred onto a nitrocellulose membrane by a semi-dry system (Trans Turbo 
Blot Bio-Rad). Non-specific binding on nitrocellulose membranes was blocked with 5% milk powder 
in PBS-T20 (Phosphate Buffer Saline-0.1% Tween-20) for 1 h at RT. After blocking treatment, the 
membranes were incubated overnight at 4 °C with the primary antibodies (Table 1) (CB1R 1:500, 
CB2R 1:1000; GPR55 1:500; PPARα 1:2000) diluted in Tris-buffered saline-T20 (TBS-T20 20 mM 
Tris–HCl, pH 7.4, 500 mM NaCl, 0.1% T-20). After washes, the blots were incubated with a goat 
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anti rabbit biotin-conjugate antibody (1:50,000 dilution in TBS-T20, 1 h at RT) and then with a 
1:1000 dilution of an anti-biotin horseradish peroxidase (HRP)-linked antibody (40 min at RT). 
Immunoreactive bands were visualized using chemiluminescent substrate (Clarity Western ECL 
Substrate Bio Rad), according to the manufacturer’s instructions. The intensity of the luminescent 
signal was acquired by Chemi-doc Instrument and the apparent molecular weight of the resultant 
bands was analyzed by Quantity One Software (Bio-Rad). Western blot analysis of CB1 revealed a 
band of ~ 52 kDa (theoretical molecular weight of canine CB1 52,782 kDa; Fig. 1). Western blot 
analysis of CB2 revealed a band of ~ 40 kDa (theoretical molecular weight of canine CB2 40,107 
kDa; Fig. 1). Western blot analysis of GPR55 revealed a band of ~ 35 kDa (theoretical molecular 
weight of canine GPR55 36,85 kDa; Fig. 1). Western blot of PPARα revealed a band of ~ 52 kDa 
(theoretical molecular weight of canine PPARα 52,123 kDa; Figure 1). Overall Wb analysis 
confirmed the specificity of the primary antibodies utilized in the present study. 
Results 
CB1 immunoreactivity 
In the pylorus, small and large intestine, CB1 receptor immunoreactivity was expressed by serotonin-
immunoreactive enterochromaffin cells (Fig.2a–f). In the small and large intestine, CB1 
immunoreactivity was detected in the cell membrane and cytoplasm of some lamina propria and 
epithelial cells (Fig. 2g, h). In the ileum of the youngest dog, in which submucosal and mucosal 
lymphatic nodules were evident, bright CB1 receptor immunoreactivity was identified in unidentified 
immunocytes localized in the portion of the lymphatic nodules within the lamina propria (Fig. 2i). In 
the enteric plexuses, faint and punctate CB1 receptor immunoreactivity was observed in some 
unidentified MP neurons (Fig. 2j–l). CB1 receptor immunoreactivity was undetectable in blood 
vessels and muscular layers. 
CB2 immunoreactivity 
CB2 immunoreactivity was widely distributed in all the digestive tracts considered. 
Mucosa 
The cell membrane of the endothelial and smooth muscle cells of mucosal (Fig. 3a, b) and submucosal 
(Fig. 3c) blood vessels showed bright CB2 immunoreactivity, above all in the small intestine, which 
allowed visualization of the blood vascular pattern along the major axis of the villi. When the villi 
were cut orthogonally, it was possible to observe CB2-immunolabelled vessels arranged like clock 
numbers around the circumference of the villus (Fig. 3b). Colocalization experiments indicated that 
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CB2 immunolabelled endothelial cells showed CD31 immunoreactivity; however, there were small 
areas in which the two different immunolabelling were non-overlapped, indicating that other cellular 
elements (most likely pericytes) expressed CB2 immunoreactivity (Supplementary Fig. 2). It is of 
note that some lamina propria tryptase-immunoreactive MCs showed cytoplasmic CB2 
immunoreactivity (Fig. 3d–f). CB2 immunoreactivity was also observed in the cytoplasm of some 
unidentified immunocytes within intestinal lymphatic nodules (Fig. 3g). The cell membrane of 
smooth muscle cells of the muscularis mucosae (mm) showed bright CB2 immunoreactivity in all the 
digestive tracts considered (data not shown). 
Muscular layers 
In the pylorus, CB2 immunoreactivity was observed on the cell membrane of the smooth muscle cells 
of both layers of the tunica muscularis (Fig. 3j). In the circular muscle layer (CML), there were some 
patchy distributed clusters of smooth muscle cells that showed stronger immunolabelling. The CB2 
immunoreactivity of the muscular layers of the small intestine showed strong immunolabelling, which 
was attenuated in the colon (small intestine > colon > pylorus) (Fig. 3k–l). In both the intestinal tracts, 
CB2 immunoreactivity decreased towards the outermost part of the longitudinal muscle layer (LML). 
Enteric neurons and glia 
In the intestinal submucosal plexus (SMP), there were a few ganglia in which neurons and glial cells 
showed weak-to-moderate CB2 immunoreactivity (Fig. 3h–i), either on the cell membrane (Fig. 3h) 
or within the cytoplasm (Fig. 3i). On the contrary, the neurons and glial cells of the myenteric plexus 
(MP) did not show any CB2 immunoreactivity (Fig. 3j–l). 
GPR55 immunoreactivity 
GPR55 immunoreactivity was mainly distributed in the mucosa (Fig. 4a–i) and muscular layers (Fig. 
4j–l).  
Mucosa 
A large number of lamina propria and epithelial cells expressed bright GPR55 immunoreactivity (Fig. 
4a–c). In the pylorus, there were some thin and elongated enterochromaffin cells, which showed 
bright nuclear and weaker cytoplasmic GPR55 immunostaining (Fig. 4a). GPR55 immunolabelled 
enterochromaffin cells were also visible in the intestine, in particular in the colon. Furthermore, 
epithelial cells of the inner portion of the mucosa also showed diffuse cytoplasmic GPR55-
immunolabelling in this tract (Fig. 4b). Co-localization experiments indicated that a large number of 
lamina propria cells showing cytoplasmic GPR55 immunoreactivity were IBA1-immunoreactive 
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macrophages (Fig. 4d–f), IgA-immunoreactive plasma cells (Fig. 4g–i), and tryptase-immunoreactive 
MCs (data not shown). 
Muscular layers 
The GPR55 receptor distribution showed regional and local differences. In the stomach, GPR55 
immunoreactivity was not homogenously distributed and the immunolabelling was more evident in 
the CML than in the LML (data not shown). In the duodenum, the CML showed faint GPR55-
immunolabelling, as did the inner portion of the LML; on the contrary, the outer third of the LML 
showed very strong GPR55 immunoreactivity (Fig. 4j). In addition, in the ileum, the smooth muscle 
cells of the outer portion of the LML showed a higher density of the GPR55 receptor, whereas in the 
colon all the LML expressed bright GPR55 immunoreactivity, with a tendency for increased 
immunolabelling in its outer portion (Fig. 4k–l). It is noteworthy that the inner portion of the CML 
(ICML), i.e., the small portion of the CML composed by 6–12 smooth muscle cells facing towards 
the submucosa (Zelcer and Daniel 1979; Eddinger 2009), showed intense GPR55-immunolabelling 
(data not shown). 
Enteric neurons and glia 
No GPR55 immunoreactivity was displayed by enteric neurons or glial cells in the tracts considered. 
PPARα immunoreactivity 
Bright PPARα immunoreactivity was expressed by lamina propria cells, epithelial cells, blood 
vessels, smooth muscle cells of the mm and tunica muscularis (Fig. 5a–h), and EGCs (Fig. 6a–i). 
Mucosa 
In the pylorus, PPARα immunoreactivity was evident in the cytoplasm and nucleus of serotonin-
immunoreactive enterochromaffin cells of the deeper portions of the gastric glands (data not shown). 
In the intestine, the strongest PPARα immunoreactivity was expressed by the mm, from which 
bundles of smooth muscle cells reached the tips of the villi (Fig. 5a); of note, the muscular cells 
showed their strongest immunolabelling on the apex of the villi. PPARα immunoreactivity was also 
expressed by blood vessel endothelial cells (Fig. 5a, b). In the lamina propria of the villi, and in 
particular in their apex, PPARα immunoreactivity was observed in a network of thin and elongated 
cellular processes arising from small cells of unknown nature (Fig. 5c); these cells were easily 
observed when the villi were cut orthogonally to their major axis. Furthermore, some small lamina 
propria cells with an irregular outline and short cellular processes, which resembled dendritic cells 
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(Junginger et al., 2014), showed brilliant PPARα- immunolabelling within the cytoplasm (Fig. 5d). 
In addition, MCs showed cytoplasmic PPARα immunoreactivity (data not shown).  
Muscular layers  
PPARα receptor, as seen for GPR55 receptor, showed a different distribution in the tunica muscularis 
and was well represented in both the muscular layers, but more concentrated in the LML, and in 
particular in its external portion, in the pylorus, duodenum and colon (Fig. 5e, g). In the LML of the 
ileum, PPARα-immunolabelling was mainly observed concentrated within its outer portion, although 
there were some ileal tracts in which PPARα receptor were seen in smooth muscle cells scattered in 
the LML (Fig. 5f). It should be noted that, in contrast to what was observed for GPR55 
immunoreactivity, the ICML was PPARα-negative (Fig. 5h). PPARα immunoreactivity was strongly 
expressed by GFAP-immunoreactive glial cells of the SMP and MP (MP > SMP), whereas the 
HuC/HuD-immunoreactive neurons were always PPARα-negative (Fig. 6a–i). 
Discussion 
CB1 receptor 
The observation of CB1 receptor immunolabelling of enteric neurons is consistent with data observed 
in pig, guinea-pig, rat, mouse, and ferret ENS (Kulkarni-Narla and Brown 2000; Van Sickle et al., 
2001; Coutts et al., 2002; Storr et al., 2004; Duncan et al., 2005a), in which the CB1 receptor was 
mainly expressed by cholinergic excitatory motor neurons. In humans, the activity of the CB1 
receptor was functionally demonstrated in the ileum by Croci et al. (1998) and CB1 receptor 
immunoreactivity has been described in enteric neurons and nerve fibres (Wright et al., 2005; 
Marquez et al., 2009). In the present study, we observed CB1 receptor immunoreactivity in the 
epithelial cells, including enterochromaffin cells. This is in line with what was observed in human 
GIT mucosa, where the CB1 receptor was identified on gastric parietal cells, epithelial cells, goblet 
cells, and enteroendocrine cells (Wright et al., 2005; Pazos et al., 2008; Marquez et al., 2009; Ligresti 
et al., 2016). It is known that under physiological conditions, the activation of the CB1 receptor 
reduces gastric acidic secretion and regulates the release of enteroendocrine peptides such as 
cholecystokinin (Sykaras et al., 2012). The presence of CB1 receptor immunoreactivity in canine 
small intestine is especially important, given the body of evidences that shows that CB1 receptor in 
the upper small intestine of rodents controls palatable food intake and overeating in diet-induced 
obesity (Di Patrizio et al., 2011; Argueta and Di Patrizio, 2017). In addition, the evidence of CB1 
receptor immunoreactivity in serotonin expressing enterochromaffin cells of the dog upper 
gastrointestinal tract may suggest a peripheral mechanism of action of cannabinoids in the modulation 
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of nausea and vomiting. In fact, it is well known that cannabinoids may inhibit nausea and vomit with 
a central (and peripheral) action, since CB1 receptor is scattered on neurons of the brainstem nuclei 
involved in emesis (Ray et al., 2009; Darmani, 2010). The activation of CB1 receptor of 5-HT 
releasing enterochromaffin cells may limit nausea and vomit by reducing 5-HT release and 
consequently decreasing the excitability of 5-HT3 receptor of the vagal sensory nerve fibers of the 
upper gastrointestinal tract (Hu et al., 2007). In the present study, we observed unidentified lamina 
propria cells expressing CB1 receptor immunoreactivity, which were more concentrated in the small 
intestine lymphatic nodules. Regarding the expression of CB1 receptor immunoreactivity on 
epithelial cells, it is interesting to consider that enteric microbiota may regulate the expression of the 
CB1 receptor on enterocytes, and this in turn may control gut permeability (Muccioli et al., 2010). 
Consistently, CB1 activation has recently been suggested to play a key role in intestinal mucosa 
permeability, both in healthy and disease states (Karwad et al., 2017a). The presence of the CB1 
receptor on lamina propria cells is consistent with the finding by Marquez et al. (2009), who reported 
CB1 receptor immunoreactivity in mucosal plasma cells. Moreover, enteric microbiota may regulate 
the expression of the CB1 receptor on enterocytes, and this in turn may control gut permeability 
(Muccioli et al., 2010). Consistently CB1 activation has recently been suggested to play a key role in 
intestinal mucosa permeability, both in healthy and disease states (Karwad et al., 2017a). 
CB2 receptor 
CB2 receptor immunoreactivity was absent in the MP, whereas it was observed in some neurons and 
EGCs of the submucosa, in which it showed different degrees of brightness. This is not surprising, 
since the CB2 receptor although usually expressed by non-neuronal elements such as immunocytes 
and inflammatory cells has been repeatedly demonstrated in the central (Cabral et al., 2008) and 
peripheral nervous system, including enteric neurons (Duncan et al., 2005b, Duncan et al., 2008; 
Wright et al., 2008). To the best of our knowledge, this is the first time that CB2 immunoreactivity 
has been reported in EGCs. Notably, this could be related to the expression of PPARα on the same 
cell type (see below). The localization of CB2 receptor in the EGCs is consistent with the expression 
of CB2 receptor on astrocytes of healthy and inflamed CNS (Sheng et al., 2005; Freundt-Revilla et 
al., 2018). We observed very strong CB2 immunoreactivity in endothelial and muscular components 
of enteric blood vessels. Our observations are consistent with the findings by Golech et al. (2004), 
Ashton et al. (2006), Marquez et al. (2009), and Dowie et al. (2014), who found CB2-
immunolabelling on endothelial vascular cells of human and rat CNS. More specifically, our data are 
reinforced by the findings of Campora et al. (2012), who observed CB2-immunolabelling on canine 
endothelial cells in skin. In co-localization studies aimed to identify the co-expression of the CD31 -
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and CB2- immunoreactivity in endothelial cells, we noted a certain degree of non-overlap between 
the two markers. This evidence may suggest that endothelial cells, and also pericytes, express CB2 
immunoreactivity. This last finding, although not demonstrated by the use of a specific marker for 
pericytes, is of some importance, because it has been shown that the contraction of pericityes can 
regulate the vascular flow of the capillaries in the intestine (Wille and Schnorr, 2003) as well in the 
CNS. Hall et al. (2014) demonstrated that ischaemia evokes capillary constriction by pericytes, which 
are major regulators of cerebral blood flow. Zong et al. (2017) showed that exogenous CB1 agonist 
promotes the vasorelaxation of pericyte-containing rat retinal capillaries. Benyó et al. (2016) showed 
that in certain cerebrovascular pathologies, activation of CB2 receptor (and probably yet unidentified 
non-CB1/non-CB2 receptors) appears to improve the blood perfusion of the brain via attenuating 
vascular inflammation. Thus, the expression of the CB2 receptor in dog gastrointestinal vessels (in 
smooth muscle cells, endothelium and, perhaps, pericytes) may have relevant therapeutic importance 
in the treatment of acute and chronic enteropathies. In fact, alteration of the microvascular perfusion 
and adhesion of leukocytes to the endothelium are hallmark events in inflammation. As already 
demonstrated in rodents (Kinian et al., 2013; Sardinha et al., 2014), it is possible that even in dogs 
the use of CB2 receptor agonists might protect the gut microcirculation during inflammation. The 
expression of CB2 immunoreactivity in lamina propria cells was expected, since the presence of this 
receptor among different classes of immunocytes and inflammatory cells has already been reported 
(Wright et al., 2008; Izzo and Sharkey, 2010; Gyires and Zádori, 2016; Lee et al., 2016). Notably, as 
already shown in experimental rodents (Facci et al., 1995), we observed CB2 receptor 
immunoreactivity in canine mucosal MCs. The finding is of particular interest if one considers that 
MCs are now recognized to be involved in a number of non-allergic diseases including IBD and food 
intolerance (Shea-Donohue et al., 2010; Wouters et al., 2016; Bednarska et al., 2017). During 
intestinal inflammation, MCs release proinflammatory mediators (e.g., tryptase, chymase, and 
histamine), which recruit and stimulate adjacent MCs, thus amplifying the inflammatory signal (He 
2004). CB2 receptor immunoreactivity on canine gut MCs renders them a potential target for CB2 
agonists. Although CB2 receptor activation is considered to exert no effect on GIT motility under 
physiological conditions (Izzo et al., 1999), upregulation during experimental GIT inflammation 
might be envisaged. Indeed, the CB2 receptor seems to be upregulated in the dog (specifically in the 
SMP) during chronic enteritis (personal observation of Dr. R. Chiocchetti; Supplementary Fig. 3). 
GPR55 receptor 
The GPR55 receptor, considered by some as the third cannabinoid receptor (Moriconi et al., 2010), 
is a G protein-coupled receptor sharing 10–14% homology with CB1 and CB2 receptors (Lauckner 
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et al., 2008). Although a detailed description of tissues and cells expressing GPR55 is still lacking, a 
growing body of evidence shows that GPR55 is widely distributed in the ENS of humans and rodents, 
in particular in the two ganglionated plexuses (Lin et al., 2011; Ross et al., 2012; Li et al., 2013; 
Goyal et al., 2017). In contrast with these findings, we did not detect the GPR55 receptor in ENS 
neurons, whereas it was abundantly expressed in smooth muscle cells, possibly playing some role in 
controlling excitability. The peculiar distribution of GPR55 immunoreactivity in the muscular layers, 
i.e., the high density of the GPR55 receptor in the ICML (small intestine) and outer portion of the 
LML (colon), suggests that the GPR55 receptor might be involved in ICML relaxation during 
inflammatory-induced excessive contraction of the intestinal wall. In fact, as hypothesized by 
Eddinger (2009), ICML cells seem to be primarily involved in maintaining basal intestinal tone, while 
the muscle cells of the outer portion of the CML are primarily involved in peristalsis. As specified 
above, GPR55 receptor immunoreactivity was also well represented in the outer portion of the LML. 
Although the enteric neurons and interstitial cells of Cajal are determinant for the beginning and 
coordination of peristalsis, smooth muscle cells of the CML and LML have intrinsic myogenic 
activity (Huizinga et al., 1998). Due to its role in the regulation (increase) of intracellular calcium 
levels (Lauckner et al., 2008); the GPR55 receptor may thus play a role in the excitability of these 
smooth muscle cells. We also found that a large number of lamina propria macrophages, plasma cells, 
and MCs showed bright GPR55 immunoreactivity (macrophages > plasma cells > MCs). The 
presence of the GPR55 receptor on macrophages was recently also shown in rodents and humans 
(Taylor et al., 2015; Lanuti et al., 2015). As reported above, pro-inflammatory mediators released by 
MCs during intestinal inflammation may induce macrophage accumulation in the basal portion of the 
lamina propria (He et al., 1997; He and Walls 1998). One could thus speculate that endocannabinoid-
related compounds acting on CB2 receptor (MCs and immunocytes) and/or GPR55 receptor 
(macrophages and MCs) may limit the inflammatory cascade during GIT disturbances. 
PPARα receptor 
The PPARα receptor is a ligand-activated transcription factor belonging to the superfamily of nuclear 
hormone receptors. By modulating gene expression, it plays key roles in maintaining glucose and 
lipid homeostasis and inhibiting inflammation (Naidenow et al., 2016). Activation of the PPARα 
receptor is known to exert anti-nociceptive and anti-inflammatory effects, even at the gastrointestinal 
level (Escher et al., 2001; Azuma et al., 2010; Petrosino and Di Marzo, 2017). The strong PPARα 
immunoreactivity observed in the mm and its mucosal emanations, as well as the peculiar localization 
of this receptor in the smooth muscle cells of CML and LML, suggests a unique role for this receptor 
(as seen for GPR55 receptor) in GIT motility. Interestingly, whereas in the LML the distribution of 
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the PPARα receptor overlapped that of the GPR55 receptor, in the ICML the former seemed to be 
missing, whereas the latter was widely distributed. At present, we are not able to speculate on the 
physiological meaning of this different receptor distribution. Although it was not possible to precisely 
identify the strong PPARα-immunoreactive cells within the lamina propria of the villi, their shape, 
cytoplasmic projections and distribution are suggestive of mucosal dendritic cells (DCs) (Junginger 
et al., 2014). Notably, DCs are widely distributed in the digestive system and play a relevant role in 
innate and adaptive immunity and in the maintenance of tolerance (Svensson et al., 2010). Finally, 
the expression of PPARα immunoreactivity on cells particularly involved in gut pathophysiology, 
i.e., the intestinal MCs (Lee et al., 2016; Bischoff, 2016; Wouters et al., 2016), suggests a potential 
role of PPARα agonists in GIT inflammation. The most intriguing localization of PPARα receptor 
revealed by our study was at the level of EGCs, i.e., cells that are functionally comparable to CNS 
astrocytes (Liu et al., 2013; Sharkey, 2015) and able to multifunctionally interact with the epithelium, 
immune system, nerve fibres, lymphatic and blood vessels (Liu et al., 2013). It has been reported that 
EGC activation may amplify intestinal inflammation (Cirillo et al., 2011; Ochoa-Cortes et al., 2016) 
and PPARα agonists mitigate it by reducing the glial expression of S100B protein (Esposito et al., 
2014). The robust expression of the PPARα receptor on the muscular and endothelial components of 
blood vessels suggests a possible role of this receptor in the control of canine GIT blood flow. The 
hypothesis is sustained by previous observations on the beneficial effects of PPARα agonists on 
inflammatory responses in vascular smooth muscle cells (Zahradka et al., 2003; Ji et al., 2010) and 
endothelial cells (Naidenow et al., 2016). 
Conclusion 
Taken together, the data of the present study show the wide distribution of the cannabinoid receptor 
ensemble in several cellular types of all layers of the canine GIT. These morphological findings, 
although not yet supported by physiological or pharmacological evidence, suggest that cannabinoid 
receptor agonists have a therapeutic potential for controlling gastrointestinal inflammatory conditions 
and visceral hypersensitivity in this species. The hypothesis is supported by a great deal of evidence 
on the intestinal protective effects of one of the most studied naturally occurring cannabinoid receptor 
ligands, PEA (Borrelli et al., 2015). PEA was originally considered to activate the CB2 receptor 
(Facci et al., 1995; Re et al., 2007; Petrosino et al., 2016), resulting in MCs down-modulation through 
the so-called ALIA mechanism (Autacoid Local Injury Antagonism) (Aloe et al., 1993; De Filippis 
et al., 2013; Petrosino and Di Marzo, 2017). Currently, PEA has been shown not only to have a strong 
affinity for other cannabinoid receptors, like GPR55 (reviewed by Petrosino et al., 2016), but also to 
reduce intestinal radiation injury in a mast cell-dependent manner (Wang et al., 2014), and to 
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normalize intestinal motility through a mechanism involving CB1 receptor (Capasso et al., 2014). 
Furthermore, using both in vitro and in vivo preclinical models of enteropathies, it has been 
demonstrated that the activation of PPAR-α by PEA results in inhibition of colitis-associated 
angiogenesis (Sarnelli et al., 2016), modulation of intestinal permeability (Karwad et al., 2017b), 
improvement of colon inflammation (Esposito et al., 2014), and protection against 
ischemia/reperfusion-induced intestinal injury (Di Paola et al., 2012). In conclusion, the findings of 
the present research support the potential therapeutic use of non-psychotropic and safe cannabinoid 
agonists such as PEA (Nestmann, 2016) in canine intestinal inflammation and may constitute a 
starting point for future comparative studies on the possible changes in the cannabinoid receptor 
ensemble during GIT inflammatory conditions in the dog. 
  





Host Code Dilution Source 
CB1 Rabbit Orb10430 1:200 Biorbyt 
CB2 Rabbit AB45942 1:200 Abcam 
CD31 Mouse M0823 Clone JC70A 1:30 Dako 
GFAP Chicken AB4674 1:800 Abcam 
GPR55 Rabbit NLS6817 1:200 Novus Biol. 
Factor VIII Rabbit A0082 1:1000 Dako 
HuC/HuD Mouse A21271 1:200 Life Technologies 
IBA1 Goat NB100-1028 1:80 Novus Biol. 
IgA Rabbit A80-103A 1:1000 Bethyl Lab. 
IgA Goat NB724 1:1000 Novus Biol. 
PPARα Rabbit NB600-636 1:200 Novus Biol. 
Serotonin Mouse Ab16007; # 5HT-H209 1:500 Abcam 
Tryptase Rabbit PAB070Ca01 1:80 Cloude-Clone Corp. 
Tryptase Mouse NBP1-40202 1:200 Novus Biol. 
Tryptase Mouse M7052 Clone AA1 1:200 Dako 
Table 1 - Primary antibodies used in the study. Primary antibodies Suppliers: Abcam, Cambridge, UK; Bethyl 
Laboratories, Montgomery, TX, USA; Biorbyt Ltd., Cambridge, UK; Agilent, Santa Clara, CA, USA; Cloude-Clone 
Corp., Huston, TX, USA; Dako Cytomation, Golstrup, Denmark; Fitzgerald Industries Int., Inc. Concord, MA, USA; Life 
Technologies, Carlsbad, CA, USA; Novus Biologicals, Littleton, CO, USA. 
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Secondary antibody Host Code Dilution Source 
Anti-mouse IgG 
Alexa 594 
Goat A11005 1:200 Life Technologies 
Anti-mouse IgG 
Alexa 488 
Donkey 20010 1:100 Biotium 
Anti-mouse IgG 
Alexa 594 
Donkey AB150132 1:1000 Abcam 
Anti-rabbit IgG 
FITC 
Goat 401314 1:200 Calbiochem-
Novabiochem 
Anti-rabbit 488 Donkey AB150073 1:800 Abcam 
Anti-goat IgG 594 Donkey AB150132 1:600 Abcam 
Anti-chicken TRITC Donkey 703-025-155 1:200 Jackson 
Table 2 - Secondary antibodies used in the stud. Secondary antibodies Suppliers: Abcam, Cambridge, UK; Biotium, Inc. 
Hayward, CA, USA; Calbiochem-Novabiochem, San Diego, CA, USA; Jackson Immuno Research Laboratories, Inc. 
Baltimore Pike, PA, USA; Life technologies, Carlsbad, CA, USA 
  




Figure 1 Representative image of Western blots (WB) analysis showing the specificity of the primary antibodies utilized: 
rabbit anti-cannabinoid receptor 1, rabbit anti-cannabinoid receptor 2, rabbit anti-G protein-coupled receptor 55 
(GPR55), and rabbit anti nuclear peroxisome proliferator-activated receptor alpha (PPARα). Each antibody showed a 
major band close to the theoretical molecular weight. Lane 1 = dog small intestine, lane 2 = mouse small intestine.  
The images of the different immunoblots were slightly adjusted in brightness and contrast to match their backgrounds. 
 
 
Figure 2. Photomicrograph showing cryosection of the mucosa of dog colon in which some lamina propria (white arrows) 
and epithelial cells (open arrows) of unknown nature were immunolabelled with the anti-cannabinoid receptor 1 antibody 
(CB1) (a). In the panel on the right (b), the nuclei of cells were labelled with the nuclear stain DAPI. Scale bar: a-b, 50 
μm.   




Figure 3. a-i) Photomicrograph showing longitudinal cryosections of dog gastrointestinal tract immunolabelled with the 
anti-cannabinoid receptor 2 antibody (CB2). In figures a, c, g-i, the cellular nuclei were labelled with the nuclear stain 
DAPI. Arrows indicate bright CB2-immunolabelled endothelial cells of blood capillaries running along the major axis 
of the duodenal villus (longitudinal section, a); when the villus was cut orthogonally (b), it was possible to observe CB2-
immunolabelled vessels arranged like clock numbers around the circumference of the villus. c) White and open arrows 
indicate, respectively, the nuclei of smooth muscle and endothelial cells expressing strong CB2 immunoreactivity. In the 
insert, the white arrow indicates a thick submucosal artery of the colon showing CB2 immunoreactivity. d-e) Open arrows 
indicate mast cells of the lamina propria of the colon which were immunoreactive for CB2 (d) and tryptase (e); white 
arrows indicate mast cells which were tryptase-immunoreactive and CB2-negative (f, merged image). g) Arrows indicate 
some CB2-immunoreactive immunocytes within a duodenal mucosa lymphatic nodule. h) Stars indicate the nuclei of small 
neurons of the submucosal plexus showing moderate CB2 immunoreactivity on cell membrane. Arrows indicate nuclei of 
smaller dimension belonging to enteric glial cells showing bright CB2 immunoreactivity. i) Stars indicate the nuclei of 
submucosal neurons showing faint and diffuse cytoplasmic CB2 immunoreactivity. The arrows indicate the nuclei of 
endothelial cells, which showed strong CB2-immunolabelling. j-l) Stars indicate the nuclei of myenteric plexus neurons 
of pylorus (j), ileum (k) and colon (l), which were CB2-negative. On the contrary, the smooth muscle cells of the 
longitudinal (LML) and circular muscle layers (CML) showed intense CB2 immunoreactivity. Scale bar: a-j, 50 μm; k, l, 
100 μm. 
  





Figure 4. Photomicrograph showing cryosections of dog gastrointestinal tract immunolabelled with the anti-GPR55 
antibody. a-c) Small white arrows indicate lamina propria cells of pylorus (a) and colon (b-c) showing bright GPR55 
immunoreactivity. The small open arrows (a, b) indicate GPR55-immunolabelled enterochromaffin cells of the pylorus 
(a) and colon (b). Large open arrows indicate epithelial cells of the inner portion of the mucosa of the colon, which 
showed diffuse GPR55 immunoreactivity. d-f) The white arrows indicate that GPR55-immunoreactive cells (d) of the 
duodenal mucosa co-expressed IBA1 immunoreactivity (e), which indicates that these cells were predominantly 
macrophages. The open arrow indicates GPR55-immunoreactive cells, which were not IBA1-positive. g-i) White arrows 
indicate lamina propria cells of the colon which co-expressed GPR55- and IgA immunoreactivity, indicating that these 
cells were plasma cells. Open arrows, on the contrary, indicate GPR55-immunoreactive cells, which were not IgA-
positive plasma cells. j-l) Distribution of GPR55-immunolabelling within the circular (CML) and longitudinal muscle 
layer (LML) of the duodenum (j), ileum (k) (cut in longitudinal sections) and colon (l) (cut in transverse section). Arrows 
indicate bright GPR55-immunolabelling in the external portions of the small intestine LML (j-k) and in the whole LML 
of the colon. Scale bar: a-c, g-i, 50 μm; d-f, j-l 100 μm 
  




Figure 5. Photomicrograph showing cryosections of dog small and large intestine immunolabelled with the antibody anti-
PPARα. a-b) Open arrows and white arrows indicate, respectively, blood vessels and fascicles of smooth muscle in a 
villus of ileal mucosa showing bright PPARα. c) Arrows indicate thin and PPARα-immunoreactive elongated cellular 
processes of unknown nature, visible in the apex of a villus cut orthogonally to its major axis. The white stars and open 
stars indicate, respectively, fascicles of smooth muscle cells and blood vessels showing PPARα immunoreactivity. d) The 
open star indicates a strong PPARα-immunoreactive lamina propria dendritic-like cell showing strong PPARα 
immunoreactivity, close to another less visible blurred cell (white star), because it is out of focus. e-h) Distribution of 
PPARα -immunolabelling within the circular (CML) and longitudinal muscle layer (LML) of the duodenum (e, h), ileum 
(f) (cut in longitudinal sections) and colon (g) (cut in transverse section). Arrows indicate bright PPARα-immunolabelling 
in the external portions of the small and large intestine longitudinal muscle layer LML, in which the immunostaining was 
more evident. In the ileum (f), PPARα-immunoreactive smooth muscle cells could also be scattered throughout the whole 
thickness of the LML. In the inner portion of the circular muscle layer (ICML) (h), PPARα immunoreactivity was almost 
undetectable. Scale bar: a-d, 50 μm; e-h, 100 μm. 
  




Figure 6. Photomicrograph showing cryosections of submucosal plexus (SMP) (a-c) and myenteric plexus (MP) (d-i) of 
the dog duodenum, immunolabelled with the anti-PPARα antibody. a-f) Stars indicate SMP (a-c) and MP (d-f) neurons 
(not visible) encircled by enteric glial cells which were immunoreactive for PPARα (a) and GFAP (b) (c, f, merge images). 
g-i) Stars indicate MP HuC/HuD immunoreactive neurons (h) which were PPARα-negative (g). On the contrary, a 
network of PPARα-positive cellular processes belonging to enteric glial cells is visible around HuC/HuD neurons. Scale 
bar: a-i, 50 μm. 
  




Supplementary Figure 1. Photomicrograph showing cryosections of the neocortex of wild-type mouse (a-c) and CB1 
null mouse (d-f), and wholemount preparations of the myenteric (g-i) and submucosal plexus (j-l) of rat ileum in which 
neurons and nerve fibers showed immunoreactivity for the CB1 receptor. In the cryosection of the wild type mouse, CB1 
immunoreactivity was expressed by axonal varicosities (b, c), which were absent in the CB1 null mouse (e, f). In the rat 
myenteric and submucosal plexuses, CB1 immunoreactivity was expressed by neurons which displayed CB1 
immunolabelling also in nucleus (arrows) or only in the nucleus (stars). Scale bar: a-l, 50 µm. 




Supplementary Figure 2. Photomicrograph showing cryosections of the dog ileum in which the mucosal blood vessels 
showed immunoreactivity for the CB2 receptor (a) and platelet endothelial cell adhesion molecule (CD31) (b). Open 
arrows indicate capillaries in which the two markers were co-localized, as visible in the merge image (c); white arrows 
indicate small areas in which the two markers were non overlapped, indicating that other cellular types (likely pericytes) 
showed CB2 immunoreactivity. Scale bar: a-c, 50 µm. 
 
Supplementary Figure 3. Photomicrograph showing a cryosection of the duodenum of a dog with chronic and severe 
enteritis immunolabelled, in which the anti-cannabinoid receptor 2 (a) and anti-HuC/HuD (pan-neuronal marker) 
antibodies (b) were co-localized. Stars indicate submucosal plexus neurons showing diffuse and moderate cytoplasmic 
CB2-immunostaining and bright cell membrane immunolabelling. Arrows indicate bright CB2 immunoreactivity in peri-
neuronal enteric glial cells. Scale bar: a-c, 50 µm. 
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Abstract  
Introduction - A growing body of literature indicates that activation of cannabinoid receptors may 
exert beneficial effects on gastrointestinal inflammation and visceral hypersensitivity.  
Objectives - The present ex vivo study was aimed to investigate immunohistochemically the 
distribution of the canonical cannabinoid receptors CB1 (CB1R) and CB2 (CB2R), and the putative 
cannabinoid receptors G protein-coupled receptor 55 (GPR55), nuclear peroxisome proliferator-
activated receptors alpha (PPARα) and gamma (PPARγ), transient receptor potential ankyrin 1 
(TRPA1), and serotonin receptor 5-HT1a (5-HT1a) in the gastrointestinal tract of the cat.  
Results - CB1R-immunoreactivity (CB1R-IR) was observed in gastric epithelial cells, intestinal 
enteroendocrine cells (EECs) and goblet cells (Figure 1 a-l), lamina propria mast cells (MCs), and 
myenteric plexus (MP) neurons (Figure 2 a-f). CB2R-IR was expressed by EECs, enterocytes, and 
macrophages (Figure 3 a-o). GPR55-IR was expressed by EECs, macrophages, immunocytes, and 
MP neurons (Figure 4 a-i). PPARα-IR was expressed by parietal cells, immunocytes, smooth muscle 
cells, and enteroglial cells (Figure 5 a-i). PPARγ-IR was expressed by the nucleus of MP neurons 
(Figure 5 j-l). TRPA1-IR was expressed by enteric neurons and intestinal goblet cells (Figure 6 a-f). 
5-HT1a receptor-IR was expressed by gastrointestinal epithelial cells and gastric smooth muscle cells 
(Figure 6 g-i). 
Conclusions and relevance - Cannabinoid receptors showed a wide distribution in the feline GIT 
layers. Although not yet confirmed/supported by functional evidences, the present research might 
represent an anatomical substrate that might be useful to support, in feline species, the therapeutic 
use of cannabinoids during gastrointestinal inflammatory diseases.  
  




Figure 1(a-l): Photomicrograph showing cryosections of the cat gastrointestinal tract immunolabeled with the antibody 
anti-cannabinoid receptor 1 (CB1) a-c). Arrows indicate some of the pyloric elongated mucosal cells, which show bright 
CB1 receptor immunoreactivity. d-f) Arrows indicate four pyloric enteroendocrine cells displaying bright cytoplasmic 
CB1 receptor immunoreactivity. g-l) Arrows indicate some of the small intestine (g-i) and large intestine (j-l) mucous 
goblet cells expressing bright CB1 receptor immunoreactivity of the cell membrane. Scale bar: a-l, 50 µm. 
  




Figure 2(a-f): Photomicrograph showing a cryosection of the cat gastrointestinal tract immunolabeled with the antibody 
anti-cannabinoid receptor 1 (CB1). Cellular nuclei were labelled with the nuclear stain DAPI. a-c). Arrows indicate four 
of the numerous lamina propria mast cells co-expressing tryptase (a) and bright CB1 receptor (b) immunoreactivity. In 
c the merge image. d-f) Some of the myenteric plexus neurons (arrows) showed faint CB1 receptor immunoreactivity. The 
large nuclei of the enteric neurons were labelled with DAPI. Scale bar: a-f, 50 µm. 
  





Figure 3(a-o): Photomicrograph showing cryosections of cat gastrointestinal tract immunolabelled with the antibody 
anti-cannabinoid receptor 2 (CB2). Cellular nuclei were labelled with the nuclear stain DAPI. a-b) Arrows indicate some 
of the numerous enteroendocrine cells identified with the antibody anti-chromogranin A (CGA) (c) co-expressing bright 
CB2 receptor immunoreactivity (b) d-f)  Arrows indicate some of the numerous enteroendocrine cells identified with the 
antibody anti-serotonin (5-HT) (c) co-expressing bright CB2 receptor immunoreactivity (b). g-h) In the small intestine of 
one subject (#2), CB2 receptor immunoreactivity was expressed by the luminal surface of enterocytes distributed along 
the outer half (apical portion) of the villi (white arrows), whereas in their inner half the epithelial cells were CB2 negative 
(open arrows). i) In the colon, CB2 receptor immunoreactivity was expressed by the cell membrane of crypts epithelial 
cells (white arrows) and goblet cells (open arrows). j-l) Arrows indicate bright CB2 receptor immunolabelling (k) of the 
enteroendocrine cells of the colon. m-o) The lamina propria macrophages, recognized for their IBA1 immunoreactivity, 
co-expressed moderate CB2 immunolabelling (arrows). Scale bar: a-f, h-o 50 µm; g, 100 µm.  




Figure 4 (a-i): Photomicrograph showing cryosections of cat small and large intestine immunolabelled with the antibody 
anti-GPR55. Cellular nuclei were labelled with the nuclear stain DAPI. a-c) Arrows indicate bright GPR55 receptor 
immunolabelling (b) of the enteroendocrine cells of the colon. d-e) Intestinal lymphatic nodules in which a large number 
of immunocytes showed bright GPR55 immunoreactivity. The arrows indicate the muscularis mucosae. f) Lamina propria 
IgA immunoreactive plasma cells (red color) did not co-express GPR55 immunoreactivity (green color). g-i) 
Gastrointestinal subsets of myenteric plexus neurons expressed moderate GPR55 immunoreactivity. The white stars 
indicate three neuronal nuclei. Abbreviations: circular muscle layer (CML); longitudinal muscle layer (LML). Scale bar: 
a-d, e-i 50 µm; d, 100 µm. 
  




Figure 5 (a-l): Photomicrograph showing cryosections of cat pylorus and intestine immunolabelled with the antibody 
anti-PPARα (a-i) and PPARγ (j-l). Cellular nuclei were labelled with the nuclear stain DAPI. a-b) Arrows indicate three 
large pyloric gland cells (putative parietal cells) which showed bright PPARα immunoreactivity. d-e) Intestinal lymph 
node in which a large percentage of immunocytes showed PPARα immunoreactivity. f) PPARα immunoreactivity was 
observed also in the smooth muscle cells of the longitudinal muscle layer (LML). Abbreviation: circular muscle layer, 
CML. g-i) Stars indicate the nucleus of some myenteric plexus neurons. Arrows indicate the nuclei of three GFAP 
immunoreactive glial cells (i) which co-expressed PPARα immunoreactivity. j-l) Stars indicate the nuclei of some 
myenteric plexus neurons, which showed weak PPARγ immunoreactivity. Abbreviations: circular muscle layer, CML; 
longitudinal muscle layer (LML). Scale bar: a-l, 50 µm.  




Figure 6 (a-i): Photomicrograph showing cryosections of cat gastrointestinal tract immunolabelled with the antibody 
anti-TRPA1 (a-f) and 5-HT1a (g-i). Cellular nuclei were labelled with the nuclear stain DAPI. a, b) Stars indicate three 
nuclei of the pyloric myenteric plexus neurons which showed TRPA1 immunoreactivity. c) Arrows indicate duodenal 
myenteric plexus neurons TRPA1 immunoreactive. d-f) Arrows indicate small intestinal goblet cells which showed bright 
TRPA1 immunoreactivity. g-i) Pyloric mucosa in which mucous and glandular cells expressed 5-HT1a immunoreactivity. 
Scale bar: a-i, 50 µm. 
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Localization of cannabinoid receptors in the canine and feline 
gastrointestinal tract 
Roberto Chiocchetti1, Giorgia Galiazzo1, Agnese Stanzani1, Fiorella Giancola2, Claudio Tagliavia1, 
Margherita de Silva1, Federico Fracassi1, Marco Pietra1 
1Department of Veterinary Medical Sciences – University of Bologna, Italy 
2 St. Orsola-Malpighi Hospital, Bologna, Italy 
Abstract 
Introduction - The endocannabinoid system (ECS) is involved in the control of gastrointestinal 
inflammation and visceral pain.  
Objectives - The present ex vivo study was aimed to investigate the distribution of the canonical [CB1 
(CB1R) and CB2 (CB2R)], and putative cannabinoid receptors [G protein-coupled receptor 55 
(GPR55), nuclear peroxisome proliferator-activated receptors alpha (PPARα), transient receptor 
potential ankyrin 1 (TRPA1), and serotonin receptor 5-HT1a (5-HT1aR)] in the gastrointestinal tract 
of the dog and the cat.  
Results - Gastrointestinal tissues (pylorus, duodenum, ileum and distal colon) from four dogs and four 
cats were collected after spontaneous death or after euthanasia, following owners’ consent. 
Specimens were processed by immunohistochemistry using species-specific primary antibodies. 
Antibodies targeting enteric neurons, glial cells (EGCs), enteroendocrine cells (EECs), mast cells 
(MCs), macrophages, and plasma cells were employed in co-localization experiments to identify the 
cell types expressing cannabinoid receptors. CB1R-immunoreactivity (CB1R-IR) was observed in 
epithelial and lamina propria (LP) cells, and in myenteric plexus (MP) neurons in both the species. 
CB2R-IR was expressed by LP MCs and immunocytes, blood vessels and smooth muscle cells in the 
dog. In the cat it was expressed by EECs, intestinal epithelial cells, and macrophages. GPR55-IR was 
expressed by LP macrophages and smooth muscle cells in the dog; in the cat it was expressed by 
EECs, immunocytes and MP neurons. PPARα-IR was expressed by smooth muscle cells and EGCs 
in both the species. In the cat PPARα-IR was also expressed by immunocytes and gastric parietal 
cells. TRPA1-IR was expressed by globet cells in both the species and enteric neurons only in the 
cat. 5-HT1aR-IR was expressed by epithelial cells in the cat and by globet cells, LP cells and MP 
neurons in the dog (Figure 1).  
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Conclusion and relevance - The present research provides an anatomical basis supporting the 
therapeutic use of cannabinoid receptor agonists in relieving motility disorders and visceral 
hypersensitivity in acute or chronic enteropathies.   
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Localization of cannabinoid receptors in the horse ileum 
Giorgia Galiazzo1, Fiorella Giancola2, Claudio Tagliavia1, Agnese Stanzani1, Margherita De Silva1, 
Alessandro Spadari1, Riccardo Rinnovati1, Roberto Chiocchetti1 
1Department of Veterinary Medical Sciences, University of Bologna, Italy 
2 St. Orsola-Malpighi Hospital, Bologna, Italy 
Abstract  
Introduction – Colic is a digestive disorder of horses and one of the most dangerous emergency 
problems in equine medicine. A growing body of literature indicates that activation of cannabinoid 
receptors could exert beneficial effects on gastrointestinal inflammation and visceral hypersensitivity. 
Objectives – The present ex vivo study was aimed to investigate immunohistochemically the 
distribution of the canonical cannabinoid receptors CB1 (CB1R) and CB2 (CB2R), and the putative 
cannabinoid receptors G protein-coupled receptor 55 (GPR55), nuclear peroxisome proliferator-
activated receptors alpha (PPARα) and gamma (PPARγ), transient receptor potential ankyrin 1 
(TRPA1), transient potential vanilloid receptor 1 (TRPV1) and serotonin receptor 5-HT1a (5-HT1aR) 
in the horse ileum. 
Results – CB1R-immunoreactivity (CB1R-IR) was observed in epithelial cells, myenteric plexus 
(MP) and submucosal plexus (SMP) neurons, nerve fibers and glial cells. CB2R-IR was expressed 
by epithelial and lamina propria (LP) cells. GPR55-IR was expressed by enteroendocrine cells 
(EECs), LP immune cells, smooth muscle cells of the circular muscular layer (CML). PPARα-IR was 
expressed by smooth muscle cells of the longitudinal muscular layer (LML), endothelial cells of 
submucosal vessels, MP and SMP glial cells, and elongated cells in proximity to the MP resembling 
interstitial cells of Cajal (ICCs). PPARγ-IR was expressed in the nuclei of neurons, glial cells, smooth 
muscle cells, epithelial cells, and LP cells. TRPA1-IR was expressed by enteric neurons and nerve 
fibers. TRPV1-IR was expressed by MP glial cells and SMP glial cells and neurons. 5-HT1aR-IR 
was expressed by Paneth cells cells and LP immune cells.  
Conclusions and relevance – Cannabinoid receptors showed a wide distribution in the ileum of the 
horse, although not yet supported by functional evidences. The present research might represent an 
anatomical substrate that might support further studies about the distribution of cannabinoids 
receptors during gastrointestinal inflammatory diseases.  




Cannabinoid receptors regulate different gastrointestinal functions, including motility, emesis, 
appetite or satiety, both in physiological and pathological conditions (Izzo and Coutts, 2005).  
Colic is a digestive disorder of horses, and includes different form of abdominal pain (Pilliner and 
Davies, 2004). It is one of the most dangerous emergency problem in equine medicine and one of the 
principal cause of death for horses, so it is a primary health concern of owners (Curtis et al., 2019). 
For this reason, several companies produce medical marjiuana and cannabinoid receptor agonists to 
be used in equine medicine, directed principally against somatic and visceral pain, although not yet 
support by anatomical or functional studies. Cannabidiol (CBD), a non-psychoactive compound 
found in cannabis sativa, seems to be one of the most promising therapeutic substances, due to its 
analgesic, anti-inflammatory, anti-spasmodic benefits (Mechoulamet al., 2007; Pertwee, 2008). 
Phytocannabinoids are known to act on multiple targets, more than CB1 and CB2 receptors. They 
interact with other G-protein coupled receptors (GPR), nuclear receptors, transient receptor potential 
(TRP) channels, serotonin (5-HT) receptors and glycine receptors (Morales et al., 2017).  
Knowing the cellular distribution of the specific receptors is fundamental to understand the action of 
a drug. To date, reliable anatomical studies regarding the cellular distribution of cannabinoid 
receptors in the horse intestinal tract are still lacking. In order to help filling these anatomical gaps, 
the present ex vivo study was designed to identify, in the equine ileum, the cellular distribution of 
two canonical cannabinoid receptors, i.e. CB1R and CB2R, and of six different putative cannabinoid 
receptors, i.e. G protein-coupled receptor 55 (GPR55), nuclear peroxisome proliferator-activated 
receptor alpha (PPARα) and gamma (PPARγ), transient potential vanilloid receptor 1 (TRPV1), 
transient potential ankyrin receptor 1 (TRPA1), and serotonin receptor 1a (5-HT1aR). 
Material and methods 
Aniamals  
Ileal samples were collected ex-vivo from six horses (about 1.5 years of age) at the public 
slaughterhouse. Animals did not show gross alteration of the gastrointestinal wall. 
According to the Directive 2010/63/EU of the European Parliament and of the Council of 22 
September 2010 on the protection of animals used for scientific purposes, the Italian legislation (D. 
Lgs. n. 26/2014) does not require any approval by competent authorities or ethics committees, 
because this research did not influence any therapeutic decisions. 




Ileal samples (about 10 cm in lenght) were harvested within 30 minutes from death and were 
longitudinally opened along the mesenteric border. Tissues were then washed in phosphate-buffered 
saline (PBS), fixed and processed to obtain cryosections (2.0 cm x 0.5 cm) which were later processed 
for immunohistochemistry, as described in a previous study (Chiocchetti et al., 2015). 
Immunofluorescence 
Cryosections were hydrated in PBS and processed for immunostaining. To block non-specific 
bindings, the sections were incubated in a solution containing 20% normal goat or donkey serum 
(Colorado Serum Co., Denver, CO, USA), 0.5% Triton X-100 (Sigma Aldrich, Milan, Italy, Europe), 
and bovine serum albumin (1%) in PBS for 1 h at room temperature (RT). The cryosections were 
incubated overnight in a humid chamber at RT with a cocktail of primary antibodies (Table 1) diluted 
in 1.8% NaCl in 0.01M PBS containing 0.1% sodium azide. After washing in PBS (3 x 10 min), the 
sections were incubated for 1 h at RT in a humid chamber with the secondary antibodies (Table 2) 
diluted in PBS. Cryosections were then washed in PBS (3 x 10 min) and mounted in buffered glycerol 
at pH 8.6 with 4',6-diamidino-2-phenylindole – DAPI- (Santa Cruz Biotechnology, CA, USA). 
Specificity of the primary antibodies  
The choice of the primary antibodies used in the study was based on the homology of the amino acid 
sequence between the immunogen of the commercially available antisera and the horse proteins, 
verified by the “alignement” tool available on the Uniprot database (www.uniprot.org) and the 
BLAST tool of the National Center for Biotechnology information (NCBI) (www.ncbi.nlm.nih.gov) 
(Table 3).  
Specificity of the secondary antibody 
The specificity of the secondary antibody was tested by applying them after omission of the primary 
antibodies. No stained cells were detected after omitting the primary antibodies. 
Fluorescence microscopy 
Preparations were examined on a Nikon Eclipse Ni microscope equipped with the appropriate filter 
cubes to distinguish the fluorochromes employed. The images were recorded with a Nikon DS-Qi1Nc 
digital camera and NIS Elements software BR 4.20.01 (Nikon Instruments Europe BV, Amsterdam, 
Netherlands). Slight adjustments to contrast and brightness were made using Corel Photo Paint, 
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whereas the figure panels were prepared using Corel Draw (Corel Photo Paint and Corel Draw, 
Ottawa, ON, Canada).  
Results  
CB1 receptor - CB1 receptor immunoreactivity was expressed by the epitelium, in particular 
enterocytes and goblet cells. These cells showed cytoplasmatic and membrane reactivity, otherwise 
the nuclei were CB1-negative. Neurons and glial cells of the MP and SMP showed CB1R-
immunoreactivity, confirmed with colocalization with HuC/HuD for neurons and GFAP for glial cells 
(Fig. 1a-f; Fig. 2a-d). Some nNOS (nitric oxide synthases )immunoreactive neurons showed CB1R 
immunoreactivity (Fig. 3a-c). In the muscular layer, near the MP, some nerve fibers showed CB1R-
immunoreactivity. Cells surrounding nerve fibers, probably Schwann cells, showed CB1R 
immunoreactivity (Figure 4 a-c).  
CB2 receptor - CB2 receptor immunoreactivity was expressed only in the mucosa, in particular 
epithelium and LP. In the epithelium, enterocytes and goblet cells showed cytoplasmatic 
immunoreactivity. In the lamina propria, immune cells showed bright cytoplasmatic 
immunoreactivity; however, the nature of these cells were not investigated by the co-localization with 
specific markers (Figure 5 a-d).  
GPR55 - GPR55 was expressed in the mucosal, submucosal and muscular layer. In the mucosa, 
enteroendocrine cells (EECs) showed bright GPR55-immunoreactivity (Figure 6 a-f). Numerous 
small round immune cells, probably lymphatic cells, showed bright GPR55-immunoractivity. They 
were distributed in the LP (Figure 6 a-c), in proximity to the muscularis mucosae, and concentrated 
in the Peyer patches (Figure 6 d-f). However, the nature of these cells was not investigated by the use 
of specific markers fot B or T cells, such as CD79 and CD3, respectively. In the LP, other immune 
cells showed GPR55-immunoreactivity, likely/probably macrophages, because of the presence of 
aspecific pigmented granules in their cytoplasm (Fig. 7a-d). Finally, GPR55-immunoreactivity was 
present in groups of smooth muscle cells in the internal portion of the CML.  
PPARα - PPARα-immunoreactivity was brightly expressed by smooth muscle cells and vascular cells. 
In the muscular layer, numerous cells in the LML were positive for PPARα (Fig. 8 g-i). Along the 
bundles of nerve fibers, glial cells (probably Schwann cells) showed bright immunoreactivity. 
Endothelial cells of large submucosal blood vessels showed bright immunoreactivity. Close to the 
MP, elongated cells between LML and CML, probably interstitial cells of Cajal (ICCs), were PPARα 
positive. In the ENS, glial cells were strongly positive both in MP and SMP (Fig. 8 a-f).  
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PPARγ - In the ENS, glial cells and neurons showed bright nuclear immunoreactivity, and weak 
cytoplasmatic immunoreactivity in some neurons (Fig. 9 a-c). A nuclear marking was also evident in 
smooth muscle cells, epithelial cells and LP cells (Fig. 9 d-f).  
TRPA1 - TRPA1-immunoreactivity was expressed by enteric neurons (nuclei> cytoplasm) and in 
nerve fibers close to the MP (Fig. 10 a-f). 
TRPV1 - TRPV1-immunoreactivity was expressed only in the ENS. In the MP, glial cells showed 
bright TRPV1-immunoreactivity (Fig. 11 a-c). Otherwise in the SMP, both glial cells and enteric 
neurons showed immunoreactvity (glial cells > neurons) (Fig. 11 d, e). 
5-HT1aR - 5-HT1aR immunoreactivity was observed only in the mucosa. Large cells in the bottom 
part of intestinal crypts showed bright cytoplasmatic immunoreactivity, mainly in cytoplasmatic 
granules located in the apycal part of the cells (Fig 12 a-c). The antibody Rb anti Lyzozyme – specific 
marker for Paneth cells - gives the same pattern as the Rb anti 5-HT1aR, confirming that these cells 
are the same (Figure 13 a-b). In the LP, immune cells (likely macrophages or mast cells) showed 
bright 5-HT1aR- immunoreactivity (Fig. 12 d-f).  
Discussion   
As we recently observed in dogs (Galiazzo et al., 2018), cannabinoid receptors are also widely 
distributed in horse intestine. CB1R-immunoreactivity in epithelial cells and ENS confirmed the 
results obtained in rat, mouse, ferret, guinea-pig, pig and dogs (Kulkarni-Narla and Brown, 2000; 
Van Sickle et al., 2001; Coutts et al., 2002; Duncan et al., 2008; Galiazzo et al., 2018). The presence 
of CB1R-immunoreactivity in enterocytes and goblet cells may reflect a possible role of the receptor 
in the regulation of intestinal permeability and enteric cells regeneration. Moreover, the intestinal 
microbiota can influence the expression of CB1R in the enterocytes (Muccioli et al., 2010). The 
expression of CB1R in goblet cells indicates that cannabinoid can modulate mucus secretion, 
probably reducing it. Different studies highlighted the presence of CB1R in enteric neurons, but 
usually not in nNOS neurons, as we observed in this study. In the horse, nNOS neurons can be 
inhibitory neurons but also interneurons (Chiocchetti et al., 2009). The presence of CB1R-
immunoreactivity in Schwann cells could be linked to a possible role of the receptor in myelinization 
process and neuronal regeneration (Costa et al., 2005; Freundt-Revilla et al., 2017).  
CB2R-immunoreactivity was observed in enterocytes and goblet cells, suggesting a possible role of 
this receptor in preserving the integrity of the intestinal mucosa (Harvey et al., 2013). The presence 
of CB2R in immunitary cells is well known, in particular macrophages, mast cells, plasmacells, 
dendritic cells and lymphocytes (Facci et al., 1995; Wright et al., 2005, Duncan et al., 2008; Svensson 
et al., 2010). The immunomodulatory effect of cannabinoids is probably mediated by CB2R (Turcotte 
Experimental studies  
87 
 
et al., 2016). GPR55-immunoreactivity was observed in the ENS of rodents and humans (Ross, 2011; 
Li et al., 2013), but not of dogs (Galiazzo et al., 2018) neither in the horse. The presence of GPR55 
in the enteroendocrine cells can explain a possible role in secretion of intestinal hormons. The 
expression of GPR55 in immunitary cells, in particular macrophages, has been demonstrated in 
rodents, humans and dogs (Taylor et al., 2015; Lanuti et al., 2015; Galiazzo et al., 2018) with 
immunomodulatory effect. Proinflammatory mediators, released by mast cells during intestinal 
inflammation, cause the accumulation of macrophages in the basal portion of the LP (He et al., 1997; 
He and Walls, 1998). Therefore, cannabinoids compounds acting on CB2R and/or GPR55, could limit 
the inflammatory cascade during GI diseases (Esfandyari et al., 2007).  
PPARα was widely distributed in the ENS, musculature and vasculature. Mielinic sheath cells, 
probably Schwann cells, distributed along the bundles of nerve fibers, showed PPARα 
immunoreactivity. The expression of this receptor in smooth muscle cells of the LML was also 
observed in the dog (Galiazzo et al., 2018). This receptor could be involved in regulation of intestinal 
motility also in the horse, reinforced by the presence of PPARα immunoreactivity in ICCs, pacemaker 
cells of the GI tract (Torihashi et al., 1995). Glial cells surrounding MP and SMP neurons expressed 
bright PPARα immunoreactivity. These cells interact with the epithelium, immune system, nerve 
fibers, lymphatic and blood vessels (Sharkey, 2015; Liu et al., 2016).  
In this study the presence of PPARγ in the nuclei of MP neurons could be explained with its 
neuroprotective potential, observed in certain central nervous system diseases (Hung et al., 2019). 
PPARγ is also involved in the regulation of intestinal homeostasis. Its expression on epithelial cells 
could be linked to the intestinal microbiota; indeed, butirrate, produced by intestinal microorganisms, 
is a PPARγ agonist. The activation of PPARγ has been demonstrated to prevent intestinal dysbiosis 
(Byndloss et al., 2017). PPARγ deletion in animal models seems to be correlated with the 
development of IBD and colon cancer, underlining a possible antiinflammatory and antineoplastic 
role of the receptor (Adachi et al., 2006; Varga et al., 2011). PPARγ is a target of CBD, which reduces 
intestinal inflammation mainly through a modulation of the neuro-immune axis (De Filippis et al., 
2011; Couch et al., 2017). 
TRPA1, an ion channel, detects specific chemicals in food and transduces mechanical, cold and 
chemical stimulation. In the present study we observed enteric TRPA1-IR neurons, which is 
consistent with data obtained on mouse intestine by Poole et al. (2011), who identified TRPA1-
immunoreactivity on inhibitory neurons. However, in the present study we did not characterize the 
phenotype of equine enteric TRPA1-positive neurons.  
TRPV1-immunoreactivity was expressed by MP glial cells and SMP glial cells and neurons. The 
expression of TRPV1-immunoreactivity in enteric neurons was observed in other studies (Anavi-
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Goffer and Coutts, 2003; Buckinx et al., 2013). TRPV1 is fundamental in the mediation of heat 
sensitivity, increased during inflammation. Hyperalgesia and allodinia during inflammation are 
mediated by TRPV1. In animal models, TRPV1 antagonists attenuated visceral pain (Ghilardi et al., 
2005).  
We observed 5-HT1aR-immunoreactivity in epithelial cells. Considering the pivotal role of serotonin 
in regulating gut motility, visceral sensitivity, and fluid secretion via specific receptors, 5-HT1aR 
may exert a role in cellular homeostasis and secretion in the horse.  
Conclusion  
This study is the first to describe the distribution of different cannabinoid receptors in the equine 
ileum. Various cellular elements (epithelial cells, immune cells, neurons and glial cells, and muscular 
cells) showed immunoreactivity for cannabinoid receptors, highlighting the important role of the 
endocannabinoid system in the gut homeostasis. However, multiple colocalizations are still missing 
(i.e. immune cells, enteroendocrine cells, neurons). Considering the importance of gastrointestinal 
diseases in equine medicine, these results can provide an anatomical basis for further functional and 
clinical studies on the therapeutic use of non psycothropic cannabinoids for horses.   
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Table 1. Primary antibodies used in the study. Primary anti bodies Suppliers: Abcam, Cambridge, UK; Life Technologies, 




Host Code Dilution Source 
Anti-mouse F(ab’)2 
fragment TRITC 
Goat ab51379 1:50 abcam 
Anti-rabbit F(ab’)2 
fragment FITC 
Goat 98430 1:300 abcam 
Anti-rabbit 555 Goat ab150078 1:500 abcam 
Anti-chicken TRITC Donkey 703-025-155 1:200 Jackson 
Table 2. Secondary antibodies used in the study. Secondary antibodies Suppliers: Abcam, Cambridge, UK; Biotium, Inc. 
Hayward, CA, USA; Jackson Immuno Research Laboratories, Inc. Baltimore Pike, PA, USA.  
Primary antibody Host Code Dilution Source 
CB1 Rabbit ab23703 1:100 abcam 
CB2 Rabbit ab45942 1:200 abcam 
GFAP Chicken ab4674 1:800 abcam 
GPR55 Rabbit NB110-55498 1:200 Novus Biol. 
HuC/HuD Mouse A21271 1:200 Life Technologies 
Lysozyme Rabbit Ab74666 1:2 abcam 
PPARα Rabbit NB600-636 1:200 Novus Biol. 
PPARγ Rabbit ab45036 1:300 abcam 
5-HT1a Rabbit ab85615 1:100 abcam 
TRPA1 Rabbit ab58844 1:100 abcam 
TRPV1 Rabbit ACC-030 1:200 Alomone 





Homology between the amino 
acidic sequences (immunogen 
and horse) 
Homology with the immunogen 
sequence 








































Table 3. Homology between the AA sequences (between the immunogen and horse) and with the specific sequence of the 
immunogen of the CBR antibodies used in the study. 
  




Figure 1 (a-f): Cryosections of equine ileum immunolabeled with the Ab CB1R and the pan-neuronal marker HuC/HuD. 
Stars indicate neurons in the MP (a-c) and SMP (d-f) which expressed both HuC/HuD (a, d) and CB1R (b, e).(c, f: 
merging). Scale bar a-f: 50 µm. 
 
Figure 2 (a-d): Photomicrograph showing a cryosection of equine ileum immunolabeled with the Ab CB1R and GFAP 
for glial cells. Stars indicate MP neurons nuclei immunolabeled with the marker DAPI (a), while arrows indicate nuclei 
of glial cells (c). Both nuclei of neurons and glial cells showed CB1R-immunoreactivity (b, d: merging). Scale bar: a-d, 
50 µm  




Figure 3 (a-c): Photomicrograph showing a cryosection of equine ileum immunolabeled with the Ab CB1R (a) and the 
Ab anti nNOS (b). Stars indicate three MP neurons which co-express CB1R and nNOS (c). Scale bar 50 µm. 
 
 
Figure 4 (a-c): Photomicrograph showing a cryosection of equine ileum (muscular layer) immunolabeled with the Ab 
CB1R. Nuclei are marked with DAPI (a). Stars indicate three nuclei of glial cells, probably Schwann cells, brightly 
immunolabeled with the ab CB1R. 
  




Figure 5 (a-d): Photomicrograph showing a cryosection of equine ileum immunolabeled with the Ab CB2R. Nuclei are 
immunomarked with the DAPI (a). Epithelial cells showed diffuse CB2 immunolabelling (b); white arrows indicate 
positive LP immune cells. Empty arrows indicate cells with autofluorescent granules, immunolabeled also with the red 
TRITC (aspecific filter, c). Scale bar: a-d, 50 μm. 
  




Figure 6 (a-f): Photomicrograph showing a cryosection of equine ileum immunolabeled with the Ab GPR55. Nuclei are 
immunolabeled with the marker DAPI (a, d). White stars indicated enteroendocrine cells immunolabeled with GPR55 in 
the LP (b) and in a lypmphatic nodule (e). Empty arrows indicate some of the numerous positive immune cells (b). Scale 
bar: a-c, 50 μm; d-f, 100 μm. 
  




Figure 7 (a-d): Photomicrograph showing a cryosection of equine ileum immunolabeled with the Ab GPR55. Nuclei are 
immunolabeled with the marker DAPI (a). White arrows indicate submucosal cells close to the mm, brightly 
immunolabeled with the Ab anti GPR55 (b). These cells were probably macrophages, because their cytoplasm contained 
granules with autofluorescent pigment (aspecific filter, c). Empty arrows indicate GPR55 positive immune cells, probably 
lymphatic cells, in the external portion of the LP, close to the mm. Scale bar 50 µm. 
  




Figure 8 (a-i): Photomicrograph showing a cryosection of equine ileum immunolabeled with the Ab PPARα. Stars 
indicate MP (a-c) and SMP (d-f) neurons, surrounded by glial cells immunoreactive for PPARα. White arrows indicate 
glial cells nuclei. Empty cells indicate presumed interstitial cells of Cajal (ICCs), brightly immunolabelled. Smooth 
muscle cells of the LML showed bright immunoreactivity for PPARα (g-i). Scale bar: a-i, 50 μm. 
  




Figure 9 (a-f): Photomicrograph showing a cryosection of equine ileum immunolabeled with the Ab PPARγ. Stars indicate 
MP neurons, which showed bright nuclear immunoreactivity for PPARγ. Arrows, indicate the positive nuclei of glial cells. 
(Figure 6 a-c). Epithelial cells were brightly positive for PPARγ, nuclear (empty arrow) or both nuclear and cytoplasmatic 
(white arrows) (Figure d-f). Scale bar a-f: 50 μm. 
 
Figure 10 (a-f): Photomicrograph showing a cryosection of equine ileum immunolabeled with the Ab TRPA1. Stars 
indicate nuclei of MP (a-c) and SMP (d-f) neurons immunolabeled with the HuC/HuD (pan-neuronal marker) (a, d). 
TRPA1-immunoreactivity was nuclear and cytoplasmatic in both MP and SMP (b, e). Scale bar a-f: 50 μm.  




Figure 11 (a-e): Photomicrograph showing a cryosection of equine ileum immunolabeled with the Ab TRPV1. Stars 
indicate MP (a-c) and SMP (d, e) neuronal nuclei, TRPV1-negative in the MP (b) but not in the SMP (e). Otherwise, 
arrows indicate the nuclei of glial cells, brightly immunolabeled both in MP and SMP (b, e). Scale bar: a-e, 50 μm. 
 
Figure 12 (a-f): Photomicrograph showing a cryosection of equine ileum immunolabeled with the Ab 5-HT1aR. Big cells 
in the bottom part of intestinal crypt showed bright cytoplasmatic 5-HT1aR-immunoreactivity, particularly evident in 
cytoplasmatic granules located in the apycal part of the cells (Paneth cells) (Figure 9 a-c). In the LP of a villus, immune 
cells showed bright 5-HT1aR- immunoreactivity (d-f). White arrows indicate voluminous immune cells 5-HT1aR-positive 
(e); empty arrows indicate pigmentated autofluorescent granules, maybe in macrophages, 5-HT1aR negative (e). Scale 
bar a-f: 50 μm. 
 




Figure 13 (a-b): Photomicrograph showing a cryosection of equine ileum immunolabeled with the Ab 5-HT1aR (a) and 
Ab Lysozyme (b). Big cells in the bottom part of intestinal crypt showed bright cytoplasmatic 5-HT1aR-immunoreactivity, 
particularly in cytoplasmatic granules located in the apycal part of the cells (Paneth cells), with the same pattern showed 
by the Lysozyme. Scale bar a-b: 50 μm. 
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Abstract 
Introduction - The endocannabinoid system (ECS) participates in many digestive processes, such as 
regulation of the appetite, intestinal motility, secretion, nausea and emesis, visceral nociception and 
inflammation (Izzo and Sharkey 2010; Taschler et al., 2017). A great body of evidences demonstrated 
a bidirectional pathway between the gastrointestinal tract and the central nervous system (CNS), both 
in healthy conditions and neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. 
The rat-induced synthetic torpor (ST) phenomenon has been demonstrated as an experimental model 
to resemble neurodegenerative processes (Cerri et al., 2013; Luppi et al., 2019).  
Objective – To characterize the cellular distribution of cannabinoid receptors 1 (CB1R) and serotonin 
5-HT1a receptor (5-HT1aR) in the myenteric plexus (MP) of the rat (control, CTRL vs ST).  
Material and methods – Ex vivo qualitative and quantitative immunohistochemical study on MP 
wholemount preparations of the ileum of six animals (3 CTRL vs 3 ST). The antibodies used in this 
study are rat-specific.  
Results – Bright CB1R immunoreactivity (CB1R-IR) was expressed by MP neurons (Figure 1 a-b). 
CB1R- immunoreactive neurons showed Dogiel type II morphology, with smooth outline and long 
immunolabelled processes In the CTRL, 35±5% of neurons were CB1R immunoreactive (246/683 
cells counted, n=3); in the ST 31±4% (200/639 cells counted, n=3). Although the percentages of 
immunoreactive neurons were similar, the CTRL showed brighter CB1R-IR than the ST. In some 
animals (both CTRL and ST), clusters of flat cells (likely mesothelial cells), with an irregular shaped 
nucleus, in close contact between each other, showed bright CB1R-IR.  
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The 5-HT1aR was analyzed only in CTRL rats; in these rats, 55±8% of MP neurons showed 5-
HT1aR-IR (142/ 205 cells counted, n=3) (Figure 2 a-b). The next step will be to evaluate the 
expression of this receptor also in ST subjects (n=3, counting in progress).  
Suggested conclusion – The wide distribution of cannabinoid receptors CB1 and 5-HT1aR in the 
neurons of the rat MP in both CTRL and ST confirms the importance of the ECS in the functional 
activity of the GI tract, but further analysis are required to understand the role in neurodegenerative 
diseases.   




Figure 1 (a-b): Photomicrograph showing cryosections of myenteric plexus (MP) of the rat ileum (CTRL), 
immunolabelled with the anti-CB1R antibody. The nuclei of cells were labelled with the nuclear stain DAPI (a). MP 
neurons showed bright CB1R - immunoreactivity (b); arrows indicate some of these neurons. Scale bar: a-b, 50 μm. 
 
 
Figure 2 (a-b): Photomicrograph showing cryosections of myenteric plexus (MP) of the rat ileum (CTRL), 
immunolabelled with the anti-5-HT1aR antibody. The nuclei of cells were labelled with the nuclear stain DAPI (a).MP 
neurons showed 5-HT1aR - immunoreactivity (b). Scale bar: a-b, 100 μm. 
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In collaboration with the Digestive Laboratory of Professor John Furness, University of Melbourne 
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enteroendocrine cells in pig gastric epithelium 
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Frank Weissenborn2, Therese E. Fazio Coles1, John B. Furness1,2,3 
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Abstract 
Introduction - Although the pig is an accepted model species for human digestive physiology, no 
previous study of the pig gastric mucosa and gastric enteroendocrine cells has investigated the 
parallels between pig and human.  
Objectives - In this study, we have investigated immunohistochemically markers for each of the 
classes of gastric endocrine cells, gastrin, ghrelin, somatostatin, 5-hydroxytryptamine, histidine 
decarboxylase, and PYY cells in pig stomach.  
Results - The lining of the proximal stomach consisted of a collar of stratified squamous epithelium 
surrounded by gastric cardiac glands in the fundus. This differs considerably from human that has 
only a narrow band of cardiac glands at its entrance, surrounded by a fundic mucosa consisting of 
oxyntic glands. However, the linings of the corpus and antrum are similar in pig and human. Likewise, 
the endocrine cell types are similar and similarly distributed in the two species. As in human, gastrin 
cells were almost exclusively in the antrum, ghrelin cells were most abundant in the oxyntic mucosa 
and PYY cells were rare. In the pig, 70% of enterochromaffin-like (ECL) cells in the antrum and 95% 
in the fundus contained 5-hydroxytryptamine (5-HT), higher proportions than in human. Unlike the 
enteroendocrine of the small intestine, most gastric enteroendocrine cells (EEC) did not contain 
colocalised hormones.This is similar to human and other species.  
Conclusion and relevance - We conclude that the pig stomach has substantial similarity to human, 
except that the pig has a protective lining at its entrance that may reflect the difference between a pig 
diet with hard abrasive components and the soft foods consumed by humans. 
Introduction 
Pigs are commonly used as a translational model of gastrointestinal function, being of similar size 
and having a comparable gastrointestinal anatomy and physiology with humans (Gonzalez et al., 
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2015; Roura et al., 2016). An animal of similar size and physiology is particularly important for the 
investigation of devices that are being developed to treat gastric conditions, for example vagal or 
gastric stimulating electrodes and implanted pulse generators for electrical stimulation (Payne et al., 
2018). One of the conditions that is amenable to gastric electrical stimulation in some patients is 
gastroparesis. Unlike most laboratory animal, the pig is a species that vomits (Szelenyi et al., 1994), 
which is important for testing the utility of electrical stimulation therapy for the treatment of nausea 
and vomiting that are common in gastroparesis. Moreover, some pathological conditions that are the 
targets for therapy are controlled by gastric hormones that have significant roles in regulating 
digestion, metabolism, appetite, and nausea. Of the major gastric hormones, gastrin and histamine are 
best known for regulating gastric acid secretion, ghrelin stimulates appetite and reduces nausea, and 
somatostatin has broad counterregulatory effects. 5-HT may have a role in signalling the presence of 
toxins and initiating expulsion of potentially noxious substances, although it has several other actions 
(Mawe and Hoffman, 2013; Diwakarla et al., 2017; Martin et al., 2017). PYY is also expressed in 
some cells of the gastric epithelium, but its roles in the stomach are unclear. Gastrointestinal 
hormones are stored in enteroendocrine cells (EEC), which were classically defined as discrete cell 
types that each produces a single hormone. In the last decade, however, studies have revealed a 
substantial degree of overlap between EEC hormones or their genes in single EEC of the small and 
large intestines (Fothergill and Furness, 2018). The co-expression patterns of gastric hormones were 
recently characterised in detail in human (Fakhry et al., 2019) and rat (Hunne et al., 2019). In contrast 
to the intestine, relatively few EEC in the stomach expressed more than one hormone, with the 
exception that 5-HT was frequently found in histamine-producing cells. Although the pig stomach is 
similar to human, there are some significant differences, one being the epithelial structure of the 
gastric fundus. In humans, the corpus and fundus both contain oxyntic glands, which are characterised 
by acid-secreting parietal cells and enzyme-secreting chief cells. In contrast, the fundic mucosa in 
pigs is composed of cardiac glands (Meulengracht, 1935). Cardiac glands can also occur in humans 
at the gastro-oesophageal junction; however, they are not always observed and their presence has 
been associated with gastro-oesophageal disease (Lenglinger et al., 2012; Chandrasoma, 2013; Kim 
et al., 2015). The lining of the rodent fundus is different once again, being covered by non-glandular 
stratified epithelium. This lining in rodents resembles that of the oesophageal groove, which occurs 
in pigs but not humans, and is characterised by a lining composed of stratified squamous epithelium. 
Other aspects of the pig gastric mucosa have yet to be characterised in detail, including the 
distribution and co-expression patterns of gastric EEC. We have investigated the distributions and 
patterns of colocalisation of gastrin, ghrelin, 5-HT, somatostatin, PYY, and histamine-producing 
cells. Histamine-producing cells were identified with an antibody raised against histidine 
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decarboxylase, an enzyme involved in the synthesis of histamine. We also characterised the anatomy 
and mucosal structure of the pig stomach. 
Methods 
Tissue sources and preparation 
All procedures were conducted according to the National Health and Medical Research Council of 
Australia guidelines and were approved by the University of Melbourne Animal Experimentation 
Ethics Committee. Large White/Landrace crossbred pigs (30–35 kg females) were from the 
University of Melbourne School of Agriculture and Food. Pigs were sedated with a xylazil and 
ketamine mix and euthanised by cardiac injection of pentobarbital sodium (150 mg/kg). Tissues for 
haematoxylin and eosin staining and immunohistochemistry were removed, opened along the 
mesenteric border, and pinned flat, mucosa up, without being stretched. Segments were washed with 
phosphate buffered saline (PBS; 0.15 mol.L−1 NaCl in 0.01 mol. L−1 sodium phosphate buffer, pH 
7.2) and fixed at 4 °C overnight with Zamboni’s fixative (2% w/v formaldehyde and 0.2% w/v picric 
acid in 0.1 mol. L−1 sodium phosphate buffer, pH 7.2). Tissues were washed three times with 
dimethyl sulfoxide and three times with PBS, before being stored in PBS-sucrose-azide (0.1% w/v 
sodium azide and 30% w/v sucrose in PBS) at 4 °C.  
Haematoxylin and eosin staining  
Tissue was placed into histology cassettes and dehydrated through graded ethanol to histolene and 
embedded in paraffin. Sections (5 μm) were cut and stained with haematoxylin and eosin (H&E). 
Slides were coverslipped with ProLong Diamond (Thermo Fisher) mounting medium. Slides were 
examined and photographed using an Axioplan microscope (Zeiss, Sydney, Australia). 
Immunohistochemistry 
Samples for immunohistochemistry were placed in PBS sucrose- azide and OCT compound (Tissue 
Tek, Elkhart, IN, USA) in a 1:1 ratio overnight before being embedded in 100% OCT and snap frozen 
in isopentane cooled with liquid nitrogen. Cryosections (12 μm) were cut and air dried for 1 h on 
SuperFrost Plus® microscope slides (Menzel-Glaser; Thermo Fisher, Scoresby, Vic, Australia). They 
were then covered with normal horse serum (10% v/v with triton-X in PBS) for 30 min at room 
temperature and incubated with mixtures of primary antibodies (Table 1) overnight at 4 °C. The 
preparations were then washed three times with PBS before a 1-h incubation with mixtures of 
secondary antibodies (Table 1) at room temperature. Sections were washed three times with dH2O 
and, in some cases, incubated with Hoechst 33258 nuclear staining solution (10 μg/mL bisbenzimide-
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blue in dH2O; Sigma-Aldrich) for 5 min. Slides were washed three times with distilled water before 
being mounted under coverslips with Dako fluorescence mounting medium (Agilent, Tullamarine, 
Vic, Australia). Slides were examined and imaged using an Axio Imager microscope (Zeiss), or an 
LSM800 or LSM880 confocal microscope (Zeiss). 
Immunofluorescence image quantification 
Sections for cell counts were imaged as tile scans with a nominal optical thickness of 7.7 μm using a 
× 10 objective on the LSM800 confocal microscope (Zeiss). A 1.5-mm-wide region from each imaged 
section, which contained the full thickness of the mucosa, was selected for analysis in Fiji 
(http://imagej.nih.gov/ij/). Cells from each channel were manually circled by one investigator and 
verified by a second investigator, and were counted as positive if their mean pixel intensity was 
clearly above a threshold determined from the background fluorescence. The total mucosal area was 
also measured in order to determine the cell density (positive cells per mm2 of mucosa). The number 
of positive cells in the luminal, middle, and submucosal portions of the mucosa was also determined. 
Data are presented as mean ± SEM, for n = 3 animals. 
Results 
Anatomy of the pig stomach  
The pig has a single chambered stomach similar in shape to human. The pig stomach was cut open 
along the greater curvature to reveal the gastric lining (Fig. 1). On gross inspection, a distinctive collar 
of epithelium with an irregular surface was observed around the oesophageal junction. On the lesser 
curvature, this extended to the boundary of the antrum as the oesophageal groove. The mucosa of the 
remainder of the stomach had large folds (rugae). The fundus, corpus, and antrum were 
distinguishable by position and colour (Fig. 1). A prominent swelling, the torus pyloricus, occurs in 
the stomach on the lesser curvature, adjacent to the gastro-duodenal junction, and there is a 
diverticulum of the fundus, on the greater curvature, adjacent to the oesophagus. Ten regions were 
selected for histological analysis by haematoxylin and eosin (H&E) staining (Fig. 2). The epithelial 
lining of the peri-oesophageal collar and groove was stratified without a cornified surface, thus being 
similar to the lining of the oesophagus, and was around 0.5 mm thick (Fig. 2b, c). There were 
subepithelial papillae, similar to those seen in the skin. The muscle layer was approximately 5 mm 
thick near the gastro-oesophageal junction but was thinner towards the antrum. The fundus mucosa 
was about 0.5 mm thick and consisted of cardiac glands (Fig. 2a). These were branched glands with 
mucous cells lining the parts near the gastric lumen, while the deeper branches were lined with a 
simple columnar epithelium. The fundic diverticulum formed a deep distendable pocket with a narrow 
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entrance, adjacent to the esophago-gastric junction. The mucosal lining of the diverticulum was 
composed of cardiac glands, similar to the rest of the fundus (Fig. 2d). The mucosa of the gastric 
corpus consisted of closely packed straight tubular oxyntic glands. The corpus mucosa was relatively 
thick, being around 1.5 mm, although the muscle layer was amongst the thinnest of the regions 
investigated (approximately 2 mm). Pyloric glands in the antrum and pyloric regions of the pig 
stomach were convoluted, similar to the cardiac glands found in the pig fundus. The luminal ends of 
the glands were branched and dominated by mucus cells (Fig. 2k). Being around 1 mm thick, the 
antral and pyloric mucosa was thinner than the corpus mucosa but thicker than the fundic mucosa. 
The muscle was especially thick in these regions, reaching around 8 mm in the mid antrum. The torus 
pyloricus is a bulging fibro-muscular structure in the pig stomach on the lesser curvature adjacent to 
the gastro-duodenal junction (Fig. 1) and accordingly had the thickest wall. 
Localisation and morphology of enteroendocrine cells in the pig gastric mucosa 
The gastric fundus, corpus, and antrum were examined for ghrelin, somatostatin, 5-HT, PYY, HDC, 
and gastrin immunoreactivity (Fig. 3). Cells immunoreactivity for each marker were identified in all 
gastric regions examined, except that gastrin cells were extremely rare in the fundus and corpus, and 
PYY was uncommon in all three regions. Cell density was quantified for each of these markers (Fig. 
5a), and the localisation of EEC within the mucosa was determined as the proportion of EEC that was 
within the submucosal, middle, or luminal thirds of the mucosa (Fig. 5b). Ghrelin cells were the most 
abundant EEC type observed in the fundus and the corpus (31 ± 5 and 67 ± 4 cells/mm2 respectively) 
but were relatively less common in the antrum compared with most other markers investigated (16 ± 
1 cells/mm2; Fig. 5a). In the fundus, ghrelin cells were primarily localised in or near the submucosal 
third of the mucosa, whereas in the corpus and antrum, they were more evenly distributed between 
the middle and submucosal thirds (Fig. 5b). In the corpus and fundus, ghrelin cells were round or 
ovoid in shape and were closed, meaning they were not in contact with the lumen (Fig. 4a). Some of 
these cells possessed short thin processes.In the antrum, ghrelin cells were frequently flaskshaped, 
although whether the apical extremities of these cells were in contact with the lumen was unclear 
(Fig. 4b). Somatostatin (SST) cells were most abundant in the antrum, followed by the corpus and 
the fundus (76 ± 8, 34 ± 3, and 18 ± 5 cells/mm2 respectively; (Fig. 5a). SST cells were fairly evenly 
distributed in the corpus mucosa and slightly more concentrated in the middle third of the antrum, 
whereas in the fundus, they were skewed towards the submucosal side (Fig. 5b). In the corpus and 
fundus, SST cells were typically round or ovoid closed cells (Fig. 4e), whereas cells were generally 
flask-like or irregular in shape in the antrum and open to the lumen (Fig. 4f). Examples of small thin 
basal processes on some SST cells were observed in all three regions. Gastrin cells were the most 
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abundant type of EEC in the antrum (118 ± 15 cells/mm2), whereas they were extremely rare in the 
corpus and fundus (fewer than 1 cell/mm2; Fig.5a). Gastrin cells were more frequent in or near the 
middle third of the antrum mucosa (Fig. 5b). These were generally flask-shaped open cells (Fig. 4c). 
Basal processes of gastrin cells were not observed. HDC cells were most abundant in the antrum but 
were also common in the fundus and corpus (47 ± 7, 18 ± 3, and 16 ± 3 cells/mm2 respectively; Fig. 
5a). HDC cells were predominantly localised to the submucosal third of the fundus mucosa, fairly 
evenly distributed in the corpus mucosa, and concentrated in or near the middle third of the antrum 
mucosa (Fig. 5b). In the corpus, HDC cells were generally round or ovoid closed cells (Fig. 4d). In 
contrast, cells in the fundus and antrum were a mixture of cell shapes, including round, ovoid, and 
flaskshaped. In the antrum, flask-shaped cells were most common. 5-HTcells were most abundant in 
the antrum but were also found in significant numbers in the corpus and fundus (41 ± 5, 19 ± 3, and 
18 ± 3 cells/mm2 respectively; Fig. 5a). As with ghrelin and SST, 5-HT cells were concentrated in 
the basal third of the fundus mucosa. In the corpus, cells were fairly evenly distributed, whereas 5-
HT cells in the antrum were predominantly localised in or near the middle third, with a tendency to 
be closer to the submucosal rather than luminal side (Fig. 5b). LikeHDC, a mixture of cell shapeswas 
observed in the fundus and antrum, whereas cells in the corpus were generally round or ovoid. Some 
thin processes were evident (Fig. 4g). PYY cells were very rare, especially in the corpus (fewer than 
1 cell/mm2 in the corpus; Fig. 5a). PYY cells were generally round or ovoid (Fig. 4h), although some 
flask-shaped cells were observed in the antrum. 
Colocalisation of EEC markers 
Colocalisation was assessed between all combinations of hormones, except for HDC and PYY since 
our only effective antibodies against these peptides were both raised in rabbit and PYY cells were 
rare. Furthermore, since gastrin cells were extremely rare in the corpus and fundus, we did not 
quantify the colocalisation of gastrin with hormones in these regions. Qualitatively, we did not 
observe much overlap of gastrin with other hormones in the corpus and fundus, except for rare cells 
containing gastrin and 5-HTor gastrin and PYYin the corpus. Overlap between gastric hormones was 
generally low (Fig. 7). One significant exception to this was between 5-HT and HDC (Fig. 6). A 
substantial degree of colocalisation occurred in all regions investigated. For example, 83 ± 2% of 5-
HT cells contained HDC in the fundus, corresponding to 94 ± 3% of HDC cells containing 5-HT. 
Although PYY cells were extremely rare throughout the pig stomach, a relatively high proportion of 
these cells, about 50%, contained other hormones, including ghrelin, somatostatin, 5-HT, and gastrin. 
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Localisation of parietal cells and ECL cells 
Histamine is known to act in a paracrine fashion to promote acid secretion from parietal cells in the 
corpus (Soll and Walsh, 1979). In the present study, however, HDC cells were more abundant in the 
antrum than the corpus (Fig. 8 a, b), which led us to investigate whetherHDC cells were situated near 
parietal cells in the antrum. However, parietal cells were extremely rare or absent in pig gastric antrum 
and not related to ECL cells, whereas they were abundant in the corpus (Fig. 8 a′, b′). In contrast, 
ghrelin cells, which are abundant in the corpus, were in close proximity to parietal cells, some 
adjacent cells forming close associations, as seen in other species (Fakhry et al., 2019; Hunne et al., 
2019). 
Discussion 
The pig gastric mucosa shares many similarities with human, including similar mucosal architecture 
in the corpus and antrum. However, in contrast to humans, where oxyntic glands cover the mucosa 
of both corpus and fundus, the lining of the pig fundus consists of mucus cell-dominated cardiac 
glands. Furthermore, a collar, around the oesophageal entrance, and the oesophageal groove in pigs 
were characterised by a thick stratified squamous epithelium. Oxyntic glands were tightly packed 
long tubular structures, whereas the cardiac and pyloric glands were branched, convoluted, and less 
dense, as observed by Meulengracht (1935) in pigs. Thus, it seems that the entrance to the pig stomach 
is protected against abrasion by a thick epithelium and adjacent to this is an epithelium with similar 
appearance to the human cardiac glands that secrete watery fluid and mucus. The cardiac gland 
secretion can be assumed to have moistening and lubricating effects. The presence of a thick 
protective epithelium at the entrance to the stomach and the adjacent cardiac glands with their 
numerous mucus cells may be in response to the varied diets of pigs in their natural environment that 
can include dry, hard, and abrasive foods. This contrasts with humans, whose diets over 1000s of 
years have been dominated by soft processed foods (Furness et al., 2015). Once food passes this 
protective zone in the pig, it enters an environment very similar to the human stomach with glands of 
the corpus and antrum being almost indistinguishable between the two species. Cells immunoreactive 
for ghrelin, somatostatin, 5-HT, PYY, HDC, and gastrin was identified in all gastric regions 
examined, although gastrin cells were extremely rare in the fundus and corpus, and PYY was 
uncommon in all three regions. These observations were on female pigs. It should be noted that EEC 
populations may differ between genders, for example, in the colon, 5-HT cell abundance during 
oestrus is 30% greater than in pro-oestrus or in males (Balasuriya et al., 2016). Unlike the small 
intestine where colocalisation of hormones is observed in the majority of EEC (Egerod et al., 2012; 
Habib et al., 2012; Sykaras et al., 2014; Cho et al., 2015; Fothergill et al., 2017), very little 
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colocalisation was seen in pig gastric EEC. One significant exception to this is that 5-HT and HDC 
(a marker of histamine producing ECL cells) were generally co-expressed in all three gastric regions 
investigated. These results are similar to findings in human oxyntic mucosa, where the only 
significant overlap observed was between 5-HT and pancreastatin (an alternative marker of 
histamine-producing cells), although the overlap involved a significantly smaller proportion of cells 
in the human (Fakhry et al., 2019). In rat, 5-HTand HDC were also frequently colocalised in the 
antrum, but overlap was rare in the corpus (Hunne et al., 2019). Colocalisation of other hormones 
was observed in fewer than 5% of ghrelin, somatostatin, or gastrin cells.  
Ghrelin cells 
Ghrelin cells were most abundant in the oxyntic mucosa, which is consistent with findings in the rat 
and human (Date et al., 2000; Rindi et al., 2002; Hunne et al., 2019). In the corpus, ghrelin cells were 
round or ovoid closed cells, meaning they were not in contact with the lumen. This is also consistent 
with findings in both rat and human (Date et al., 2000; Dornonville De La Cour et al., 2001; Fakhry 
et al., 2019; Hunne et al., 2019). However, in the antrum, cells were frequently flask-shaped, which 
is often indicative that the cell is in contact with the lumen. This is contrary to the literature describing 
ghrelin cells. However, there were no clear examples of the apical ends of these cells reaching all the 
way to the lumen, so it is possible that these are closed cells, despite the flask-shaped morphology. 
Gastric ghrelin has an important role in stimulating appetite, and it also increases gastric emptying in 
humans and laboratory animals (Levin et al., 2006; Kojima and Kangawa, 2010; Avau et al., 2013). 
In pigs, the relationship between ghrelin and feeding behaviour is less obvious than in other mammals. 
Plasma ghrelin is elevated in fasting pigs and is reduced by feeding; however, administration of 
ghrelin did not alter food intake but did increase weight gain in weaner and grower pigs fed ad libitum 
(Salfen et al., 2004; Lents et al., 2016). Thus, in pigs, ghrelin has a similar distribution as in other 
mammals, being dominant in the stomach, with lesser amounts in the upper small intestine (Vitari et 
al., 2012), but seems to have a stronger effect on metabolism than on appetite. 
Gastrin cells 
Consistent with other species, gastrin cells were extremely rare in the corpus and fundus but were 
abundant in the gastric antrum. These cells were generally flask-shaped open cells, which relates to 
their role in sensing luminal contents (Rehfeld et al., 2007). Gastrin cells were clustered within the 
middle third of the mucosa in contrast to rat gastrin cells which are concentrated in a band near the 
base of the mucosa (Hunne et al., 2019). Gastrin’s major role is to promote acid secretion in the 
stomach (Feldman et al., 1978; Eysselein et al., 1984). This is achieved by stimulating histamine 
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secretion, which in turn promotes acid secretion from parietal cells (Friis-Hansen, 2002). 
Furthermore, gastrin promotes the expression and activity of histidine decarboxylase, the enzyme 
responsible for producing histamine, and promotes the development of ECL cells and parietal cells 
(Sandvik et al., 1994; Friis-Hansen et al., 1998). This relationship is interesting given that 
histamineproducing cells were most abundant in the pig antrum, in contrast to rat and human where 
they are related to oxyntic glands; the antral ECL cells in pigs are well situated for interactions with 
gastrin cells, but not with parietal cells. 
Somatostatin cells 
Somatostatin cells were more abundant in the antrum than the corpus, which is also observed in the 
rat (Hunne et al., 2019). However, this contrasts with the human, where somatostatin cell density is 
higher in the corpus (Kasacka et al., 2012; Choi et al., 2014). Somatostatin cells in the rat and human 
frequently possessed large basal processes, which in the antrum appear to selectively connect with 
gastrin cells (Larsson et al., 1979; Fakhry et al., 2019; Hunne et al., 2019). This relationship is 
consistent with the physiological role of somatostatin to provide a negative feedback control of gastrin 
secretion, thereby limiting acidification of the antrum in human and in animal models (Schubert et 
al., 1988; Chuang et al., 1993; Vuyyuru et al., 1997; Schubert and Peura, 2008), including in the pig 
(Holst et al., 1992). Thus, it is surprising that prominent basal processes of somatostatin cells were 
not observed in the pig. Although small thin processes were sometimes seen, these did not appear to 
extend to any particular cell type. The antral cells are generally of the open type and respond to acid 
in the lumen as well as neural signalling and gut hormones, including CCK, GIP, GLP-1 and secretin 
(Schubert et al., 1988; Gribble et al., 2018). Somatostatin cells in the corpus were round or ovoid. 
This is consistent with the literature which suggests that oxyntic SST cells are typically closed type 
and are predominantly regulated by neural and hormonal signalling (Schubert et al., 1988; Gribble et 
al., 2018). Somatostatin inhibits acid production and histamine release (Schubert et al., 1988; 
Vuyyuru et al., 1995). SST cells associated with oxyntic glands are tonically active between meals, 
providing a basal inhibition of gastric acid secretion. These SST cells are temporarily inhibited 
following the ingestion of food, providing time for gastrin to promote gastric acid release (Li, 2003; 
Gribble et al., 2018).  
Histamine and 5-HT cells 
5-HTcells were more abundant in the antrum than the corpus, consistent with human, rat, and mouse 
(Ito et al., 1986; Reynaud et al., 2016; Hunne et al., 2019). HDC cells were also more common in pig 
antrum than the corpus, which contrasts to the rat and human where they are significantly more 
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abundant in the corpus (Choi et al., 2014; Hunne et al., 2019). Over 70%ofHDC cells contained 5-
HTin pig antrum, similar to rat antrum where 65% of HDC cells contained 5-HT (Choi et al., 2014; 
Hunne et al., 2019). In pig corpus, a high proportion of HDC cells also contained 5-HT (80%), which 
contrasts with both rat corpus (1%) and human corpus (11%) (Choi et al., 2014; Hunne et al., 2019). 
HDC cell morphology also differed between species, generally being round or ovoid in the pig corpus, 
whereas they are elongated, flattened cells at the bases of the epithelial cell layer in rat corpus 
(Håkanson et al., 1986; Hunne et al., 2019). From this, we can infer that a population of cells in which 
5-HTand histamine are colocalised occurs in pig, rat, and human, but that the pig seems to lack a 
large population of HDC-positive 5-HT-negative cells (‘classical’ ECL cells) in the corpus. The 
overlap between histamine and 5-HT in all species is peculiar given that histamine promotes acid 
secretion whereas 5-HT inhibits acid secretion (Canfield and Spencer, 1983; LePard et al., 1996). 
Given histamine’s role in promoting acid secretion from parietal cells (Friis-Hansen, 2002), it is 
peculiar that ECL cells were sparse in the corpus. On the other hand, ECL cells were common in the 
antrum, where histamine is unlikely to act on parietal cells, which were rare or absent in this region. 
The roles of histamine in the antrum are not resolved. 
Concluding remarks 
In many respects, the pig stomach is very similar to human. It is similar in size and shape and, like 
human, has prominent mucosal rugae. One difference is the thick protective layered epithelium and 
the mixed mucus and simple columnar (cardiac) glands at and beyond the gastric entrance. The 
difference here may reflect differences in the physical properties of typical pig and human food, as 
discussed above. Beyond the gastric fundus, the human and pig corpus and antrum are remarkably 
similar, suggesting similar gastric digestive physiology. In both species, ghrelin, somatostatin, 5-HT, 
PYY, HDC, and gastrin EEC are present with similarities in distributions and cell types, for example 
gastrin cells are extremely rare in the fundus and corpus, PYY cells are uncommon in all three regions, 
and ghrelin cells are numerous in the corpus. Some quantitative differences were noted, for example 
the greater proportion of somatostatin and histamine (ECL) cells in the antrum of pig, whereas they 
are more abundant in the corpus of human. Similar to human and rat, colocalisation of the peptide 
hormones was rare.  





















Host Code Dilution Source 
5-HT Goat #20079 1:5000 Incstar 
5-HT Rabbit #20080 1:2000 Immunostar 
CCK/gastrin Mouse 28.2 1:2700 
Gift from Drs JH 
Walsh and H. 
Wong, UCLA 
(Kovacs et al., 
1997) 
Gastrin Rabbit #8007 1:3000 
Gift from Dr JF 
Rehfeld 
Ghrelin Chicken Ab15861 1:800 Abcam 
Ghrelin Rabbit #RY1601 1:5000 
Mizutani et al., 
(2009) 
H+/K+ ATPase Mouse #12.18 1:200 
Smolka et al., 
2000 




PYY Rabbit HPA010973 1:100 Sigma- Aldrich 
Somatostatin Mouse #S895 1:1000 
Buchan et al., 
1985 





Host Code Dilution Source 
Anti-chicken IgG 
Alexa Fluor® 647 
Donkey #703-605-155 1:400 Jackson laboratories 
Anti-Goat IgG 
Alexa Fluor® 555 
Donkey 
A21432 1:400 Molecular Probes 
Anti-mouse IgG 
Alexa Fluor® 555 
Donkey 
Ab150110 1:500 Abcam 
Anti-mouse IgG 
Alexa Fluor® 647 
Donkey 
A31571 1:1000 Molecular Probes 
Anti-rabbit IgG 
Alexa Fluor® 555 
Donkey 
Ab150070 1:1000 Abcam 
Anti-rabbit IgG 









Table2: Secondary antibodies used in the present study.  




Figure 1 Photograph of the stomach from a 35-kg pig opened along the greater curvature to reveal the gastric lining. 
The regions are indicated. Esoph. indicates the gastric end of the oesophagus. The arrow adjacent to “Torus” indicates 
the torus pyloricus (point of arrow is on the torus). The arrows next to ‘Antrum’ indicate the extent of the antrum along 
the lesser curvature. Note that the antrum extends to the collar of stratified squamous epithelium that surrounds to 
oesophageal entry to the stomach.  




Figure 2: Histological appearance of the pig gastric mucosa stained with haematoxylin and eosin (H&E) and diagram 
of the pig stomach indicating the regions sampled for histological analysis (f). The fundus (a), including the fundic 
diverticulum (d), was lined with cardiac glands that had prominent gastric pits lined with mucus cells (circled). A collar 
of thick non-keratinised stratified squamous epithelium surrounded the oesophageal entrance (asterisks mark dermal 
papillae) that continued as the oesophageal groove (b, c). The antrum and pylorus (h–j) were lined by an epithelium 
characterised by branched glands (examples circled). Note that the full thickness of the mucosa is not shown for thicker 
regions of mucosa such as the corpus. Scale bars are 100 μm 
  




Figure 3 (a-c’): EEC immunoreactivity for ghrelin (a) and PYY (a′) in gastric fundus, 5-HT (b) and somatostatin (b′) in 
gastric corpus, and HDC (c) and gastrin (c′) in gastric antrum. The bases of the glands and the surface of the mucosa 
are marked with dotted white lines. The image is oriented with the submucosal (basal) ends of the glands at the bottom 
of the image. Scale bars: 200 μm. 
  





Figure 4 (a-h): EEC morphologies and relationships. Examples of cells immunoreactive for ghrelin (a, b), gastrin (c), 
HDC (d; a marker for histamine-producing cells), somatostatin (SST) (e, f), 5-HT (g), and PYY (h). The luminal surfaces 
of the epithelial cells forming the glands are marked with dotted white lines. Arrows indicate small basal processes in a, 
e, f, and g. Scale bars: 20 μm 
 
 
Figure 5 (a, b):a) Cell density of gastric EEC in the gastric fundus (F), corpus (C), and antrum (A). Numbers of cells 
counted were around 100 cells or more per pig per region, except for the rare PYY cells in all regions and rare gastrin 
cells in the corpus and fundus.b) Distribution of EEC across the width of the mucosa in pig gastric fundus, corpus, and 
antrum. The proportion of EEC immunoreactivity for each hormone marker (indicated below each column) situated in 
the submucosal third of the mucosa is indicated by a striped pattern, cells in the middle third are indicated by a spotted 
pattern, and cells in the luminal third are indicated with no pattern. Due to their rarity, the distribution of gastrin cells 
in the fundus and corpus and PYY cells in all regions was not accurately determined. 
 
a b 




Figure 6 (a-a’’): Examples of cells showing colocalisation of HDC (a) and 5-HT (a′). Colour merge images also show 
Hoechst nuclear staining in blue. Most cells contain both hormones (indicated by an arrow), but two cells are 
immunoreactive for HDC and not 5-HT (indicated by an arrow with an asterisk). Scale bar is 20 μm. 
 
Figure 7 (a-c): Quantitation of overlaps between hormones in pig gastric fundus (a), corpus (b), and antrum (c). 
Colocalisation of two hormones is expressed as a percentage of cell immunoreactivity for the marker indicated at the top 
of each group of columns. 0= no colocalisation.  




Figure 8 (a-b’’): The relationship between parietal cells and ECL cells in the gastric corpus (a), and the gastric antrum 
(b). ECL cells (circled in a) are stained with an anti-HDC antibody and parietal cells (circled in b′) are marked by anti-
proton pump (H+/K+ ATPase). The bases of the glands and the surface of the mucosa are marked with dotted white lines. 
The image is oriented with the base of the glands at the bottom of the image. Scale bars: 100 μm. 
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Paper published on the Israel Journal of Veterinary Medicine (2017, 72 (3): 22-27. Modified from:  
The Relationship between Duodenal Enterochromaffin Cell 
Distribution and degree of Inflammatory Bowel Disease (IBD) In Dogs 
Twito R1, Famigli Bergamini P2, Galiazzo G2, Peli A2, Cocchi M3, Bettini G2, Chiocchetti R2, 
Bresciani F2, and Pietra M2. 
1 Private Practitioner, Tierklinik Dr. Krauß, Düsseldorf GmbH, Germany. 
2Department of Veterinary Medical Sciences – University of Bologna, Italy. 
3 L.U.DE.S. University, Lugano, Switzerland. 
Abstract 
Introduction - Despite numerous studies carried out over the last 15 years in veterinary medicine, the 
pathogenesis of canine Inflammatory Bowel Disease (IBD) has still not been completely elucidated. 
In particular, unlike what has been demonstrated in human medicine, the influence of serotonin on 
clinical signs in canine IBD has not yet been clarified.  
Objective - The objective of this paper has been to seek a possible correlation between duodenal 
epithelial distribution of serotonin-producing cells (enterochromaffin cells) and disease-grading 
parameters (clinical, clinico-pathological, endoscopic and histopathological) in dogs with IBD. The 
medical records of dogs with a diagnosis of IBD were retrospectively reviewed and 21 client-owned 
dogs with a diagnosis of IBD were registered. Clinical score (by Canine Chronic Enteropathy Clinical 
Activity Index), laboratory examinations (albumin, total cholesterol, folate, cobalamin), endoscopic 
score and histopathological score, were compared by regression analysis with duodenal 
enterochromaffin cell percentage.  
Results - The study results suggested a relationship between a decrease in folate absorption and an 
increase in duodenal enterochromaffin cell percentage (regression equation y=16.89-6.14x; 
coefficient of determination r2= 0.7; significant level: P=0.007). However, no significant relationship 
was evidenced between duodenal enterochromaffin cell percentage and the other analyzed variables. 
Conclusion and relevance – Further researchs are required to improve our understanding of the 
involvement of 5-HT in the pathogenesis of canine IBD, evaluating if SERT activity is related with 
IBD severity, and therefore if the decrease in 5-HT reuptake is linked to nociception and clinical signs 
in these patients. 
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In collaboration with the Gastrointestinal Laboratory, College of Veterinary Medicine and 
Biomedical Sciences, Texas A&M University (Texas). Paper published on the Journal of Veterinary 
Internal Medicine (2018), 32(6), 1903-1910.Modified from:  
Effect of an extruded animal protein-free diet on fecal microbiota of 
dogs with food-responsive enteropathy 
Francesca Bresciani1, Yasushi Minamoto2, Jan S. Suchodolski2, Giorgia Galiazzo1, Carla Giuditta 
Vecchiato1, Carlo Pinna1, Giacomo Biagi1, Marco Pietra1 
1Department of Veterinary Medical Sciences – University of Bologna, Italy 
2Gastrointestinal Laboratory, Texas A&M University, College Station, TX, USA 
Abstract 
Introduction - Dietary interventions are thought to modify gut microbial communities in healthy 
individuals. In dogs with chronic enteropathies, resolution of dysbiosis, along with remission of 
clinical signs, is expected with treatment. 
Objective - To evaluate changes in the fecal microbiota in dogs with foodresponsive chronic 
enteropathy (FRE) and in healthy control (HC) dogs before and after an elimination dietary trial with 
an animal protein-free diet (APFD). Fecal microbiota was analyzed by Illumina 16S rRNA 
sequencing and quantitative polymerase chain reaction (PCR). 
Results - A significantly lower bacterial alpha-diversity was observed in dogs with FRE compared 
with HC dogs at baseline, and compared with FRE dogs after the trial. Distinct microbial communities 
were observed in dogs with FRE at baseline compared with HC dogs at baseline and compared with 
dogs with FRE after the trial. Microbial communities still were different in FRE dogs after the trial 
compared with HC dogs at baseline. In HC dogs, the fecal microbiota did not show a significant 
modification after administration of the APFD. 
Conclusion and relevance - Our results suggest that, in FRE dogs, treatment with the APFD led to a 
partial recovery of the fecal microbiota by significantly increasing microbiota richness, which was 
significantly closer to a healthy microbiota after the treatment. In contrast, no changes were detected 
in the fecal microbiota of HC dogs fed the same APFD. 
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Paper published on EC GASTROENTEROLOGY AND DIGESTIVE SYSTEM (2018) 5.6 415-425. 
Modified from:  
Effects of Chronic Enteropathies on VIPergic and Nitrergic 
Immunoreactive Neurons in the Dog Ileum 
Giorgia Galiazzo1, Fiorella Giancola2, Gianfranco Militerno1, Marco Pietra1, Agnese Stanzani1, 
Martina Asti1, Roberto Chiocchetti1 
2Department of Veterinary Medical Sciences – University of Bologna, Italy 
2St. Orsola-Malpighi Hospital, Bologna, Italy 
Abstract  
Introduction - The enteric nervous system (ENS) comprises a huge amount of neurons and nerve 
fibers interposed between the two muscular layers of the tunica muscularis and in the submucosa. 
Neuropeptides produced by the ENS neurons act as neurotransmitters/neuromodulators, which 
control intestinal motility and mucosal functions, and play a crucial role also in the regulation of 
inflammatory processes via cross talk with the local immune system. A growing body of evidence 
indicates that the gastrointestinal inflammatory response damages the enteric neurons themselves, 
thus resulting in deregulations in gut motility and mucosal functions. 
Objective - The purpose of this study was to evaluate quantitatively enteric neurons immunoreactive 
for the vasoactive intestinal polypeptide (VIP) and neuronal nitric oxide synthase (nNOS) in the 
myenteric (MP) and submucosal (SMP) plexus of the ileum of dogs without (CTRL-dogs, n= 6) and 
with spontaneous chronic enteritis (inflamed dogs, INF-dogs, n=10). In addition, the percentage of 
nNOS immunoreactive neurons co-expressing VIP immunoreactivity (and vice versa) was evaluated. 
Data were expressed as mean ± standard deviation. 
Results - In the myenteric plexus of INF-dogs, the percentage of VIPergic neurons (16 ± 7%) was 
significantly greater than that observed in the CTRL-dogs (8 ± 3%) (P = 0,022). Conversely, in the 
submucosal plexus of CTRL- and INF-dogs the percentages of VIPergic neurons were similar (31 ± 
9% and 30 ± 11%, respectively; P = 0,786). In the myenteric plexus of INF-dogs, the percentage of 
nitrergic neurons (24 ± 5%) showed only a tendency to decrease in comparison to that evaluated in 
the CTRL-dogs (29 ± 5%) (P= 0.138); also in the submucosal plexus the percentages of nitrergic 
neurons of CTRL-dogs (8 ± 5%) and INF-dogs (7 ± 2%) did not show meaningful differences (P = 
0.884). Co-localization studies indicated that also the percentages of nitrergic neurons co-expressing 
VIP immunoreactivity did not change between CTRL- and INF-dogs in the MP (23 ± 12% and 24 ± 
10%, respectively; P = 0.935) and SMP (26 ± 16% and 23 ± 15%, respectively; P = 0.810). 
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Conclusion and relevance - This is the first quantitative study about the VIPergic and nitrergic 
neurons harbored in the in MP and SMP of the canine ileum and the first comparison between these 
subclasses of neurons in dogs with and without chronic enteritis. Our findings showed significant 
neuroplasticity only of myenteric VIP immunoreactive neurons during chronic enteritis, which may 
influence intestinal motility. 
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Paper published on Frontiers in Veterinary Science (2019) 6:313 doi:10.3389/fvets.2019.00313 
Modified from: 
Cellular Distribution of Canonical and Putative Cannabinoid 
Receptors in Canine Cervical Dorsal Root Ganglia 
Roberto Chiocchetti1, Giorgia Galiazzo1, Claudio Tagliavia1, Agnese Stanzani1, Fiorella Giancola2, 
Marika Menchetti1, Gianfranco Militerno1, Chiara Bernardini1, Monica Forni1, Luciana Mandrioli1 
1 Department of Veterinary Medical Sciences – University of Bologna, Italy 
 2St. Orsola-Malpighi Hospital, Bologna, Italy 
Abstract 
Introduction - Growing evidence indicates cannabinoid receptors as potential therapeutic targets for 
chronic pain. Consequently, there is an increasing interest in developing cannabinoid receptor 
agonists for treating human and veterinary pain. To better understand the actions of a drug, it is of 
paramount importance to know the cellular distribution of its specific receptor(s). 
Objective - The distribution of canonical and putative cannabinoid receptors in the peripheral and 
central nervous system of dogs is still in its infancy. In order to help filling this anatomical gap, the 
present ex vivo study has been designed to identify the cellular sites of cannabinoid and cannabinoid-
related receptors in canine spinal ganglia. In particular, the cellular distribution of the cannabinoid 
receptors type 1 and 2 (CB1 and CB2) and putative cannabinoid receptors G protein-coupled receptor 
55 (GPR55), nuclear peroxisome proliferator-activated receptor alpha (PPARα), and transient 
receptor potential vanilloid type 1 (TRPV1) have been immunohistochemically investigated in the 
C6-C8 cervical ganglia of dogs. 
Results - About 50% of the neuronal population displayed weak to moderate CB1 receptor and TRPV1 
immunoreactivity, while all of them were CB2-positive and nearly 40% also expressed GPR55 
immunolabeling. Schwann cells, blood vessel smooth muscle cells, and pericyte-like cells all 
expressed CB2 receptor immunoreactivity, endothelial cells being also PPARα-positive. All the 
satellite glial cells (SGCs) displayed bright GPR55 receptor immunoreactivity. In half of the study 
dogs, SGCs were also PPARα-positive, and limited to older dogs displayed TRPV1 
immunoreactivity. 
Conclusion and relevance - The present study may represent a morphological substrate to consider 
in order to develop therapeutic strategies against chronic pain. 




Spinal ganglia, also referred to as dorsal root ganglia (DRG), contain the cell bodies of 
pseudounipolar primary sensory neurons, which are surrounded by a layer of satellite glial cells 
(SGCs), also called amphicytes because of their position around each neuron. Chronic pain, both 
inflammatory and neuropathic, is associated with hyperexcitability of DRG cellular elements and 
their down-modulation could thereby decrease pain (Krames, 2015). A growing body of literature 
suggests that cannabinoid receptors play a critical role in nociception through central and peripheral 
mechanisms (Hohman et al., 1995; Martin et al., 1996; Tsou et al., 1996; Calignano et al., 1998; 
Richardson et al., 1998; Stella, 2010; Davis, 2014). Recent studies have shed some light on the 
expression of cannabinoid receptors on neurons and glial cells of the canine nervous system (Pirone 
et al., 2016; Freundt-Revilla et al., 2017; Freundt-Revilla et al., 2018). In particular, CB1 receptor 
was observed in central nervous system (CNS) neurons (Pirone et al., 2016) and in DRG neurons and 
glial cells (Freundt-Revilla et al., 2017), whereas CB2 receptor was found in glial cells (astrocytes) 
of the spinal cord (Freundt-Revilla et al., 2018).  
In addition to the known canonical (i.e. prototypical) cannabinoid receptors CB1 and CB2, other 
receptors, such as G protein-coupled receptor 55 (GPR55), nuclear peroxisome proliferator-activated 
receptor alpha (PPARα), and transient receptor potential vanilloid type 1 (TRPV1) are currently 
considered putative cannabinoid receptors (Petrosino and Di Marzo, 2017; Pertwee et al., 2010; Yang 
et al., 2016). 
The anti-nociceptive potential of the endocannabinoid system (Donvito et al., 2018) has prompted 
the development of therapeutic cannabinoid receptors agonists or medical marjiuana to be used in 
pets in order to treat chronic pain. The clinical/medical properties of botanical and synthetic 
cannabinoids in the management of neuropathic pain, allodynia, and chronic non-cancer pain have 
been recently reviewed (Pergolizzi et al., 2018). Methodological challenges (quali-quantitative 
variability in cannabinoid content of cannabis plant extracts, inconsistent dosing) as well as acute and 
chronic impacts on cognition, immune and cardiovascular system are still unsolved issues associated 
with the therapeutic use of phytocannabinoids (Sachs et al., 2015; Bonn-Miller et al., 2017; Pavlovic 
et al., 2018; Carcieri et al, 2018). This is why many research efforts are currently focused on body’s 
own cannabinoids (i.e. endocannabinoids) and related physiological compounds, acting through 
canonical and putative cannabinoid receptors (Donvito et al., 2018; Skaper et al., 2015). 
Although there is a growing interest in the subject, reliable anatomical studies regarding the cellular 
distribution of cannabinoid receptors in the canine central and peripheral nervous system (PNS) are 
still lacking. In order to help filling this anatomical gap, the present ex vivo study 
Experimental studies  
129 
 
immunohistochemically investigated the cellular distribution of the cannabinoid and cannabinoid-
related receptors CB1, CB2, GPR55, PPARα, and TRPV1 in cervical DRG of pet dogs. 
Material and Methods 
Animals  
Cervical sensory ganglia and related spinal cord were collected from eight dogs (Table 1). None of 
them had history of neurological disorders and any gross changes of the spinal cord and vertebral 
canal. Dogs died spontaneously or were euthanized for human reasons due to different diseases and 
tissues were collected following owner’s permission. According to the Directive 2010/63/EU of the 
European Parliament and of the Council of 22 September 2010 on the protection of animals used for 
scientific purposes, the Italian legislation (D. Lgs. n. 26/2014) does not require any approval by 
competent authorities or ethics committees, because this research did not influence any therapeutic 
decisions.  
Since the suppliers of the antibodies employed in the present study state them to rat-specific (CB2 
and TRPV1) or react with rat tissues (CB1, PPARα), rat cervical sensory ganglia were used for 
comparison purposes (authorization no. 112/2018-PR of 12 February 2018). The distribution of the 
study receptors in subclasses of rat sensory neurons was out of the scope of the present study, and 
was not evaluated. 
Tissue collection 
Tissue Samples (C6-C8 DRG) were collected within 1 hour from death through a dorsal laminectomy. 
DRG were localized by counting them from the last cervical spinal nerve (C8) located just cranial to 
the first rib. C6-C8 cervical DRG were selected for the present study because of technical and 
pathophysiological implications, i.e. large size, involvement in chronic pain (caused by cervical disk 
herniation and vertebral column instability), presence of all the subsets of sensory neurons activated 
by mechanical, thermal and nociceptive inputs from the forelegs. Once removed from the spinal cord, 
DRG were fixed for 12 hours in 4% paraformaldehyde in phosphate buffer (0.1M, pH 7.2) at 4°C. 
Tissues were subsequently rinsed overnight in phosphate-buffered saline (PBS; 0.15 M NaCl in 0.01 
M sodium phosphate buffer, pH 7.2) and stored at 4°C in PBS containing 30% sucrose and sodium 
azide (0.1%). The following day, the tissues were transferred to a mixture of PBS–30% sucrose–azide 
and Optimal Cutting Temperature (OCT) compound (Sakura Finetek Europe, Alphen aan den Rijn, 
The Netherlands) at a ratio of 1:1 for an additional 24 hours before being embedded in 100% OCT in 
Cryomold® (Sakura Finetek Europe). The sections were prepared by freezing the tissues in 
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isopentane cooled in liquid nitrogen. Serial longitudinal sections (14-16 µm thick) of C6-C8 DRG 
were cut on a cryostat, and mounted on polylysinated slides. 
Immunofluorescence 
Cryosections were hydrated in phosphate-buffered saline (PBS) and processed for immunostaining. 
To block non-specific bindings, the sections were incubated in a solution containing 20% normal goat 
or donkey serum (Colorado Serum Co., Denver, CO, USA), 0.5% Triton X-100 (Sigma Aldrich, 
Milan, Italy, Europe), and bovine serum albumin (1%) in PBS for 1 h at room temperature (RT). The 
cryosections were incubated overnight in a humid chamber at RT with a cocktail of primary 
antibodies (Table 2) diluted in 1.8% NaCl in 0.01M PBS containing 0.1% sodium azide. After 
washing in PBS (3 x 10 min), the sections were incubated for 1 h at RT in a humid chamber with the 
secondary antibodies (Table 3) diluted in PBS. Cryosections were then washed in PBS (3 x 10 min) 
and mounted in buffered glycerol at pH 8.6.  
Cellular nuclei were identified with the DAPI Fluorishield (F6057-20ML, Sigma Aldrich, Milan, 
Italy, Europe), DRG neurons were identified with the blue fluorescent Nissl staining solution 
(NeuroTrace®, # N-21479, Molecular Probes, Eugene, OR, USA; dilution 1:200). Satellite glial cells 
were identified with a polyclonal chicken anti-glial fibrillary acid protein (GFAP) antiserum. 
Schwann cells were identified with a polyclonal chicken anti-myelin Protein Zero (P0) antiserum. 
Since CB2 receptor may also be expressed by blood vessels (Kunos et al., 2002; Lípez-Miranda et 
al., 2008; Galiazzo et al., 2018), the endothelial cells were recognized with two different antibodies, 
i.e. the mouse anti-CD31 antibody (Kader et al., 2001; Ren et al., 2002), and the rabbit anti-Factor 
VIII-related antigen/von Willebrand factor (Preziosi et al., 2004), herein referred to as FVIII-Rag. 
In order to determine the proportion of neurons immunoreactive for each of the markers, sections 
subjected to single immunohistochemistry for cannabinoid receptors were counterstained with blue 
fluorescent Nissl stain solution (NeuroTrace®, see above) following the manufacturer’s instructions. 
At least one hundred Nissl stained neurons were counted for each marker. Data were collected from 
preparations obtained from at least three animals (n=3). The percentage of immunopositive neurons 
was expressed as mean ± standard deviation. 
Specificity of the primary antibodies  
The specificity of the anti-cannabinoid receptors CB1, CB2 and PPARα antibodies in dog tissues has 
been recently tested by Western blot (Wb) analysis on canine intestinal tissues (Galiazzo et al., 2018). 
In the present study we used the antibody anti-human GPR55 (NB110-55498; Novus Bio) which, 
based on sequence identity (85%), is predicted to cross-react also with canine tissues. However, we 
tested its specificity on canine tissue by Wb analysis. 
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To identify TRPV1 immunoreactive neurons, we utilized two different antisera raised in rabbit 
(Alomone, ACC-030) and goat (Santa Cruz, c12498), directed against two different portions of the 
rat TRPV1. The immunogen of the rabbit anti-TRPV1 (Alomone) was the peptide [(C)EDAEVFK 
DSMVPGEK] (824–838) of rat TRPV1. The immunogen of the goat anti-VR1 antibody (Santa Cruz) 
was a synthetic peptide [PHIFTTRSRTRLFGKGDSE(C)] (38–57) from N-terminus of the rat 
TRPV1. The manufacturer’s datasheets for both the anti-TRPV1 antibodies state that the antibodies 
are specific only for rodents (mouse and rat) and human DRG neurons. The specificity of the goat 
anti-VR1 antibody has been tested on canine tissues with Wb (Vercelli et al., 2015). Thus, we tested 
the specificity of the two antibodies on rat and canine DRG cryosections beforehand, by using a 
double-staining protocol. On rat DRG cryosections, the anti-TRPV1 antibody raised in rabbit 
(Alomone) and the anti-VR1 antibody raised in goat, showed full correspondence within the same 
neurons, which appeared brightly labeled, providing additional value to the specificity of both the 
anti-TRPV1 antibodies (data not shown). As observed in porcine DRG (Russo et al., 2013), only the 
rabbit anti-TRPV1 antibody identified TRPV1-immunoreactivity in the canine ganglia. However, the 
specificity of the rabbit anti-TRPV1 antibody was not tested on canine tissues by Wb. 
The specificity of the endothelial markers antibodies (anti-CD31 and anti FVIII-Rag) was tested by 
using a double-staining protocol. Both antibodies recognized the same endothelial cells; however, the 
antibody anti-CD31 showed a sharper and more delicate immunolabeling of the cells (data not 
shown). For this reason, the anti-CD31 antibody was used as endothelial marker. 
The specificity of the anti-myelin marker protein zero (P0) antiserum was tested by using a double-
staining protocol. The anti-P0 antiserum was co-localized with the anti-S100 antiserum; both the 
myelin markers were co-localized in all the Schwann cells (data not shown). 
Fluorescence microscopy 
Preparations were examined on a Nikon Eclipse Ni microscope equipped with the appropriate filter 
cubes to distinguish the fluorochromes employed. The images were recorded with a Nikon DS-Qi1Nc 
digital camera and NIS Elements software BR 4.20.01 (Nikon Instruments Europe BV, Amsterdam, 
Netherlands). Slight adjustments to contrast and brightness were made using Corel Photo Paint, 
whereas the figure panels were prepared using Corel Draw (Corel Photo Paint and Corel Draw, 
Ottawa, ON, Canada). 
Western blot 
Tissue sample (small intestine/jejunum) was collected, frozen in liquid nitrogen and stored at -80°C 
until sample processing. 100 mg of tissue were homogenized in 1 ml of SDS buffer (Tris-HCl, 62.5 
mM; pH 6.8; SDS, 2%; and glycerol, 20%) supplemented with a protease inhibitor cocktail (Sigma-
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Aldrich, Co, St. Louis, MO, USA). Total protein content was determined by Peterson’s Modification 
of Lowry Method using a Protein Assay Kit. 20 μg of total proteins were separated on NuPage4–12% 
bis-Tris Gel (Life Technologies Ltd, Paisley, UK) for 30 minutes at 200V. The proteins were then 
electrophoretically transferred onto a nitrocellulose membrane by a semi-dry system (Trans Turbo 
Blot Bio -Rad). Non-specific bindings on nitrocellulose membrane were blocked with 5% milk 
powder in PBS-T20 (Phosphate Buffer Saline-0.1% Tween-20) for 1 h at room temperature. After 
blocking treatment, the membrane was incubated overnight at 4°C with the primary antibodies 
(GPR55 NB110-55498), 1:500 diluted in PBS added with 1,5% of milk. After washes, the blot was 
incubated with a goat anti rabbit biotin-conjugate antibody (1:50,000 dilution in TBS-T20, 1 h at RT) 
and then with a 1:1000 dilution of an anti-biotin horseradish peroxidase (HRP)-linked antibody (40 
min at RT). Immunoreactive bands were visualized using chemiluminescent substrate (Clarity 
Western ECL Substrate Bio Rad), according to the manufacturer’s instructions. The intensity of the 
luminescent signal was acquired by Chemidoc Instrument (Bio Rad) and the apparent molecular 
weight of the resultant bands was analyzed by Quantity One Software (Bio-Rad). Western blot 
analysis of GPR55 revealed a single band of expected molecular weight (~ 40 kDa) (Fig. 1). 
 
Figure 1: Representative image of Western blots (WB) analysis showing the specificity of the primary antibody rabbit 
anti-G protein-coupled receptor 55 (GPR55). The antibody revealed a single band of expected molecular weight (~ 40 
kDa). The images of the different immunoblots were slightly adjusted in brightness and contrast to match their 
backgrounds. 
Results 
CB1 receptor immunoreactivity – About half neuronal population (55±6%; 278/507 counted sensory 
neurons, n= 4) displayed weak to moderate cytoplasmic CB1 receptor immunoreactivity (Fig. 2 a-d). 
CB1 receptor immunoreactivity was occasionally observed in SGCs, although it could be confused 
with background. This finding is partially consistent with observation in the rat DRG, in which 
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neurons and SGCs expressed CB1 receptor immunoreactivity also in the nuclei (neurons>SGCs) 
(Supplementary Fig. 1 a-c). 
CB2 receptor immunoreactivity – CB2 receptor immunoreactivity was brightly expressed by 
Schwann cells and cells surrounding blood capillaries (most likely pericytes) (Fig. 3 a-l), while 
smooth muscle cells of blood vessels showed moderate CB2 receptor immunolabeling 
(Supplementary Fig. 2). SGCs did not display CB2 receptor immunolabeling (Fig. 3 a-f). Faint CB2 
immunolabeling was expressed by the nuclei of all the DRG neurons (Fig. 3 d, f). GFAP 
immunostaining was stronger at the periphery of the ganglia, while CB2 receptor immunoreactivity 
was stronger in the central portion of the ganglia (data not shown). The expression of the CB2 receptor 
on Schwann cells depicted the path of nerve fibres, rolling between neurons before abandoning the 
ganglion at its central and peripheral pole (Fig. 3 g-i). In the oldest subjects, the CB2 receptor 
immunolabeling was less intense than in the younger dogs (data not shown). The co-localization of 
CB2 receptor with the myelin marker P0 showed that both the markers were expressed by all Schwann 
cells (Supplementary Fig. 3 a-d). CB2 receptor immunoreactivity was brightly expressed by pericyte-
like cells (Fig. 3 j-l). The co-localization study between CB2 receptor and the endothelial marker 
CD31 showed that the endothelium was CB2 receptor negative whereas the vascular smooth muscle 
cells showed faint CB2 receptor immunoreactivity (Fig. 3 j-l). The CB2 receptor immunolabeling 
was also observed within the neuronal nuclei of the rat DRG, whereas Schwann cells and blood 
vessels were CB2 receptor negative (Supplementary Fig. 1 d-f). 
GPR55 immunoreactivity –Bright GPR55 immunoreactivity, with grainy appearance, was expressed 
by all (GFAP positive and GFAP negative) SGCs (Fig. 4 a-f). Also a percentage of different size 
sensory neurons (38±14%; 214/542 cells counted, n=3) showed faint to moderate GPR55 
immunolabeling (Fig. 4 d-f). This finding is consistent with that obtained in neurons and SGCs of the 
rat DRG (Supplementary Fig. 1 g-i). 
PPARα immunoreactivity – PPARα immunoreactivity was expressed by SGCs (Fig. 4 g-i) and 
endothelial cells of blood vessels (data not shown). Quite surprisingly, four out of eight dogs did not 
show PPARα immunoreactivity. In the remainders, all the SGCs were PPARα-positive. These data 
are partially consistent with those obtained in rat DRG, in which also the neuronal cytoplasm showed 
faint PPARα immunoreactivity (Supplementary Fig. 1 j-l). 
TRPV1 immunoreactivity – TRPV1 immunoreactivity was unevenly distributed and highly variable 
within the study cases. In the younger subjects, it was limited to different size neurons (and neuronal 
processes) while in older dogs, TRPV1 immunolabeling was expressed also by SGCs (Fig. 5 a-f). In 
all the subjects, the brightest TRPV1 immunolabeling was displayed by small neurons. The 
percentage of TRPV1 immunoreactive neurons was 55±11% (563/1017 cells counted, n=4). In the 
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rat DRG, TRPV1 immunolabeling was expressed only by the cytoplasm of a subset of sensory 
neurons and nerve fibers (Supplementary Fig. 1 m-o). 
The results of the cellular distribution and intensity of the immunolabeling in the canine DRG are 
summarized in Table 4. 
Discussion 
The present study showed the expression of canonical and putative cannabinoid receptors in different 
cellular elements of canine cervical DRG, such as neurons (CB1 and GPR55), SGCs (GPR55 and 
CB1), Schwann cells and muscle cells of blood vessels (CB2). These findings further substantiate the 
hypothesis that endogenous ligands, e.g. endocannabinoids and related compounds, may play 
important roles in modulating the responses associated with hyperexcitability of DRG, such as 
chronic pain (Krames, 2015). While the role of DRG in pain physiology (i.e., on the crossroads 
between PNS and CNS) is well established (Woodhams et al., 2017), much less is known about its 
active involvement in processing chronic pain (Krames, 2015; Berta et al., 2017). Given the 
involvement of the endocannabinoid system in pain modulation (Woodhams et al., 2017; Donvito et 
al., 2018; Guerrero-Alba et al., 2019), our findings may help to shed new light on this challenging 
issue. 
CB1 and CB2 receptors - The expression of CB1 receptor in DRG neurons and SGCs is in agreement 
with previous studies in laboratory rodents (Sanudo-Pena et al., 1999), humans (Anand et al., 2008) 
and dogs (Freundt-Revilla et al., 2018). However, the neuronal subpopulation expressing CB1 
receptors (i.e., small sensory neurons) was different from a previous in situ hybridization study by 
Hohmann and Herkenham (1999) who found medium-and large-sized cells in rat DRG to 
predominantly express CB1 receptor mRNA. Although, in the present study, the area of DRG neurons 
was not measured, it is possible to state with some confidence that, in the rat DRG, CB1 receptor 
immunoreactivity was expressed also by large-sized neurons. 
The expression of faint CB2 receptor immunolabeling in neurons and its absence in SGCs of canine 
DRG, partially agrees with previous findings in laboratory rodents, where only very weak 
immunoflorescence was found in basal conditions (Svíženská et al., 2013). Although CB2 receptor 
was considered lacking in neurons and glial cells, recent literature highlights its expression in these 
cell types (Sánchez-Zavaleta et al., 2018; Stella, 2009), even in humans (Anand et al., 2008) and dogs 
(Fernández-Trapero et al., 2017; Freundt-Revilla et al., 2018). Similarly to CB1 (Mitrirattanakul et 
al., 2006), CB2 receptor is upregulated in a variety of PNS and CNS diseases and is suggested as a 
promising pharmacological target in the management of chronic pain and neuroinflammation (Skaper 
et al., 2013; Svíženská et al., 2013; Navarro et al., 2016; Cassano et al., 2017). At present we are not 
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able to explain the presence of the CB receptors in neuronal nuclei of canine (CB2 receptor) and rat 
(CB1 and CB2 receptors) DRG. The study on the subcellular distribution and function of cannabinoid 
receptors is still expanding. The nuclear envelope, which is a part of the endoplasmic reticulum, may 
be one of the sources of nuclear Ca2+; Currie et al. (2008) identified the expression of CB1 and CB2 
receptors on the nuclear membrane of cardiac muscle cells and demonstrated that these receptors, 
when activated by anandamide, can (negatively) modulate nuclear Ca2+ release and, very likely, gene 
transcription.  
To the best of our knowledge, this is the first time that CB2 receptor immunoreactivity in Schwann 
cells has been reported. Up to now, endocannabinoid receptor immunolabeling of Schwann cells was 
limited to CB1, which was shown in about 100% of this cell type in the canine sciatic nerve (Freundt-
Revilla et al., 2017). Besides forming the myelin sheath, Schwann cells orchestrate much of the 
regenerative response that occurs after nerve injury in order to restore nerve function (Glenn and 
Talbot, 2013). The expression of CB1 (Freundt-Revilla et al., 2017) and CB2 receptors (present 
study) in Schwann cells could thus support the neuroprotective and/or neuroreparative role suggested 
for cannabinoids and related compounds in the PNS (Svíženská et al., 2013; Truini et al., 2011).  
The presence of thin interneuronal GFAP-negative cellular processes expressing CB2 receptor-
immunoreactivity is at present not easy to interpret. These CB2 receptor immunoreactive slender 
evaginations might belong to GFAP-negative SGCs (Tongtako et al., 2017) or to a different type of 
DRG glial cells, i.e. pericyte-like satellite cells (Wyburn, 1958; Bunge et al., 1967). Also the presence 
of different cell types with elongated cellular processes immunoreactive for CB2 receptor, such as 
fibroblasts and histiocytes (Bunge et al., 1967; Tongtako et al., 2017), cannot be excluded.  
Some considerations are needed when dealing with DRG blood vessels. First, little information is 
available and it mainly refers to laboratory rodents. Second, blood-nerve barrier is lacking in intact 
DRG (Jacobs et al., 1978) and fenestrations together with open intercellular junctions characterize 
ganglionic vessels (Anzil et al., 1976; Bush et al., 1991). Although the sheath of SGCs is considered 
to control the traffic of substances from blood to ganglionic neurons - thus functionally substituting 
for the vascular barrier (Pannese, 2010) - circulating signalling molecules are allowed to diffuse into 
the microenvironment of DRG. This was recently confirmed by Svíženská et al. (2013), who 
demonstrated that sciatic nerve injury induces bilateral increase of CB2 receptor (both protein and 
mRNA) in lumbar L4–L5 as well as cervical C7–C8 DRG.  
In the present study we detected CD31 and FVIII-RAg immunoreactivity in a small proportion of 
DRG vessels, mostly confined to the periphery of the ganglion rather than among sensory neurons. 
The finding is quite unexpected, since the endothelial marker CD31 allowed to trace an extensive 
network of blood vessels in the mouse L4 DRG, that was found to encapsulate and encircle sensory 
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neurons (Jemenez-Andrade et al., 2008). The paucity of vascularization of canine DRG did not seem 
to depend on methodological issues since the antibody anti-CD31 was recently found to perfectly 
label the endothelium of canine blood vessels, at least in the intestinal mucosa (Galiazzo et al., 2018).  
In the present study CB2 receptor immunoreactivity was limited to smooth muscle cells of blood 
vessels, being absent from CD31-positive endothelium, differently from what observed in canine 
intestinal (Galiazzo et al., 2018) and skin blood vessels (Campora et al., 2012), or human brain 
endothelium (Zhang et al., 2011). One possible explanation for this discrepancy might be the well 
known regional distribution of the cannabinoid receptors in blood vessels (Stanley and O'Sullivan, 
2014). Indeed, CB2 receptor immunoreactivity of vascular smooth vessels was recently detected in 
bovine pancreas (Dall’Aglio et al., 2017) and mice skin (Zheng et al., 2012). Endocannabinoids exert 
a prohomeostatic function on vascular biology through complex mechanisms often involving 
canonical as well as putative cannabinoid receptors (e.g., TRPV1 and GPR55, Ho and Kelly, 2017). 
In particular, vasodilating effect occurs at different cellular site, i.e., nerves, endothelial cells, vascular 
smooth muscle cells, perycites (Benyó et al., 2016), employing different receptors and leading to 
nitric oxide release (Ho and Kelly, 2017).  
GPR55 – The GPR55 represents a novel target for various cannabinoids (Morales and Reggio, 2017). 
Strong expression of GPR55 immunoreactivity in different size neurons and SGCs was found in the 
present study. GPR55 immunoreactivity was expressed also by GFAP negative SGCs; a recent study 
showed that GFAP recognizes up to 89% of all SGCs of the canine DRG (Tongtako et al., 2017). 
This finding indicates that GPR55 might be utilized as canine SGCs marker. In the present study, a 
similar pattern of GPR55 immunoreactivity has been observed also in the neurons and SGCs of rat 
DRG. This is a relatively new finding, since up to now GRP55 immunoreactivity has been detected 
only in the neuronal component of DRG (Lauckner et al., 2008). Consistently, the GPR55 
immunoreactivity in medium- and large-sized DRG neurons as detected here agrees with the finding 
of Lauckner et al. (2008), who observed strong GPR55 signal in mice DRG large neurons. 
Interestingly, large sensory neurons may mediate inflammatory and neuropathic pain hypersensitivity 
by switching their phenotype and expressing the nociceptive neurotransmitter Subtance P (Neumann 
et al., 1996; Ruscheweyh et al., 2007). It is noteworthy to recall that some phytocannabinoids, e.g. 
Δ9-tetrahydrocannabinol (THC), cannabidiol, synthetic cannabinoids (AM251 and O-1602), as well 
as palmitoylethanolamide (PEA) have been described as GPR55 ligands (Stella, 2010; Kramar et al., 
2017).  
Although further functional investigations are necessary, GPR55 immunoreactivity in both SGCs and 
neurons as detected in the present study likely may suggest a relevant role of this receptor in neuron-
SGCs crosstalk, which is currently considered a critical component of neuroinflammatory changes 
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eventually leading to chronic pain (Cairns et al., 2015; Hanani, 2012;Iwata et al., 2017; Skaper et al., 
2018).  
PPARα – The PPARα is a ligand-activated transcription factor belonging to the superfamily of 
nuclear hormone receptors. By modulating gene expression, it plays key roles in maintaining glucose 
and lipid homeostasis and inhibiting inflammation (Naidenow et al., 2016). The PPARα activation 
has also been shown to induce rapid, cellular changes without requiring transcription (Lo Verme et 
al., 2005). In the present study PPARα immunoreactivity has been detected in the canine SGCs and 
endothelial cells. In the comparative study on rat DRG, we observed bright PPARα immunoreactive 
SGCs, whereas neurons were faintly immunolabeled. These findings are in line with previous data 
on the expression of PPARα in mice DRG (Lo Verme et al., 2006; D’Agostino et al., 2009; Khasabova 
et al., 2012) and canine gastrointestinal tract (Galiazzo et al., 2018). The ganglia of four out of eight 
dogs did not show PPARα immunoreactivity. At present we do not have any clear explanation for 
this discrepancy. No apparent correlation with any particular factor (e.g., age or cause of death) was 
found. Nonetheless, we cannot exclude that it was due to an undetected subclinical state, given that 
metabolic disorder, for example, is associated with significantly decreased spinal PPARα expression 
(Wang et al., 2014). 
TRPV1 – The TRPV1 is a ligand-gated nonselective cation channel usually expressed by peptidergic 
nociceptors of rodents (Zwick et al., 2002; Yu et al., 2008) and large mammals (Russo et al., 2013) 
as well as nonpeptidergic nociceptors (Tominaga et al., 1998; Breese et al., 2005). The TRPV1 is 
activated by heat (>43°C), low pH and capsaicin (Caterina et al., 1997) and desensitized by 
endocannabinoids (Zygmunt et al., 1999; Ambrosino et al., 2013).  
In accordance with previous studies in rodent and human DRG (Caterina et al., 1997; Helliwell et al., 
1998; Hoffman et al., 2010; Anand et al., 2008) we have observed diffuse TRPV1 immunoreactivity 
in neurons of canine DRG, with the brightest immunolabeling being displayed by small size neurons. 
This latter finding agreed with the study of Binzen et al. (1996), who found TRPV1 to be mainly 
expressed in small-sized neurons of rat DRG, the vast majority of which co-expressed CB1 receptors. 
Our comparative study on rat DRG confirmed that the brightest TRPV1 immunoreactivity was mainly 
expressed by small neurons. Moreover, SGCs from two old dogs were also brightly immunolabeled, 
in accordance with TRPV1 expression by DRG glial cells (Doly et al., 2004).  
To the best of our knowledge no information is yet available about the influence of age on neuronal 
and/or glial expression of TRPV1, however one could tentatively speculate that aging itself has an 
impact on pain pathophysiology through changes in the pain involved receptor TRPV1. Actually, 
increased expression of TRPV1 was recently observed in rat DRG after neuropathic pain induction 
(Chukyo et al., 2018). Marrone et al. (2017) reported TRPV1 immunoreactivity in microglial cells 
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rather than neurons of the mice brain areas. Moreover, they showed that in mice suffering from 
neuropathic pain, TRPV1 was also functionally expressed in cortical neurons. Together with the 
present morphological data, the findings by Marrone et al. (2017) indicate that TRPV1 might be a 
key player of glia-neuron communication. 
Recent studies have shown that TRPV1 is desensitized by a number of cannabinoids, including THC, 
cannabinol, synthetic cannabinoid WIN 55,212-2, AEA, rimonabant (Stella, 2010) as well as PEA 
(Ho et al., 2008; De Petrocellis and Di Marzo, 2010; Ambrosino et al., 2013; Aldossary et al., 2019). 
This ability is very important as TRPV1 channel desensitization is considered to be responsible for 
analgesic and anti-inflammatory effects (Marrone et al., 2017).  
A limitation of the study is the lack of unquestionable specificity test of the employed TRPV1 
antibody in dog tissue. The TRPV1 has been cloned and functionally characterized from different 
species, including dogs. Peptide alignment of the dog TRPV1 orthologue with other species of the 
TRPV1 family revealed a high degree of sequence homology (human, 89.1%; rat, 87.5%; mouse, 
83.3%) (Phelps et al., 2005). Actually, the antibody performs well in an optimized IHC assay, binding 
the indicated target, not only in dog tissue (TRPV1 immunolabeled SGCs were observed also in cat 
and horse cervical DRG, while in small rodents and guinea-pig the TRPV1 immunoreactivity was 
always limited to DRG neurons – RC personal observation). Thus, since the dog was proposed as a 
good model for studying the role of TRPV1 in inflammatory diseases and nociception and the effects 
of TRPV1 antagonists in humans (Phelps et al. 2005), additional molecular analysis, such as knockout 
cell lines and Western blot (assuming the IHC-based antibody also works in Western blots), might be 
necessary to strength the results of TRPV1 immunolabeling, and to increase confidence for the 
validity in the dog. 
Conclusion 
The present study highlighted the expression of canonical and putative cannabinoid receptors on 
different DRG cell types, in particular neurons and glial cells (SGCs and Schwann cells). Given the 
key role of DRG elements and cannabinoid receptors in the pathophysiology of chronic pain, targeting 
and modulating these receptors, possibly through a multifaceted approach, may become a novel way 
to manage pain in veterinary patients.   
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Controls Breed Gender Age Cause of death 
Dog 1 Chihuahua F 8 mo Head trauma 
Dog 2 Great Dane M 2 yr 
Peritonitis/ 
intussusception 
Dog 3 Pitbull M 13 yr 
Splenic neoplasia, 
skin neoplasia 
Dog 4 Mongrel M 11 yr Mast cell tumor 
Dog 5 Mongrel F 11 yr 
Mast cell tumor, 
Cushing’s 
syndrome 










F 8 yr Gastric tumor 
Table 1 Clinico-pathological data of the dogs included in the present research (M, male; F, female. FS, female spayed). 
  





Host Code Dilution Source 
CB1 Rabbit Orb10430 1:200 Biorbyt 





GFAP Chicken AB4674 1:800 Abcam 
GPR55 Rabbit NB110-55498 1:200 Novus Biol. 
Factor VIII Rabbit A0082 1:1000 Dako 
PPARα Rabbit NB600-636 1:200 Novus Biol. 
TRPV1(VR1) Rabbit ACC-030 1:200 Alomone 
Table 2: Primary antibodies used in the present research. Primary antibodies Suppliers: Abcam, Cambridge, UK; 




Host Code Dilution Source 
Anti-rabbit IgG 
FITC 
Goat 401314 1:200 
Calbiochem-
Novabiochem 
Anti-rabbit 488 Donkey AB150073 1:800 Abcam 
Anti-chicken 
TRITC 
Donkey 703-025-155 1:200 Jackson 
Table 3: Secondary antibodies used in the present research. Secondary antibodies Suppliers: Abcam, Cambridge, UK; 
Biotium, Inc. Hayward, CA, USA; Calbiochem-Novabiochem, San Diego, CA, USA; Jackson Immuno Research 
Laboratories, Inc. Baltimore Pike, PA, USA. 
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Cervical dorsal root ganglion CB1 CB2 GPR55 PPARα TRPV1 
Neurons 
N, nucleus; C, Citoplasm 
C ++ N + C ++ - C+/+++ 
Satellite glial cells C + - C +++ C ++ C +++ 
Schwann cells - +++ - - - 
Blood vessels 





- E ++ - 
Table 4: Semiquantitative evaluation of the density of CB1, CB2, GPR55, PPARa, and TRPV1 receptors immunoreactivity 
in different cellular elements (neurons, satellite glial cells, Schwann cells, blood vessels) of the canine C8 cervical dorsal 
root ganglia.  
 
Figure 2 (a-d): Photomicrographs of cryosections of canine cervical (C8) dorsal root ganglion showing cannabinoid 
receptor 1 (CB1) immunoreactivity. Small stars indicate small neurons showing CB1 receptor weak to moderate 
immunoreactivity. Large stars indicate CB1 receptor negative neurons. Arrows indicate satellite glial cellsshowing weak 
CB1 receptor immunoreactivity. Bar: a–d = 50μm. 
  




Fig. 3 (a-l): Photomicrographs of cryosections of canine cervical (C8) dorsal root ganglion showing cannabinoid 
receptor 2- (CB2), glial fibrillary acidic protein- (GFAP), and CD31-immunoreactivity. a-c) Stars indicate NeuroTrace 
labelled (a) dorsal root ganglion sensory neurons which were CB2 receptor negative (b), as well as the satellite glial 
cells (white arrows). d-f) Stars indicate sensory neurons encircled by satellite glial cells (white arrows) which were 
GFAP-immunoreactive (e) and CB2 receptor negative. CB2 receptor immunoreactivity was expressed by Schwann cells 
and neuronal nuclei (open arrow). g-i) The empty arrow indicates one neuronal axon that bifurcates (T-junction) in its 
central and peripheral portions (large white arrows). The small arrows indicate the nuclei of Schwann cells. j-l) Open 
arrows indicate smooth muscle cells (vessel on the left) and pericyte-like cells (elongated and thin blood vessel on the 
right) showing CB2 receptor immunoreactivity (j). White arrows indicate endothelial cells showing CD31 
immunoreactivity (k). Bar: a-f, j-l = 50 μm; g-i = 100 μm.  




Figure 4 (a-i): Photomicrographs of cryosections of canine cervical (C8) dorsal root ganglion showing GPR55 (a–f) and 
PPARalpha (g–i) immunolabeling. (a–c) Arrows indicate the Neurotrace-labeled nuclei of satellite glial cells (a) which 
showed bright GPR55 immunolabelling (b). White stars indicate unlabeled sensory neurons; open stars indicate empty 
spaces in which sensory neurons were no more evident. (d–f) White arrows indicate satellite glial cells which co-
expressed bright GPR55- (d) and glial fibrillary acidic protein (GFAP) immunoreactivity; open arrows indicate SGCs 
which were GPR55 immunoreactive and GFAP negative (e). Stars indicate sensory neurons of different dimension, which 
expressed faint –to-moderate GPR55 immunoreactivity. (g–i) White arrows indicate the Neurotrace labeled nuclei of 
SGCs which showed PPARalpha immunoreactivity (h). Open arrows indicate autofluorescent pigment. Bar: a–i = 50μm. 
 
Figure 5 (a-f): Photomicrographs of cryosections of the C8 cervical dorsal root ganglia belonging to two aged dogs 
showing transient receptor potential vanilloid type 1 (TRPV1) immunoreactivity. White stars indicate neurons showing 
bright TRPV1 immunoreactivity, while open stars indicate larger neurons showing weaker TRPV1 immunoreactivity. 
Arrows indicate the Neurotrace labeled nuclei of satellite glial cells showing bright TRPV1 immunolabeling (b, e). Bar: 
a–f = 50μm. 




Supplementary Figure 1(a-o): Photomicrographs of cryosections of rat cervical (C8) dorsal root ganglion showing CB1 
(a-c), CB2 (d-f), GPR55 (g-i), PPARalpha (j-l), and TRPV1 (m-o) immunolabeling. a-c) CB1 immunoreactivity was 
brightly expressed by the nuclei of sensory neurons (stars), whereas the nuclei of satellite glial cells (arrows) showed 
weaker CB1 immunolabeling. The neuronal cytoplasm showed, on the contrary, weak or undetectable CB1 receptor 
immunoreactivity d-f) Stars indicate some of the nuclei of the sensory neurons expressing CB2 immunoreactivity. g-i) 
Sensory neurons expressing weak to moderate GPR55 immunoreactivity; arrows indicate the nuclei of some satellite glial 
cells which expressed brighter GPR55 immunoreactivity. j-l) Arrows indicate the nuclei of SGCs expressing bright 
PPARalpha immunoreactivity. m-o) Arrows indicate sensory neurons expressing bright TRPV1 immunoreactivity. Larger 
neurons were TRPV1 negative (stars) or showed weaker TRPV1 immunolabeling (white stars). Scale Bar: a-c, g-l = 50 
μm; d-f, m-o = 100 μm.  




Supplementary Figure 2: a-d) Photomicrographs of cryosections of canine cervical (C8) dorsal root ganglion (DRG) 
showing cannabinoid receptor 2- (CB2) and endothelial marker CD31 immunoreactivity. Large and empty arrows 
indicate the DAPI labelled nuclei of vascular smooth muscle cells (a), which showed weak CB2 receptor immunoreactivity 
(b). The small empty arrows indicate the nuclei of CD31 immunoreactive endothelial cells (c). White arrows indicate the 
nuclei of CB2 receptor immunoreactive Schwann cells (b) Scale Bar: a-d= 50 μm 
 
Supplementary Figure 3 (a-d): Supplementary Fig. 3. a-d) Photomicrographs of cryosections of canine cervical (C8) 
dorsal root ganglion (DRG) showing cannabinoid receptor 2- (CB2) and myelin protein zero (P0) immunoreactivity. 
Arrows indicate the nuclei of Schwann cells showing co-localization between CB2 receptor and P0 immunoreactivity. 
Scale Bar: a-d= 50 μm 
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Localisation of cannabinoid receptors in the equine dorsal root 
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Capodanno Y1, Spadari A1 
1Department of Veterinary Medical Sciences – University of Bologna, Italy 
2St. Orsola-Malpighi Hospital, Bologna, Italy 
Abstract  
Introduction – The activation of cannabinoid receptors by endogenous, plant-derived or synthetic 
cannabinoids may exert beneficial effects on somatic and visceral pain perception. 
Objectives – The aim of this study was to localise the cellular distribution of nine canonical and 
putative cannabinoid receptors [cannabinoid receptors 1 (CB1R) and 2 (CB2R), G protein-coupled 
receptor 3 (GPR3) and 55 (GPR55), nuclear peroxisome proliferator-activated receptor alpha 
(PPARα) and gamma (PPARγ), transient receptor potential vanilloid type 1 (TRPV1) and ankyrin 1 
(TRPA1), serotonin 5-HT1a receptor (5-HT1aR)] in the equine cervical dorsal root ganglia. Ex vivo 
qualitative and quantitative immunohistochemical study. 
Results – All the receptors were expressed by neurons, SGCs, or both cellular types. The neurons 
showed immunoreactivity for CB1R (100%), CB2R (88±18%), GPR3 (66±16%), GPR55 (64±16%), 
PPARα (100%), PPARγ (100%), TRPV1 (66±18%), TRPA1 (73±12%), and 5-HT1aR (83±7%). 
Neuronal processes showed CB1R and TRPA1 immunoreactivity. The SGCs showed 
immunoreactivity for CB2R, GPR55, PPARα, PPARγ, TRPA1, and 5-HT1aR.  
Conclusions and relevance - The present study highlighted the expression of cannabinoid receptors 
in the DRG neurons and/or glial cells. Given the key role of DRG elements and cannabinoid receptors 
in the pathophysiology of chronic pain, these findings could support the use of cannabinoid agonists 
in the horse with chronic pain and encourage the development of new drugs to manage neuropathic 
pain in equine medicine. 
Introduction 
A growing body of literature indicates that the activation of cannabinoid receptors by endogenous, 
plant-derived or synthetic cannabinoids may exert beneficial effects on inflammatory and neuropathic 
pain perception (Ligresti et al., 2016). Their scientific evidence has prompted several companies to 
produce medical marjiuana and cannabinoid receptor agonists to also be used in equine medicine to 
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treat different forms of somatic and visceral pain. For instance, cannabidiol (CBD), a non-
psychoactive compound found in cannabis sativa, seems to be one of the most promising therapeutic 
substances, due to its numerous health-related benefits, including analgesic, anti-inflammatory, anti-
spasmodic and anti-anxiety benefits (Mechoulam et al., 2007; Pertwee 2008). 
For many years, it was assumed that the beneficial effects of the cannabinoids were mediated by 
cannabinoid receptors 1 (CB1R) and 2 (CB2R). However, it is currently known that 
phytocannabinoids may act on multiple targets. These compounds have been shown to interact with 
other G-protein coupled receptors, nuclear receptors, transient receptor potential (TRP) channels, 
serotonin receptors and glycine receptors, among others (Morales et al. 2017). In particular, CBD, 
which shows indirect interaction with CB1R and CB2R, seems to be involved in the modulation of 
receptors outside the endocannabinoid system, such as the serotoninergic 5-HT1a receptor (5-
HT1aR), and the transient receptors potential vanilloid 1 (TRPV1) and ankyrin 1 (TRPA1), the latter 
two being excitatory ion channels expressed by the sensory neurons mediating somatic and visceral 
pain (Ligresti et al. 2016).  
As a general rule, to better understand the actions of a drug, it would be of extreme importance to 
know the cellular distribution of its specific receptors. To date, reliable anatomical studies regarding 
the cellular distribution of cannabinoid receptors in the horse central and peripheral nervous system 
are still lacking. In order to help filling these anatomical gaps, the present ex vivo study was designed 
to identify, in the equine dorsal root ganglia (DRG), the cellular distribution of two canonical 
cannabinoid receptors, i.e. CB1R and CB2R, and of seven putative cannabinoid receptors, i.e. G 
protein-coupled receptor 3 (GPR3) and 55 (GPR55), nuclear peroxisome proliferator-activated 
receptor alpha (PPARα) and gamma (PPARγ), TRPV1 and TRPA1, and 5-HT1aR. 
Material and Methods 
Animals  
The cervical (C6-C8) dorsal root ganglia were collected from six horses (1.5 years of age) at the 
public slaughterhouse, following the division of the trunk of the animals into two half-carcasses. The 
tissues were fixed and processed to obtain cryosections as described elsewhere (Russo et al. 2011). 
Immunofluorescence 
The cryosections were hydrated in phosphate–buffered saline (PBS) and processed for 
immunostaining. To block non-specific bindings, the sections were incubated in a solution containing 
20% normal goat serum, 0.5% Triton X-100b and bovine serum albumin (1%) in PBS for 1 h at room 
temperature (RT). The cryosections were incubated overnight in a humid chamber at RT with primary 
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antibodies (Table 1) diluted in 1.8% NaCl in 0.01M PBS containing 0.1% sodium azide. After 
washing in PBS (3 x 10 min), the sections were incubated for 1 h at RT in a humid chamber with the 
secondary antibody [goat F(ab)2 anti-Rabbit FITC; ab98430] diluted in PBS. After washing in PBS 
(3 x 10 min) to identify the DRG neurons and the SGCs, the sections, single-stained with each marker 
studied, were counterstained with Blue fluorescent Nissl stain solution (NeuroTrace®, # N-21479, 
dilution 1:200). The cryosections were then washed in PBS (3 x 10 min) and mounted in buffered 
glycerol at pH 8.6.  
In order to determine the proportion of neurons immunoreactive for each of the studied marker, at 
least one hundred Nissl stained neurons were counted for each marker. Data were collected from 
preparations obtained from at least three animals (n=3). The percentages of immunopositive neurons 
were expressed as mean ± standard deviation. 
Specificity of the primary antibodies  
The choice of the primary antibodies utilised in the study was based on the homology of the amino 
acid sequence between the immunogen of the commercially available antisera and the horse proteins, 
verified by the “alignement” tool available on the Uniprot database (www.uniprot.org) and the 
BLAST tool of the National Center for Biotechnology information (NCBI) (www.ncbi.nlm.nih.gov). 
Details are summarized in Table 2.  
Specificity of the secondary antibody 
The specificity of the secondary antibody was tested by applying them after omission of the primary 
antibodies. No stained cells were detected after omitting the primary antibodies. 
Fluorescence microscopy 
The preparations were examined, and the images were recorded and adjusted as described elsewhere 
(Giancola et al. 2017).  
Results 
CB1R immunoreactivity 
Bright CB1R immunoreactivity (CB1R-IR) was displayed, with different degrees of intensity, by the 
cytoplasm (and nucleolus) of all sensory neurons (100%; 604/604 cells counted, n=4) (Figure 1 a-c); 
no distinction of CB1R immunolabelling was observed among neurons of different sizes. The nerve 
processes also showed CB1R-IR, although it was weaker than that observed in the neuronal somata. 
Also the SGCs showed faint CB1R-immunolabeling. 




The CB2R-IR was expressed by the majority of neurons (88±18%; 597/678 cells counted, n=3) and 
all SGCs. In general, there was an inverse correlation between the brightness of CB2R 
immunoreactivity in neurons and SGCs. In addition, small-to-medium-sized neurons showed brighter 
granular CB2R cytoplasmic immunolabeling, in comparison with largest ones, wich were encircled 
by strongly labeled SGCs (Fig. 1 d-f). Large and faintly CB2R labeled neurons were about 40% of 
the total neuronal population, whereas the brighter and smaller neurons accounted for about 60%. 
TRPA1 immunoreactivity 
The TRPA1-IR was expressed by the cytoplasm and nucleus of both the neurons (73±12%; 385/551 
cells counted, n=3) and the SGCs, and by the nerve processes (Fig. 2 a-c). Of the nerve processes, 
thin and unmyelinated nerve fibres showed brighter TRPA1 immunolabelling than large myelinated 
nerve fibers. 
TRPV1 immunoreactivity 
The TRPV1-IR was expressed by the cytoplasm of the sensory neurons (66±18%; 356/570 cells 
counted, n=3) (Fig. 2 d-f). Whilein some horses it was challenging to establish whether the SGCs 
showed TRPV1-IR or not due to the presence of a faint signal, in other subjects SGCs showed a bright 
TRPV1 labeling. When looking at TRPV1-IR in terms of signal intensity, different-sized neurons did 
not show any apparent differences. TRPV1 was brightly expressed also by nerve fibers. 
PPARα immunoreactivity 
The PPARα-IR was brightly displayed by the cytoplasm of the SGCs, whereas in the cytoplasm of 
the sensory neurons (100%; 456/456 cells counted, n=4) it was very weak (Fig. 2 g-i). The 
endothelium of blood vessels showed bright PPARα-IR (data not shown). 
PPARγ immunoreactivity 
The PPARγ-IR was brightly expressed by the nuclei of all the neurons; the nuclei of SGCs also 
showed moderate PPARγ immunolabelling (Fig. 2 j-l). 
GPR3 immunoreactivity 
Faint and granular GPR3-IR was displayed, albeit with different degrees, by the cytoplasm of a subset 
of neurons (66±16%; 474/740 cells counted, n=3) (Fig. 3 a-c). 




The GPR55-IR was expressed, with different degrees, by the cytoplasm of a subset of neurons 
(64±16%; 293/469 cells counted, n=4). In addition, GPR55-IR was also displayed by some SGCs 
(Fig. 3 d-f) and perineuronal cellular elements (probably macrophages) (data not shown). 
5-HT1aR immunoreactivity 
The 5-HT1aR-IR was expressed by the cytoplasm of the sensory neurons (83±7%; 367/437 cells 
counted, n=3) and the SGCs (Fig. 3 g-i), and by the Schwann cells (Fig. 3 j-l). 
Discussion 
Cannabinoid receptors may play a critical role in nociception by means of central and peripheral 
mechanisms (Hohmann et al., 1995; Calignano et al., 1998; Richardson et al., 1998; Stella 2010; 
Ligresti et al., 2016; Pergolizzi et al., 2018). 
To the best of our knowledge, this is the first immunohistochemical study regarding the distribution 
of cannabinoid receptors in the equine DRG. The observation of a prodigious level of cannabinoid 
receptors in different cellular elements of the equine DRG, such as neurons, SGCs and Schwann cells, 
indicated that endocannabinoids and cannabinoid agonists may play a notable role in pain 
transmission, inflammation, myelination and, possibly, neuroprotection. However, at present it is not 
possible to know whether the elevated expression of these receptors in the horse peripheral sensory 
pathways corresponds to effective functional activity.  
Despite their apparent simplicity and the total lack of synaptic contacts, the DRG sensory neurons are 
the site of a certain degree of processing of sensitive information (Hanani 2012; Krames 2015). In 
fact, the perykaria of primary sensory neurons show specific receptors for several neurotransmitters 
and may release extracellular neurotransmitters, such as glutamate, adenosine triphosphate (ATP), 
Substance P (SP) and calcitonin gene-related peptide (CGRP), which can change the membrane 
potential of the neighboring sensory neurons and also activate the SGCs (Kung et al., 2013). 
Conversely, the SGCs can modulate the activation of the nociceptive neurons by means of the release 
of ATP and other neuromodulators, cytokines, chemokines, and proteases (Zhang et al., 2007; Ohara 
et al., 2009; Ji et al., 2013). Thus, the SGCs also play a pivotal role in neurotransmission and pain 
regulation, and their release of small molecules could contribute to the sensitisation of pain 
transmission nociceptors. The observation that several types of cannabinoid receptors are expressed 
by horse DRG neurons and SGCs indicated the relevant role of these receptors in the neuron-SGC 
synergy.  
Cannabinoid CB1R is widely expressed throughout the nociceptive system and its activation by 
endogenous or exogenous cannabinoids modulates the neurotransmitter release. The expression of 
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CB1R-IR in the horse DRG is in line with data obtained in laboratory rodents and dogs (Hohmann 
and Herkenham 1999; Ross et al., 2001; Freundt-Revilla et al., 2017), which show that CB1R is 
mainly expressed in the myelinated fibres of the DRG neurons (Hohmann and Herkenham 1999; Ross 
et al., 2001; Bridges et al., 2003;Freundt-Revilla et al., 2017) and co-localise with CGRP and TRPV1, 
at least in rodents (Hohmann and Herkenham 1999; Ahluwalia et al., 2000; Bridges et al., 2003). 
Cannabidiol acts as an “indirect” CB1R/CB2R agonist by inhibiting the enzymatic hydrolysis of the 
endogenous cannabinoid anandamide (AEA) (Bisogno et al., 2001) which is an endogenous agonist 
of TRPV1 (Muller et al., 2019). The data of the present study may also support some analgesic effects 
of natural and synthetic cannabinoids in the horse, mainly for the treatment of neuropathic pain 
(Pergolizzi et al., 2018).  
The CB2R was initially presumed to be well represented in the immune system (Pacher et al., 2011) 
and was absent in the central nervous system (CNS), whereas recent literature points out its 
expression in the astrocytes, microglia and neurons of the CNS (Hsieh et al., 2011; Malfitano et al., 
2014; Freundt-Revilla et al., 2018), and also in the nociceptive sensory neurons (Ross et al., 2001; 
Anand et al., 2008; Svízenská et al., 2013). Since the CB2R is upregulated in a variety of CNS 
neuroinflammatory diseases, characterised by microglia and/or astroglia activation, it might represent 
a promising pharmacological target. (Chen et al. 2012). It has been shown that, when nerve damage 
occurs, the CB2R is upregulated in the DRG and the superficial laminae of the dorsal horn of the 
spinal cord (Wotherspoon  et al., 2005; Anand et al., 2008; Svízenská et al., 2013), and functional 
studies regarding sensory neurons have pointed to an antinociceptive role of the CB2R (Burston and 
Woodhams 2014).  
In the present study, bright CB2R-IR was observed in the SGCs and a weaker signal in the sensory 
neurons. The presence of CB2R-IR in the DRG neurons suggested that the CB2R agonists could 
modulate pain transmission by means of glial and neuronal action. These findings appeare somewhat 
useful for the peripheral modulation and treatment of painful sensation in the horse. Cannabidiol 
increases the levels of endocannabinoid 2-arachidonoylglycerol (2-AG) which is an endogenous 
agonist of the CB1R and the primary endogenous ligand for the CB2R (Stella et al., 1997).  
Concerning the TRP channels (a group of membrane proteins involved in the transduction of chemical 
and physical stimuli including pressure, temperature and pain) (Wu et al., 2010; Moran et al., 2011; 
Morales et al., 2017), the data obtained in the present study demonstrated that, in the horse DRG, 
TRPV1 was expressed by the sensory neurons, and TRPA1 by the sensory neurons and also SGCs, 
with bright immunolabelling in thin unmyelinated nerve fibres. This is, in part, in line with previous 
studies in rodents, showing that the DRG neurons co-expressing TRPV1, substance P, and CGRP 
also express TRPA1 (Story et al., 2003; Bautista et al., 2005; Kobayashi et al., 2005). The TRPV1 is 
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activated by a multitude of endogenous and exogenous chemical agents, such as capsaicin, an active 
ingredient contained in chili pepper (Caterina et al., 1997) and its analogs, and by different 
phytocannabinoids, such as CBD (Di Marzo and De Petrocellis 2010; Caterina 2014). Moreover, the 
TRPV1 is also activated by high temperatures (T> 42° C), due for example to local inflammation and 
osmotic changes, such as acid pH which also develops inflammation (Nagy et al., 2014). The TRPA1 
is required for normal mechano- and chemosensory functions in specific subsets of vagal, splanchnic, 
and pelvic afferents (Brierley et al., 2009). The TRPA1 also mediates somatic and visceral pain in 
response to a stimulation of chemical, mechanical or thermal origin (McNamara et al., 2007; Wang 
et al., 2019), and can be desensitised by different mechanisms (Akopian et al., 2007).  
The TRPA1 is closely associated with the TRPV1 and, together, they are pain and neurogenic 
inflammation players in terms of both expression and function (Anand et al., 2008; Huang et al., 
2019). The endogenous presynaptic TRPA1 and TRPV1 activity at the spinal level contributes to 
increased nociceptive input from the primary sensory nerves to the dorsal horn neurons in 
inflammatory pain (Huang et al., 2019). The anti-inflammatory, anti-nociceptive and analgesic effects 
of CBD might be due, in part, to the capability of phytocannabinoids to activate and desensitise the 
TRPA1 (De Petrocellis et al., 2008) and the TRPV1 (Bisogno et al., 2001; Costa et al., 2007; Ligresti 
et al., 2016). All together, these evidences strongly supported the hypothesis that, also in the horse, 
the TRPV1 and the TRPA1 may exert a pivotal role in pain and neurogenic inflammation. 
Peroxisomal proliferation receptors (PPARs) belong to the family of intranuclear receptors which act 
as transcription factors, modulating different physiological functions. Once activated by their ligand, 
PPARs induce the expression of hundreds of genes in each cell type (Issemann and Green 1990). 
However, their activation has also been shown to result in rapid cellular changes which do not require 
transcription, including reduction of inflammation (Lo Verme et al., 2005; O'Sullivan 2007). Recent 
studies have shown that cannabinoids activated PPARs (Burstein 2005; O'Sullivan 2007; Morales et 
al., 2017), and that this activation is associated with some of the pain-relieving, anti-inflammatory 
and neuroprotective properties of cannabinoids. In the present study, PPARα-IR was observed in the 
SGCs and PPARγ-IR in the sensory neurons and SGCs. Both these types of immunolabelling 
suggested that, also in the horse, phytocannabinoids may offer prospects for the treatment of painful 
somatic and visceral diseases by acting on these receptors. 
Another finding of this study was the expression of 5-HT1aR in the cytoplasm of the sensory neurons, 
SGCs and Schwann cells. It is well established that serotonin (5-HT) exerts a pivotal role in sensory 
information processing (Richardson 1990). At the level of the spinal cord, 5-HT is primarily released 
from the descending bulbospinal serotonergic neurons and causes analgesia by inhibiting dorsal horn 
neuronal responses to noxious stimuli by means of the activation of the 5-HT1aR (Liu et al., 2002). 
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In addition, the activation of the 5-HT1aR inhibits glutamate release from the sensory neurons, 
reducing pain transmission (Haleem et al., 2018). Functional studies have suggested the presence of 
the 5-HT1aR in the DRG and its role in nociception (Todorovic and Anderson 1992). The 5-HT1aR-
IR was observed in both the neurons and the SGCs of the horse DRG, in line with the presence of this 
receptor on glial cells (Miyazaki and Asanuma 2016). Thus, it is plausible to consider that, in the 
horse, the 5-HT1aR might play a role in pain perception/modulation. Clinical studies have indicated 
that CBD also interacts with the serotonin 5-HT1aR and exerts analgesic and anxiolytic effects (De 
Gregorio et al., 2019). It has been shown that, under certain conditions of experimentally induced 
nociception, different receptors (5-HT1a, 5-HT3, TRPA1) are simultaneously activated (Krimon et 
al., 2013; Fischer et al., 2017); thus, CBD may reduce nociception by simultaneously desensitising 
these receptors. 
The orphan receptor GPR3 is phylogenetically related to the cannabinoid receptors and is considered 
to be a novel molecular target for CBD (Laun et al., 2019). The GPR3 is expressed in the CNS and 
has been implicated in the health and disease states of the brain. The GPR3 alters emotional behavior, 
is involved in the development of neuropathic pain and regulates morphine-induced antinociception 
(Ruiz-Medina et al., 2011). The GPR3 expression also seems to be involved in neurite outgrowth 
(Tanaka et al., 2007). A subset of neuronal cell bodies of the horse DRG showed GPR3-IR. 
The GPR55, considered the third cannabinoid receptor (Moriconi et al., 2010), in the present study 
was expressed by a DRG neurons and glial cells; its presence in both SGCs and neurons likely 
indicates a relevant role of this receptor in neuron-SGCs crosstalk. Studies in mice indicate a 
pronocioceptive role of GRP55 in DRG neurons (Lauckner et al., 2008). It is worth noting that CBD 
acts as a GPR55 antagonist. 
The study of the phenotype (neurochemical code) of the sensory neurons expressing cannabinoid 
receptors was not the aim of the present study; thus, additional studies are needed to better 
characterise these receptors and their potential therapeutic effects in the horse. 
Conclusions and relevance  
Canonical and putative cannabinoid receptors had a wide distribution in the sensory neurons and 
SGCs of the horse DRG, with a close functional relationship between the sensory neurons and the 
SGCs in the peripheral processing of nociceptive imputs. These findings represented an important 
anatomical basis upon which it would be possible to continue with other preclinical and clinical 
studies aimed at investigating and possibly supporting the specific therapeutic uses of non-
psychotropic cannabinoid agonists against noxius stimulation in horses.  
  





Host Code Dilution Source 
CB1R Rabbit ab23703 1:100 abcam 
CB2R Rabbit AB45942 1:200 abcam 
GPR3 Rabbit ab106589 1:300 abcam 
GPR55 Rabbit NB110-55498 1:200 Novus Biol. 
PPARα Rabbit NB600-636 1:200 Novus Biol. 
PPARγ Rabbit ab45036 1:300 abcam 
5-HT1aR Rabbit ab85615 1:100 abcam 
TRPA1 Rabbit ab58844 1:100 abcam 
TRPV1 Rabbit ACC-030 1:200 Alomone 
Table 1 - Primary antibodies used in the study. Primary antibodies Suppliers: abcam, Cambridge, UK; Alomone, 
Jerusalem, Israel; Novus Biologicals, Littleton, CO, USA. 
  




Homology between the amino 
acidic sequences (immunogen 
and horse) 
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immunogen sequence 













































Table 2: Homology between the AA sequences (betweenthe host and horse) and with the specific sequence of the 
immunogen of the CBR antibodies used in the study 
  




Figure 1 (a-i): Photomicrographs of cryosections of a horse cervical (C8) dorsal root ganglion showing cannabinoid 
receptor 1 (CB1R) (a-c) and cannabinoid receptor 2 (CB2R) (d-i) immunoreactivity (IR). a-c) CB1R-IR was expressed 
by the sensory neurons whereas the satellite glial cells, whose nuclei are indicated by arrows, were CB1R-negative. d-i) 
Arrows indicate satellite glial cells which were CB2R immunoreactive. Sensory neurons, in particular the smallest ones, 
showed very faint granular CB2R immunolabelling. Scale bar = 50µm 
  




Fig. 2 (a-l). Photomicrographs of cryosections of a horse cervical (C8) dorsal root ganglion showing TRPA1-(a-c), 
TRPV1- (d-f), PPARα- (g-i), and PPARγ- (j-l) immunoreactivity (IR). a-c) Sensory neurons and satellite glial cells (small 
arrows) expressed TRPA1-IR. Large arrows indicate groups of amyelinic sensory fibres which showed very bright 
TRPA1-IR, whereas the nerve fibres with a larger diameter (stars) showed a weaker immunostaining. d-e) Only the 
sensory neurons were TRPV1 immunoreractive whereas satellite glial cells (arrows) were TRPV1-negative. g-i) Only the 
satellite glial cells (arrows) showed PPARα-IR. j-l) Bright PPARγ-IR was expressed by neuronal nuclei (large arrows) 
whereas the nuclei of the glial cells (small arrows) showed fainter immunolabelling. Scale bar = 50µm 
  




Fig. 3 (a-l) Photomicrographs of cryosections of a horse cervical (C8) dorsal root ganglion showing GPR3-(a-c), GPR55 
(d-f) and 5-HT1a receptor- (g-i) immunoreactivity (IR). a-c) Three arrows indicate the sensory neurons expressing weak 
GPR3-IR. The star indicates the nucleus of one large sensory neuron expressing moderate GPR3-IR. d-f) White star 
indicate a sensory neurons expressing bright GPR55-IR, whereas open star indicate a neurons with weaker 
immunolabeling. Arrows indicate some SGCs showing GPR55-IR. g-i) Sensory neurons expressed bright 5-HT1a 
receptor-IR; satellite glial cells (arrows) were also moderately 5-HT1a receptor-IR. j-l) The Schwann cells (arrows) 
showed 5-HT1a receptor-IR. Scale bar = 50 µm. 
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Paper published on Veterinarni medicine (2017), 62(11), 614-619. Modified from:  
A rare case of nasal osteoma in a dog: a case report 
Galiazzo G, Pietra M, Tinto D, Linta N, Morini M, Capitani O 
Department of Veterinary Medical Sciences – University of Bologna, Italy 
Abstract 
A 35-month-old female German shepherd weighing 33.2 kg was referred to our department with a 
10-month history of sneezing and left nasal swelling. On clinical examination, the dog showed 
deformity of the left nasal plane in the absence of any cutaneous lesions or nasal discharge, and 
presented with nasal snoring noises during both the inspiratory and expiratory phases. The patency 
of nasal cavities was evaluated using the cotton swab test, and was found to be preserved only on the 
right side. Endoscopic, radiographic and computed tomographic examination revealed an 
osteoproductive lesion that distorted the nasal, maxillar and frontal bones, completely occupying the 
left nasal cavity and frontal sinuses, resulting in destruction of the nasal septum and invasion of the 
contralateral nasal cavity. Five bioptic samples of the mass were collected from the cutaneous surface 
using a 9G Jamshidi bone marrow bioptic instrument. Histologically, the lesion consisted of a non-
encapsulated, multilobulated mass composed of dense coalescing trabeculae of well-differentiated 
bone, which was lined by osteogenic cells. The morphology was suggestive of nasal osteoma. Due to 
the large size of the mass, evidenced by computed tomography, chronic systemic nonsteroidal anti-
inflammatory treatment with carprofen was proposed instead of surgery. The description of this case 
is useful for veterinarians, who should consider osteoma as a possible differential diagnosis for nasal 
tumours. 
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In collaboration with the Gastrointestinal Laboratory, College of Veterinary Medicine and 
Biomedical Sciences, Texas A&M University (Texas). Abstract presented to the ACVIM Forum 
(2017). 
Ileal and colonic mucosal microbiota in dogs with steroid responsive 
chronic enteropathies 
Francesca Bresciani1, Yasushi Minamoto2, Jan S. Suchodolski2, Giorgia Galiazzo1, Carla Giuditta 
Vecchiato1, Carlo Pinna1, Giacomo Biagi1, Marco Pietra1 
1Department of Veterinary Medical Sciences – University of Bologna, Italy 
2Gastrointestinal Laboratory, Texas A&M University, College Station, TX, USA 
Abstract 
Introduction - Exact etiology for inflammatory chronic enteropathies in dogs remains unknown. 
Accumulating evidence suggests a pivotal role for intestinal dysbiosis in disease pathogenesis. Many 
studies have evaluated the alteration of fecal microbiota in canine chronic gastrointestinal (GI) 
disease, and less research is focused on mucosal microbiota, especially in the ileum and colon.  
Objective - The objectives of the current study were to evaluate ileal and colonic mucosal microbiota 
in dogs with steroid responsive enteropathy (SRE) before and after 4 months of treatment, and to 
compare them to control dogs (CD). A total of 10 dogs diagnosed with SRE were enrolled. Complete 
GI endoscopy was performed and samples were collected by a cytology brush at diagnosis (SRE-
Baseline, n=10) and after 4 month of treatment (SRE-After, n=8). Oral laxative and 2-4 water enemas 
were performed before endoscopy. A total of 6 CD that were euthanized for reasons unrelated to this 
study, with no GI disease, were included. Samples from CD were obtained during necropsy within 3 
hours of death. Mucosal genomic DNA was extracted and used for Illumina sequencing of 16S rRNA 
genes. Sequence data were analyzed using the QIIME pipeline. Statistical significance was set at p < 
0.05.  
Results - Clinical signs improved significantly after 4 month of treatment in SRE, but no improvement 
was seen on endoscopic or histological evaluation. Significant differences in microbial communities 
between SRE baseline and CD were observed in the colon (ANOSIM p=0.002), but not in the ileum 
(ANOSIM p=0.180). In dogs with SRE, both ileal and colonic microbial communities remained 
similar after 4 month of treatment (ANOSIM p=0.189 and p=0.637, respectively), and were different 
from CD (ANOSIM p=0.001 and p=0.004, respectively).  
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Conclusion and relevance - Results of this study suggest that the mucosal microbiota in the colon of 
dogs with SRE is different from that of CD. Although clinical signs improved, colonic mucosal 
dysbiosis was still present after 4 months of treatment. 
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This project was presented as poster at the 28th ECVIM-CA Congress, Rotterdam 2018 
Endoscopic bronchial anatomy in the dog 
Galiazzo G, Pietra M, Chiocchetti R, Grandis A, Tagliavia C 
Department of Veterinary Medical Sciences – University of Bologna, Italy 
Abstract 
Introduction - Bronchoscopy is an important diagnostic procedure for the evaluation of many 
respiratory diseases and the removal of foreign bodies. During bronchoscopy, it is essential to know 
precisely the bronchial topography, in order to recognize abnormal anatomy or pathological changes. 
Few authors treat bronchial anatomy: currently, the endoscopic anatomy is based on a paper of 1986. 
However, the appearance of bronchial division during a canine endoscopy seems to differ from the 
proposed map. Moreover, it seems that some subjects present individual differences from the standard 
topography.  
Objective - The aim of this study was to obtain a description of topographic anatomy and 
morphometric value of the canine bronchial tree, to introduce a new standardised nomenclature and 
to draw a correct bronchial map. Twelve dogs, different in age, sex and breed, which died 
spontaneously for reasons other than pulmonary diseases, were included in the study. They were 
distinguished by weight in three groups: small (<10 kg), medium (10-25 kg), and large (>25 kg) size. 
All the subjects were examined endoscopically in a systematic manner with a flexible endoscope (Ø 
6mm). After that, on the same lungs, casts of polyurethane foam2 were made and diameter and length 
of the bronchial branches were measured. Furthermore, to name the structures and to draw the 
bronchial map, we defined them by looking at their direction and position. 
Results - The casts confirmed the orientation, the branching pattern and the topographic relationship 
of the bronchial system seen during bronchoscopy (Figure 1). However, even with reduced case 
studies, individual variables are present. The morphometric examination allowed us to obtain a mean 
value of diameter (Table 1) and length (Table 2) of bronchi for each group of weight and to confirm 
the monopodial branching system. Due to their diameter, principal bronchi were accessible in all 
groups, while lobar bronchi were accessible in medium and large size dogs, not always in small size 
group. Segmental bronchi were always accessible only in large size dogs.  
Conclusion and relevance - In conclusion, this study allowed the identification of bronchial 
architecture with a new map and the definition of a nomenclature for the first three series of bronchial 
division. The morphometric examination provided accurate references useful in diagnostic imaging, 
especially during bronchoscopy. 




Figure 1 (I-VI). Endoscopic images and corresponding cast portions. The trachea ends at the tracheal bifurcation with a 
right principal bronchus (RPB) and a left principal bronchus (LPB)VI, which diverges laterally more than the RPB, 
confirming the monopodial branching system. The RPB gives off a right cranial lobar bronchus (RCrLB), a middle lobar 
bronchus (MLB), an accessory lobar bronchus (ALB) and finally a right caudal lobar bronchus (RCdLB), to the 
corresponding right lung lobes. The RCrLB gives off a dorsal-caudal branch, and then continues with a cranial- ventral 
branchIII. The MLB originates from the ventral floor of the RPB and releases a series of segmental bronchi, while the 
ALB divides in two main branches: a ventral-medial and a caudal branchII. The RCdLB gives off three ventral branches 
and then continues as caudal branchI. The LPB gives off the left cranial lobar bronchus (LCrLB), divided in a cranial-
ventral and caudal-ventral branchesV, while the left caudal lobar bronchus (LCdLB) behaves as the RCdLBIV. 
  




Table 1. Mean value of bronchi diameter (mm) of the three groups of dogs. 
 
Table 2. Mean value of bronchi lenght (mm) of the three groups of dogs. 
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This project was presented as poster at the 29th ECVIM-CA Congress, Milano 19th–21th September 
2019. Paper ready for submission. Modified from:  
Water immersion vs air insufflation in canine duodenal endoscopy: is 
the future underwater? 
Galiazzo G1, Costantino F1, Bitelli G2, Romagnoli N1, Lambertini C1, Francolini C2, Gaspardo A1, 
Chiocchetti R1, Pietra M1. 
1Department of Veterinary Medical Sciences – University of Bologna, Italy 
2Department of Civil, Chemical, Environmental, and Materials Engineering – University of Bologna, Italy 
Abstract 
Introduction - Endoscopy is a routinary approach for canine enteropathy. Randomized controlled 
trials in human colonscopy suggest that the introduction of warm-to touch water to distend the 
intestinal lumen, instead of air, decreases pain and increases the visualization of mucosal texture.  
Objective - To compare air insufflation (AI) and water immersion (WI) during duodenoscopy in 
anesthetized dogs (n=25), in order to evaluate differences in nociception and in the quality of mucosal 
visualization. To evaluate cardiocircolatory differences, heart rate and arterial blood pressure were 
measured. A random sequence of AI or WI was applied and the same image of the descending 
duodenum was recorded with AI and WI (Figure 1). Every image was subjected to a texture analysis 
and to a subjective blind evaluation by three expert endoscopists. The distribution of the data was 
evaluated with a D'Agostino and Pearson omnibus normality test. A T test for paired data was applied 
for the image analysis, while a Fleiss’ Kappa test was applied for the subjective evaluation. 
Anesthesiological paramethers were compared with a Friedman test. 
Results - The subjective evaluation identified the WI images as qualitatively better (fixed-marginal 
K =0.74; range 0.61 – 0.80), otherwise no significant differences were evidenced by applying texture 
analysis.  Anesthesiological parameters between AI and WI did not show any significant difference. 
Conclusions and relevance - The results of the study highlight how the painful answer does not 
change between AI and WI (Figure 2 a-d), maybe influenced by the good control of nociception given 
by the anesthesia. The insufflation of water instead of air, during duodenoscopy in dogs, can provide 
an increase in the quality of the endoscopic images, confirmed by a subjective analysis but not by 
texture analysis, without side effects. 
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Figure 1: Images of the descending duodenum with the two methods: water immersion (a) and air insufflation (b). 
 
Figure 2 (a-d): Results of the evaluation of the cardiovascular parameters (a: HR: heart rate; b: DAP: diastolic arterial 
pressure; c: MAP: mean arterial pressure; d: SAP: systolic arterial pressure). The parameters were analyzed, every 5 
minutes, for 30 minutes from time of intubation, and divided in 4 steps. On the X-axis are represented the four steps to 
compare: baseline (from time of intubation to application of the first method), water (WI method), air (AI method) and 
post (from the end of the application of the second method to the end of the 30 minutes). On the Y axis is represented for 
HR the mean value of the frequence in beats per minute (BPM) for each step, and for pressure the mean value in mmHg 
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